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The fungal opportunistic pathogen, Pneumocystis jirovecii (formerly Pneumocystis carinii f. sp. 
hominis) (Pc) is the causative agent of Pneumocystis Pneumonia (PcP) in immunocompromised 
persons.  Despite improvements in anti-retroviral treatments and Pc prophylaxis, Pc remains an 
important pathogen in immunocompromised populations.  Pc colonization, the presence of Pc in 
subjects without clinical signs or symptoms of PcP, is common in HIV+ subjects; however, the 
clinical consequences of colonization are undefined.  The non-human primate model of Pc 
infection in simian immunodeficiency virus (SIV)- or chimeric simian-human immunodeficiency 
virus (SHIV)-infected macaques has been developed to study Pc colonization pathogenesis in the 
context of AIDS immunosuppression.   
Using this model, immunologic parameters associated with natural Pc colonization of 
macaques were evaluated to gain understanding of protective immune responses to Pc.  Humoral 
immunity to the recombinant Pc-antigen, kexin (KEX1), correlated with protection from 
subsequent Pc colonization, despite declining CD4+ T cells.  Furthermore, macaques that 
remained Pc-negative were protected against lung injury observed in macaques that became Pc-
colonized, supporting a role for Pc in pulmonary obstruction development.  These experiments 
suggest KEX1-specific antibodies may provide protection of immunocompromised individuals 
from developing obstructive pulmonary disease.   
Humoral Immunity to the Opportunistic Pathogen, Pneumocystis,  
in a Simian Model of HIV Infection 
 
Heather M. Kling, PhD 
University of Pittsburgh, 2010
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Because B cell deficits and dysfunctions are reported in HIV+ subjects, we examined 
peripheral blood B cell populations in SHIV-infected macaques.  We report declines in total 
(CD20+), memory (CD20+CD27+) and IgM+ memory B cell numbers, increased percentages of 
activated (CD95+) B cells, and hypergammaglobulinemia in SHIV-infected macaques, similar to 
what has been reported for HIV+ patients, suggesting the relevance of this model for studying 
HIV-related B cell dysfunctions.  Pc colonization status did not correlate with deficits in total B 
cell populations.  Rather, protection from Pc-colonization appears associated with a KEX1-
specific memory B cell pool, despite early loss of total CD27+ B cells.  These results suggest 
exposure to Pc prior to immunosuppression, resulting in high levels of circulating 
antibodies/plasma cells, contributes to maintenance of a Pc-specific memory B cell pool 
following immunosuppression.   
These results demonstrate importance of a Pc-specific humoral response in protection 
from Pc colonization and pulmonary damage, thereby providing a rationale for Pc-KEX1 vaccine 
development to protect at-risk populations against this opportunistic pathogen.   
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1.0  INTRODUCTION 
The fungal opportunistic pathogen, Pneumocystis jirovecii (formerly Pneumocystis carinii f. sp. 
hominis) (Pc) is the causative agent of Pneumocystis pneumonia (PcP), which is a major cause of 
morbidity and mortality among immunocompromised persons.  Mistakenly first reported as 
phase in the Trypanosoma cruzi lifecycle by Carlos Chagas in 1909 (Chagas, 1909), 
Pneumocystis was recognized as a unique organism in 1912 (Delanoe and Delanoe, 1912) but 
was mostly considered clinically irrelevant for the next 40 years (Kovacs and Masur, 2009).  In 
the 1940s and 1950s Pc was identified as the cause of a particular pneumonia that was causing 
epidemics in premature and malnourished infants (Gajdusek, 1957).  With the expansion of 
immunosuppressive therapy use, clinicians began to recognize PcP as a life-threatening disease 
in immunosuppressed hosts, especially in children receiving chemotherapy for treatment of 
leukemia (Walzer et al., 1974).  Then in June of 1981, a case series in the CDC’s Morbidity and 
Mortality Weekly Report described incidence of PcP in five homosexual male patients, all 
without any previously known immunodeficiency.  The occurrence of PcP and mucosal 
candidiasis in previously healthy patients was subsequently reported to be evidence of a new 
cellular immunodeficiency (Gottlieb et al., 1981) and would later be recognized as the onset of 
the AIDS epidemic.   
PcP is now considered an AIDS-defining illness and remains one of the most common 
serious opportunistic infections in those with AIDS (Kaplan et al., 2000; Morris et al., 2004b), 
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even with the availability of effective Pc treatment and anti-retroviral therapies in the developed 
world (Kaplan et al., 2000; Morris et al., 2004b).  One study reported mortality from PcP as high 
as 25 percent in patients receiving ART, which although lower than the reported 63 percent in 
those not on ART, is still significant (Morris et al., 2003).  Several studies have shown that 
subpopulations of HIV-infected individuals remain at risk for development of PcP despite anti-
retroviral therapy (Connors et al., 1997; Morris et al., 2004b), although the basis of susceptibility 
is poorly understood.  In the developing world, PcP still occurs frequently, affecting as many as 
40 percent of the HIV+ population in Thailand (Wannamethee et al., 1998) and has been 
reported at a prevalence as high as 50 percent of HIV-infected persons in Brazil (Weinberg and 
Duarte, 1993).  In sub-Saharan Africa, PcP is thought to be rare among HIV+ adults (Abouya et 
al., 1992), but this may be due to underreporting because of limited diagnostic resources.   This 
hypothesis is supported by high rates of anti-Pc antibodies as well as high rates of PcP among 
African children (Lucas et al., 1996; Ikeogu et al., 1997; Graham et al., 2000; Ruffini and Madhi, 
2002).  Decline of CD4+ T cell levels below 200 cells/μl is a major risk factor for HIV+ patients; 
however, other factors such as cigarette smoking and environmental factors contribute to 
development of disease (Morris et al., 2004a). 
Several hypotheses exist regarding the development of PcP in immunocompromised 
persons, including reactivation of latent infection acquired during childhood, active acquisition 
of infection from environmental exposure, and active infection acquired from person-to-person 
transmission (Morris et al., 2002). Although major declines in PcP incidence as well as increased 
survival from PcP (Morris et al., 2003) have occurred in the post-ART era, this disease remains a 
significant source of morbidity, even in industrialized countries.  Possible reasons for this 
include lack of medical care, noncompliance with treatment regimens, possible drug resistance 
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resulting in decreased efficacy of prophylaxis, and lack of prophylactic prescription (Morris et 
al., 2004b).   
1.1 BIOLOGY OF PNEUMOCYSTIS 
The taxonomy of Pc has changed continuously over the years.  It was originally named P. 
carinii, for its lung tropism and crediting the investigator, Antonio Carinii, who identified the 
organism in the lungs of rats in 1910 (Thomas and Limper, 2007; Krajicek et al., 2008).  Pc was 
originally classified as a protozoan based on histological characteristics of the two life-cycle 
forms, the trophozoite and the cyst.  Additionally, successful treatment of Pc-infected persons 
with the anti-protozoan medication, pentamidine, lent further support to this hypothesis.  
However, in 1988, following the sequencing of its small ribosomal RNA subunit, Pc was 
phylogenetically placed in the fungal kingdom (Edman et al., 1988), and is now classified within 
the phylum Ascomycota.  It resides in a unique class (Pneumocystidomycetes), order 
(Pneumocystidales) and family (Pneumocystidaceae).  Pc possesses a high level of host-
specificity, such that a unique species, each with different genetics, has been identified in 
virtually every mammal.  The various forms were historically designated with forma specialis 
(e.g., Pneumocystis carinii forma specialis hominis, the form that infects humans); however, in a 
recent nomenclature shift, the form that infects humans has been renamed P. jirovecii, in 
deference to the pathologist Jirovec, who initially described the organism in humans (Stringer, et 
al 2003). 
Pc exists almost exclusively within the alveoli of the lung of an infected host.  Transient 
proliferation of Pc is possible in the presence of lung epithelial cells in tissue culture medium; 
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however, sustained growth has yet to be achieved.  This obstacle has been an impediment to 
studying the genetics and life cycle of Pc species, and life cycle events have been described only 
by microscopic observation.  The trophic form and the cyst form are the two predominant life-
cycle forms (Figure 1).  During infection, trophic forms greatly predominate over cyst forms.  
Trophic forms during infection are mostly haploid, though a few diploid forms are also present 
(Wyder et al., 1998).  The trophic forms may be able to conjugate and develop into cysts.  
Electron microscopy has revealed the existence of three intermediate cyst stages: early, 
intermediate and late precysts, which contain 2, 4 and 8 nuclei, respectively (Matsumoto and 
Yoshida, 1984).  Eight nuclei are contained within the mature cyst, which ruptures to generate 
trophic forms emanating from the nuclei.  As a form of sexual reproduction, trophic forms can 
then conjugate to re-form the cyst, or undergo vegetative growth (Matsumoto and Yoshida, 
1984).  Asexual reproduction can also be achieved by trophic forms, which may conjugate by 
binary fission.  
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Figure 1. The hypothesized life cycle of Pneumocystis sp. 
Copyright permission was obtained from Nature Publishing Group for use of this figure 
for reproduction within this dissertation. 
 
 
The Pc cell wall is composed of polymerized carbohydrates, chitins and associated 
proteins, with the main structural component being β-1,3-glucan. This component not only 
contributes structural stability, but also elicits an inflammatory response during infection of the 
host.  This inflammation contributes to alveolar epithelial damage, which is associated with Pc 
infection. 
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1.2 PNEUMOCYSITS INFECTION 
1.2.1 Pneumocystis Pneumonia – Clinical Disease, Diagnosis and Treatment 
Pneumocystis Pneumonia is a common AIDS-defining illness, but is also diagnosed in patients 
with other immunodeficiencies, such as those receiving chronic immunosuppressive 
medications, those with hematologic or solid malignancies, transplant recipients, and others with 
immune system alterations (Thomas and Limper, 2004).  PcP diagnosis is a challenge for 
physicians, compounded by the observation that PcP symptoms in HIV-negative patients differ 
from those seen in HIV-infected persons.  HIV+ patients typically present with progressive 
dyspnea, non-productive or productive cough (with clear sputum), low-grade fever, and malaise.  
In contrast, non-HIV-infected patients usually develop acute, fulminant respiratory failure, which 
is associated with dry cough and fever, and may frequently require mechanical ventilation.  The 
preferred clinical sample used for diagnosis of PcP is bronchoalveolar lavage (BAL) fluid 
(Huang et al., 2006).  However, some clinicians rely on induced sputum or oropharyngeal wash 
samples, which, although have decreased sensitivity compared with BAL fluid samples, require 
less invasive procedures (Wang et al., 2007).  Pc organisms, in the trophic or cyst forms, from 
patient samples can be stained using standard histochemical methods, such as modified Giemsa 
stains for visualizing the trophic form and Grocott-Gomori methenamine stain (GMS) for 
visualization of the cystic form (Krajicek et al., 2008).  Immunofluorescent staining, which has 
been reported to be the most sensitive but least specific visualization method, is also available for 
direct staining of both trophic and cyst forms of Pc (Procop et al., 2004; Krajicek et al., 2008).  
Molecular techniques including PCR for a variety of targets, nested PCR (Wakefield et al., 
1990a; Wakefield et al., 1990b), real-time PCR (Alvarez-Martinez et al., 2006; Huggett et al., 
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2008), and reverse transcriptase PCR for Pc messenger RNA (mRNA) detection (de Oliveira et 
al., 2007), offer the advantage of increased sensitivity and objectivity over visualization methods 
for Pc detection, especially for patients or experimental animals with low organism burden.  
These techniques also have other advantages, such as the quantitative capacity of real-time PCR 
and the use of reverse transcriptase PCR for determination of organism viability.  However, less 
invasive methods for diagnosis of Pc infection are desirable, and several studies have 
investigated the predictive capacity of various serum antigens that may be used as indicators of 
Pc infection.  Preliminary studies of β-ᴅ-Glucan, a major component of the cell wall of most 
fungi, reported high sensitivity; however, other studies report that levels decrease during PcP 
treatment (Kawagishi et al., 2007; Marty et al., 2007; Krajicek et al., 2008).  Therefore, the 
diagnostic capacity of this test and investigation into other potential serum markers of Pc 
infection warrant further research. 
Prior to the AIDS epidemic, the major chemoctherapeutic agents available for treatment 
of PcP were parenteral pentamidine and trimethoprim-sulfamethoxazole (TMP-SMX).  To date, 
TMP-SMX remains the drug of choice for both treatment and prophylaxis of PcP, because of its 
established safety and efficacy, as well as low cost.  Intravenous pentamidine has equivalent 
efficacy; however, adverse drug reactions, which may limit treatment, are more common than in 
patients treated with TMP-SMX.   TMP-SMX is recommended as first-line prophylaxis against 
PcP in HIV+ patients with CD4+ T cell counts less than 200 cells/µl, those with oral candidiasis, 
and those with PcP after completion of PcP treatment regimen (Kaplan et al., 2002).  Prophylaxis 
is also recommended for non-HIV-infected patients who are receiving immunsuppressive 
medications or who have an underlying acquired or inherited immunodeficiency.  Development 
of resistance to TMP-SMX is also a concern.  The two targets of TMP-SMX, the dihydrofolate 
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reductase (DHFR), the target of TMP, and dihydropteroate synthase (DHPS), the target of SMX 
and other sulfa drugs, are both enzymes involved folate biosynthesis.  Mutations in the DHPS 
gene have been identified in Pc, and evidence from the literature suggests that these mutations 
may be associated with prophylaxis failures in HIV-infected patients (Kazanjian et al., 1998).   In 
the case of adverse reactions to TMP-SMX, which are relatively common, or in patients with 
known allergies to sulfa, alternative choices for treatment include dapsone, a sulfone which also 
targets the DHPS, or atovaquone, which targets the mitochondrial cytochrome b.  Mutations in 
the mitochondrial cytochrome b have been demonstrated to confer resistance to atovaquone.  
Because mutations in target genes, which may be associated with drug resistance, have already 
been reported in Pc, and because of the prevalence of patients’ adverse reactions to anti-Pc 
medications, it remains important for researchers to explore other avenues for treating or 
preventing PcP. 
1.2.2 Pneumocystis Colonization  
Despite abundant research, a general lack of understanding regarding Pc transmission and life 
cycle still exists, mostly due to the inability to culture this organism.  Pc appears to be 
ubiquitous, and the identity of the reservoir(s) is still unknown.  Although it is known that most 
children develop anti-Pc antibodies early in life (Pifer et al., 1978; Vargas et al., 2001), the rate 
of asymptomatic carriage in adults is unknown.  The hypothesis of environmental exposure is 
supported by studies which have reported detection of Pc in samples of pond water (Casanova-
Cardiel and Leibowitz, 1997), air filters (Wakefield, 1994), and soil (Navin et al., 2000).   
Pc colonization or carriage, defined as the presence of Pc in respiratory samples from 
subjects without signs of clinical disease, has been reported to be uncommon in healthy subjects 
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(Wakefield et al., 1990c; Peters et al., 1992; Leigh et al., 1993; Tamburrini et al., 1997).  
However, recently, the prevalence of Pneumocystis in an immunocompetent, HIV-negative adult 
population was shown to be as high as 20 percent (Medrano et al., 2005), with some month-to-
month variability in tested samples, supporting the idea of transient colonization.  This suggests 
that healthy persons may be able to transmit organisms to other immunocompetent hosts.  
Transient colonization of healthy individuals also occurs in macaque populations (Demanche et 
al., 2005) and in colonies of healthy, immunocompetent rodents (Vestereng et al., 2004).  In a 
healthy population of macaques, the prevalence of Pc as detected by nested PCR is highly 
variable from one month to the next, as is the duration of Pc carriage (Demanche et al., 2005).  
Rates of Pc colonization, though variable (Huang et al., 2003; Larsen et al., 2004; Morris et al., 
2004b), have been reported as relatively common in HIV+ patients (Morris et al., 2002; Morris et 
al., 2004a; Morris et al., 2004b; Demanche et al., 2005) despite the use of anti-Pc prophylaxis.  
In one cohort of HIV+ subjects who died from causes other that PcP, Pc was detected by nested 
PCR in 46 percent of lung samples (Morris et al., 2004a).   Another study reported Pc 
colonization rates as high as 69 percent (Huang et al., 2003).  Pc colonization rates are also 
somewhat variable in those with pulmonary diseases (Sing et al., 1999; Morris et al., 2004c; 
Respaldiza et al., 2005), perhaps a consequence of the detection limitations of PCR or the 
transient nature of Pc colonization.  There may also exist geographic regional differences in 
colonization rates (Morris et al., 2004a; Nevez et al., 2006).  Although the clinical consequences 
of Pc colonization are undefined, it is likely that even at low levels, Pc colonization of the lung 
can result in inflammatory changes, such as increases in neutrophils, CD8+ T cells or 
macrophages, which may release potentially destructive inflammatory mediators.   
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1.3 ANIMAL MODELS OF PNEUMOCYSTIS INFECTION 
1.3.1 Mouse Models of Pneumocystis Infection 
To date there is no reliable in vitro culture system for propagation and proliferation of Pc 
organisms.  The lack of an in vitro culture system for Pc necessitates the use of animal models 
for the study of host immune responses, transmission, and other factors of disease.  Traditional 
animal models of Pc have been rodents, for which immunosuppression is achieved through 
corticosteroid treatment or genetic knock-outs (Steele et al., 2002), as in severe combined 
immune deficiency (SCID) mice (Walzer et al., 1989; Harmsen and Stankiewicz, 1990) or nude 
mice (Powles et al., 1992), or through CD4+ T cell depletion (Shellito et al., 1990; Nevez et al., 
1997; Hanano and Kaufmann, 1998).  In these models, mice or rats are either infected through 
intranasal or intratrachial inoculation or naturally acquire Pc through co-housing with infected 
animals (Gigliotti et al., 2002).  Although the vast majority of information known about host 
immune responses to Pc has been generated through the use of these rodent models, there are a 
number of inadequacies. Corticosteroid treatment generates broad immunosuppressive effects 
that may mask immune effector mechanisms of interest.  Additionally, although CD4+ T cell 
depletion is a central mechanism for AIDS immunosuppression, there are other immune 
dysfunctions caused by HIV infection, which may be relevant to the study of host immune 
responses to Pc in the context of AIDS-associated immunosuppression.  Finally, given recent 
evidence regarding the genetic variation among Pc species, and high degree of host specificity of 
these species, it may be more relevant to study Pc disease in an animal model that can be 
infected by a Pc species more closely related to that which infects humans.  Phylogenetically, Pc 
derived from non-human primates is more closely related to human-derived Pc (Norris et al., 
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2003).  For these reasons, it may be more relevant to examine immune responses to Pc infection 
in a model that more closely approximates human disease. 
1.3.2 Non-human Primate Model of Pneumocystis Infection 
To address these concerns, the Norris lab has developed a non-human primate model of Pc in the 
context of AIDS immunosuppression (Croix et al., 2002; Board et al., 2003; Patil et al., 2003).  
SIV-infected macaques naturally develop opportunistic infections associated with AIDS 
(Reimann et al., 1996).  SIV-infected macaques co-infected with Pc exhibit lymphocyte and 
neutrophil infiltration in bronchoalveolar lavage (BAL) fluid, eosinophilic exudates in alveolar 
spaces, and an increase in CD8+ to CD4+ T cell ratio in BAL fluid (Croix et al., 2002; Board et 
al., 2003; Patil et al., 2003) as well as increased levels of pro-inflammatory cytokines (interferon 
(IFN)-γ, tumor necrosis factor (TNF), and interleukin (IL)-8 in the lungs (Croix et al., 2002).  
The disease course observed in this model closely resembles that of PcP in AIDS patients (Dei-
Cas et al., 1998), making this a useful model for studying this disease.  An alternative to SIV-
induced immunosuppression is the use of a chimeric Simian-Human Immunodeficiency Virus 
(SHIV) to infect macaques.  Researchers have developed a chimeric virus, composed of SIV, 
expressing HIV-1 env, and usually various combinations of HIV-1 auxiliary genes (Li et al., 
1992; Dunn et al., 1996; Reimann et al., 1996).  It has been shown that these chimeric viruses 
replicate efficiently in macaques (Li et al., 1992), induce lymphadenopathy, CD4+ T cell 
depletion, and AIDS-like disease, including wasting and occurrence of opportunistic infections 
(Dunn et al., 1996; Reimann et al., 1996).  Additionally, the virulence of SHIV for rhesus and 
cynomolgus macaques appears to closely resemble that of HIV-1 for humans in the acute phase 
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of infection (Dunn et al., 1996).  These aspects of clinical relevance lend support to the use of the 
SIV/SHIV macaque model of immunosuppression for the study of immune responses to Pc. 
 
1.4 HOST IMMUNOLOGIC DEFENSE AGAINST PNEUMOCYSTIS INFECTION 
1.4.1 Innate Immune Response to Pneumocystis  
Alveolar macrophages are the first line of host defense against Pc infection (Hidalgo et al., 1992; 
Laursen et al., 2003).  This cell type is ultimately responsible for clearing Pc infection from the 
lungs of an infected host.  The macrophage mannose receptor has been shown to mediate uptake 
of Pc organisms (Ezekowitz et al., 1991) via the ligand the major surface glycoprotein (gpA) on 
the surface of Pc organisms (O'Riordan et al., 1995).  The importance of the mannose receptor in 
facilitating uptake and subsequent clearance of Pc organisms is further supported by reports of 
down-regulation of mannose receptor expression on alveolar macrophages from HIV-infected 
subjects, which correlated with impaired phagocytosis of Pc, compared with alveolar 
macrophages from healthy subjects (Koziel et al., 1998).  This impairment may therefore 
contribute to the high incidence of Pc colonization and PcP in the HIV+ population.   However, 
this is in contrast to studies from mouse experiments, which report that mannose receptor-
deficient mice are able to clear Pc infection (Swain et al., 2003).  Beta-glucan receptors, notably 
Dectin-1 (Steele et al., 2003), are also reported to be important for Pc update and clearance by 
alveolar macrophages.  Binding of Pc beta-glucans has been shown to elicit production of pro-
inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), macrophages 
 13 
inflammatory protein-2 (MIP-2) (Vassallo et al., 1999), and IL-6 (Vassallo et al., 2001).  
Additionally, the importance of toll-like receptor (TLR) function for alveolar macrophage 
recognition of Pc has been suggested by the impaired responses of alveolar macrophages in 
MyD88-defecient mice (Lebron et al., 2003).  In addition to uptake, the importance of alveolar 
macrophages in host defense against Pc is highlighted by their role in killing of Pc organisms, 
likely through hydrogen peroxide production (Hidalgo et al., 1992; Laursen et al., 1994; Steele et 
al., 2003).  Supporting this observation are data showing that the respiratory burst of 
macrophages and neutrophils is impaired in HIV-infected persons, whether they have PcP or are 
asymptomatic (Koziel et al., 2000), and possibly contributes to the pathogenesis of PcP.  Finally, 
experiments in which mice are depleted of alveolar macrophages, and then challenged with Pc 
inoculation, demonstrate significantly higher Pc burden in the lungs, compared with alveolar 
macrophage-replete mice (Limper et al., 1997). 
Neutrophils also play a role in Pc infection, although the outcome of their involvement 
may be more detrimental than beneficial to the host.  Neutrophil infiltration of the lung likely 
occurs in response to increased levels of the chemoattractant, IL-8.  Like alveolar macrophages, 
neutrophils produce superoxide when cultured with Pc organisms (Laursen et al., 2003), and the 
respiratory burst response of neutrophils from HIV-infected subjects with a history of PcP has 
been reported to be decreased compared with neutrophils from AIDS patients without previous 
PcP incident (Laursen et al., 1995).  However, a correlation has been suggested between 
neutrophil counts and compromised pulmonary function in patients with PcP, as well as clinical 
severity of disease (Jensen et al., 1991; Sadaghdar et al., 1992), suggesting that neutrophils play 
a role in the pathogenesis of Pc infection. 
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An important step in establishment of Pc infection is adherence of organisms to alveolar 
epithelial cells (Limper et al., 1998), which are the predominant cell types for Pc contact.  
Binding of the Pc organisms, which likely occurs via integrins on the epithelial cell surface 
(Pottratz and Martin, 1990), induces alveolar epithelial cell production and secretion of 
inflammatory cytokines, such as IL-6 (Pottratz et al., 1998) IL-8, and monocyte chemoattractant 
protein-1 (MCP-1) (Benfield et al., 1999).  In this way, alveolar epithelial cells mediate immune 
function and participate in host defense against infection, but may also contribute to lung 
inflammation and resulting pathogenesis. 
1.4.2 T cell Responses to Pneumocystis  
The role of CD4+ T cells in Pc infection is widely recognized as being critical in host defense.  
This was initially shown in studies of Pc infection using mice experimentally depleted of CD4+ 
T cells, which are susceptible to the development of PcP (Shellito et al., 1990).  In these 
experiments, selective CD4+ T cell depletion was achieved through the use of monoclonal 
antibodies, and when antibody treatment was removed, animals were able to clear Pc infection 
from the lungs.  The use of SCID mice for experimental Pc infection additionally supports the 
importance of CD4+ T cells (Walzer et al., 1989).  SCID mice are highly susceptible to PcP, but 
are able to resolve the infection following adoptive transfer of splenocytes from naïve mice 
(Harmsen and Stankiewicz, 1990).  When reconstituted SCID mice are then depleted of CD4+ T 
cells, they are again unable to clear Pc infection (Harmsen and Stankiewicz, 1990).  The precise 
role of this T cell subset has not been defined, but they may provide help for antibody production 
of Pc, as well as in production of cytokines such as IFN-γ, which has also been shown to 
promote control of Pc infection (Kolls et al., 1999).  In HIV+ patients and in experimental rodent 
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models of CD4+ T cell depletion, there is an influx of CD8+ T cells in the lungs; however, the 
role of these cells is somewhat controversial (Beck et al., 1996; Kolls et al., 1999; Wright et al., 
1999).  Some reports support a role for CD8+ T cells as protective in Pc infection and 
instrumental in clearance of the pathogen (Beck et al., 1996; Kolls et al., 1999).  Researchers 
have previously demonstrated that mice experimentally depleted of both CD4+ and CD8+ T cells 
experienced more intense Pc infection than mice depleted of CD4+ T cells alone (Beck et al., 
1996).  However, this study also reported that mice depleted only of CD8+ T cells were able to 
clear Pc infection, suggesting that although it appears that CD8+ T cells participate in host 
defense during Pc infection, they are not required when CD4+ T cells are present.   In vitro 
experiments using CD8+ T cells purified from the lungs of CD4+ T cell-depleted mice 
demonstrated proliferation in response to Pc antigen and IFN-γ production, likely revealing a 
mechanism of protection (Beck et al., 1996).  The importance of IFN-γ in control of Pc infection 
has been demonstrated elsewhere, through experiments in which IFN-γ was introduced by gene 
transfer into the lungs of CD4+ T cell-depleted, Pc-infected mice (Kolls et al., 1999).  This 
introduction of IFN-γ promoted clearance of Pc and was associated with increased recruitment of 
IFN-γ-producing CD8+ T cells and NK cells to the lungs.  However, IFN-γ gene transfer in 
SCID mice and in mice depleted of both CD4+ and CD8+ T cells did not enhance Pc clearance, 
indicating that IFN-γ itself may not be sufficient for organism clearance.  Rather, this study 
suggests that IFN-γ is likely part of a cytokine response optimal for cell recruitment needed for 
host defense (Kolls et al., 1999).  In contrast, others report that CD8+ T cells contribute to lung 
injury and impairment of pulmonary function (Wright et al., 1999).  It has been demonstrated 
that although mice depleted of both CD4+ and CD8+ T cells develop PcP, they do not develop 
lung injury.  However, mice depleted of only CD4+ T cells demonstrate severe lung 
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inflammation and pulmonary complications, suggesting that CD8+ T cells are responsible for 
this pathology (Wright et al., 1999).  It has been suggested that the mechanism for damage from 
CD8+ T cell-associated lung inflammation may be related to altered surfactant function in the 
presence of CD8+ T cells (Wright et al., 2001), or increased levels of cytokine or chemokine 
production. 
1.4.3 B cell and Antibody Responses to Pneumocystis  
It is generally accepted that B cells play an important role in protection against Pc (Beck and 
Harmsen, 1998), however, the precise mechanism is as yet unknown.  Transgenic µMT mice, 
which are highly susceptible to Pc infection, do not develop mature B cells and cannot produce 
immunoglobulins, but have normal numbers of T cells (Marcotte et al., 1996).  Marcotte and 
colleagues described an outbreak of P.carinii in a colony of µMT mice, during which greater 
than 50 percent of animals died of pneumonia (Marcotte et al., 1996).  Results from this study 
suggested a critical role for B cell or antibody responses against Pc infection.  Additionally, the 
report highlighted how easily Pc is transmitted by the airborne route, despite the fact that the 
mouse colony was maintained under sterile conditions (Marcotte et al., 1996). 
Control of Pc infection appears to be enhanced by passive transfer of polyclonal immune 
sera or monoclonal Pc-specific antibodies (Gigliotti et al., 2002; Empey et al., 2004), as well as 
immunization with soluble Pc antigens (Pascale et al., 1999).  Using a SCID mouse model, it has 
been shown that topical, intranasal administration of Pc-specific IgM or IgG1 switch variant 
monoclonal antibodies provide protection against Pc challenge, which was administered by co-
housing with Pc-infected mice.  In this experiment, Pc organism burden was greatly reduced in 
mice which were inoculated with antibody, compared with negative control mice (Gigliotti et al., 
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2002).   In a subsequent study, Wells et al. demonstrated that the Fc region of this monoclonal 
antibody and functional complement are necessary for the antibody to have optimal prophylactic 
effect against PcP development in Pc-challenged SCID mice (Wells et al., 2006b).  Another 
study examining passive immunization demonstrated that neonatal mice born to immunized 
adults and challenged with Pc organisms exhibited enhanced clearance of Pc, compared with 
neonatal mice born to naïve adults (Empey et al., 2004).   
Furthermore, evidence from the literature demonstrates that effective immunization of 
immunocompetent mice can provide protection against development of PcP even when CD4+ T 
cells are no longer present.  In one study, immunocompetent mice were intratracheally 
inoculated with Pc organisms, and were then CD4+ T cell-depleted, followed by challenge with a 
second Pc inoculation.  Pc-vaccinated mice produced high levels of Pc-specific serum IgG, and 
exhibited significantly reduced Pc organism burden, compared with naïve mice that were Pc-
challenged (Harmsen et al., 1995).  In a subsequent study, again using Pc organisms for 
immunization, the role of skewing T-helper responses was examined through the use of IL-4(-/-) 
mice and IFN-γ (-/-) mice (Garvy et al., 1997).  It was found that protection was elicited by 
specific antibodies generated from either T-helper type 1 or type 2 responses; thus, clearance of 
organisms from the lungs of Pc-challenged mice was independent of the antibody isotype profile 
produced (Garvy et al., 1997).  Additional studies with other Pc antigens, such as nonviable 
inocula (Pascale et al 1999) and recombinant Pc kexin proteins or proteins with homology to Pc 
kexin (Gigliotti et al., 2002; Zheng et al., 2005; Wells et al., 2006a), followed by CD4+ T cell 
depletion and Pc challenge, have also demonstrated protective capacity in the mouse model of 
PcP.   Similar to results observed with immunization with whole Pc organisms, immunized mice 
in these studies also demonstrate a Pc-specific antibody response and reduced burden upon Pc 
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challenge, compared with naïve mice that were CD4+ T cell depleted and Pc challenged.  
Together these studies indicate that in the absence of CD4+ T cell help, B cells that are 
sufficiently primed are capable of providing protection against the development of PcP.   
Human studies have examined antibody production in response to Pc in HIV-infection, 
and have demonstrated a deficit in IgA and IgG production in BAL fluid of HIV+ patients with 
PcP, suggesting that development of PcP in these patients may not only be because of declining 
CD4+ T cell numbers, but also a defect in local humoral immunity (Jalil et al., 2000).  Together, 
these studies indicate that Pc-specific antibodies have a role in protection from Pc infection and 
against the development of PcP.    
Antibody production is an important facet of  B cell contribution to host defense; 
however, it has been suggested that B cells are critical to the host immune response to Pc in other 
capacities (Lund et al., 2003), as B cells also function as antigen-presenting cells and also 
produce cytokines (Lund, 2008).   CD40 is an important co-stimulatory marker expressed on B 
cells as well as other antigen-presenting cells.  Experiments involving CD40 knock-out mice 
(Lund et al., 2003) demonstrated that these animals have reduced numbers of activated CD4+ T 
cells in the lungs and lymph nodes compared with wild-type controls, suggesting that B cells are 
important for activation of T cells in response to Pc infection.  These mice produce normal levels 
of Pc-specific IgM, but were unable to clear the infection (Lund et al., 2003).  Thus, it is 
hypothesized that functional CD40-expressing B cells, may be responsible for co-stimulation of 
T cells during Pc infection, thus regulating the strength or quality of the CD4+ T cell response 
(Lund et al., 2003).  Other experiments have used adoptive transfer to demonstrate the 
importance of B cells in resolving Pc infection.  Researchers adoptively transferred CD4+ T cells 
from draining lymph nodes of Pc-infected, normal mice or B-cell deficient mice into SCID mice.  
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Mice receiving CD4+ T cells from B cell-deficient mice had a delayed T cell response in the 
lungs, compared with those that received T cells from normal mice, and were unable to clear Pc 
infection (Lund et al., 2006).  These studies suggest that B cells are necessary for the generation 
of effector and memory CD4+ T cells in response to Pc infection (Lund et al., 2006).    
1.5 ANTIGENS USED IN EVALUATING ANTIBODY RESPONSES TO 
PNEUMOCYSTIS  
1.5.1 Antibody Responses to Whole Pneumocystis Organisms 
The CD4+ T cell-depleted mouse model has also been used to investigate the effect of 
immunization with different Pc antigens on subsequent development of PcP.  In initial 
investigations of host antibody response to Pc infection, investigators used either viable or 
nonviable Pc organisms for immunization (Harmsen et al., 1995; Pascale et al 1999).  As 
mentioned above, intratracheal immunization with whole P. carinii organisms protects mice 
against the development of PcP.  These whole-cell immunized, CD4+ T cell-depleted mice 
showed reduced Pc burden, improved development of systemic Pc-specific IgG response, and 
reduced likelihood of PcP development, upon challenge with Pc organisms (Gigliotti et al., 
1998b).  These studies examine antibodies against soluble total Pc protein from lungs of Pc-
infected mice (usually SCID or CD4+ T cell depleted) as a readout of host humoral response to 
Pc infection (Harmsen et al., 1995).  However, these are crude preparations and require the use 
of an infected animal for source organisms; therefore, this type of preparation, either for 
immunization or for antibody detection, is not ideal.  The potential for vaccine development of 
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this type of antigen preparation is further complicated by the high level of host-specificity of Pc; 
thus, organisms derived from one host species (e.g., mice) may not be capable of eliciting a 
protective immune response against Pc infection of another species (e.g., humans). 
1.5.2 Pneumocystis Major Surface Glycoprotein 
An abundance of heavily glycosylated antigens with mannose carbohydrates exist on the surface 
of Pc organisms.  The family of glycoproteins referred to as the major surface glycoprotein 
(MSG) or glycoprotein A (gpA), with a molecular mass of 95-120 kDa, is the most abundant.  
These surface proteins are involved in Pc attachment to host alveolar epithelial cells, 
hypothesized to occur via integrin-fibronectin interaction (Pottratz et al., 1994).  This is a 
multigene family of glyoproteins, with approximately 80 MSG genes present in the Pc genome; 
however, only one isoform of MSG is expressed at any one time during infection of a host.  The 
expressed isoform is also antigenically distinct for any single host-specific Pc species.  
Expression of a different isoform of MSG may enable Pc to establish infection by evading host 
immune recognition.   
MSG has been explored by researchers for its immunogenic potential.  Immunization 
with a recombinant form of MSG was initially shown to elicit a protective response in the 
corticosteroid-treated rat model (Theus et al., 1998), with MSG-immunized animals exhibiting 
lower organism burden and improved survival, compared with ovalbumin- or adjuvant-alone-
immunized control rats (Theus et al., 1998).  Studies of passive immunoprophylaxis using 
monoclonal antibodies also suggested that immune recognition of MSG be instrumental in Pc 
clearance (Gigliotti et al., 1996).  However, other studies using the CD4+ T cell depleted-mouse 
model of infection have reported that although immunization with gpA elicited a strong gpA-
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specific antibody response, experimental animals were not protected from developing PcP 
(Gigliotti et al., 1998a).  MSG is also capable of antigenic variation, and may not consistently 
present the immunodominant epitope recognized by B cells (Gigliotti et al., 1998a), as it was 
reported that B cells isolated from tracheobronchial lymph nodes were more likely to produce 
antibodies specific to Pc antigens other than MSG (Theus et al., 1995; Gigliotti et al., 1998b; 
Theus et al., 1998).   
   
1.5.3 Pneumocystis Kexins 
The protease PRT1, known as KEX1 in both human- and mouse-derived Pc species, possesses 
homology to fungal subtilisin-like serine proteases Kex1 from Kluyveromyces lactis and Kex2 
from Saccharomyces cervisiae and S. pombe (Lugli et al., 1997; Lee et al., 2000; Kutty and 
Kovacs, 2003).  Kexins, initially described in S. cerevisiae, function in processing and/or 
maturation of hormones and other proteins.  The deduced amino acid sequence of mouse Pc 
Kex1 demonstrated several structural features similar to the subtilisin-like proteases (Lee et al., 
2000).  Reports also indicate that mouse Pc kex1 (Lee et al., 2000), as well as kex1 from P. 
jiroveci are single-copy genes (Lugli et al., 1997; Lee et al., 2000; Kutty and Kovacs, 2003), 
unlike what had been previously described for rat-derived Pc.  Kex1 is hypothesized to be 
involved in the proteolytic processing of Pc surface antigens, in particular, MSG.   
Initial studies suggesting the immunogenicity of kexins were performed using IgM and 
IgG1 switch variant monoclonal antibodies directed against a Pc kexin-like molecule, 
successfully generating a specific antibody response and resulted in reduced organism burden in 
the lungs of immunized SCID mice (Gigliotti et al., 2002).   A subsequent study investigated the 
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use of a thioredoxin-fusion protein, which exhibited homology to Pc kexin, in an active 
immunization model.  Following immunization of mice with the recombinant protein (A12), Pc-
specific antibody responses were detectable by Western blot in mouse serum.  Serum antibodies 
also were capable of binding to the surface of Pc organisms, whereas sera from control mice, 
which were immunized with thioredoxin alone, did not recognize Pc cysts.  Immunization with 
this protein also reduced organism burden in CD4+ T cell-depleted, Pc-challenged mice (Wells 
et al., 2006a).   Finally, a Kexin-DNA vaccination, using CD40 ligand (CD40L) as an adjuvant 
for elicitation of CD4+ T cell-independent responses, has been shown to generate significant 
anti-Pc IgG1 and IgG2a titers in CD4+ T cell-depleted mice (Zheng et al., 2005).  Additionally, 
mice immunized with Kexin-DNA and CD40L exhibited significantly lower Pc organism 
burden, compared with control mice, when challenged with Pc inoculation (Zheng et al., 2005).  
In these experiments, serum was collected from Kexin-DNA/CD40L-immunized mice and 
incubated ex vivo with Pc organisms, followed by incubation with peritoneal macrophages.   
Serum from immunized mice resulted in significant opsonic killing of Pc organisms, compared 
with killing resulting from incubation with serum from naïve mice (Zheng et al 2005).  Together 
these studies demonstrate that Pc Kexin is an important target in murine immunization against Pc 
infection.  However, because of the aforementioned host specificity of Pc, studies examining the 
immunogenicity and protective capacity of this antigen in primate models of Pc infection are 
worth pursuing.   
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1.6 CHRONIC OBSTRUCTIVE PULMONARY DISEASE  
Chronic Obstructive Pulmonary Disease (COPD) is a usually progressive disease that is 
characterized by airflow limitation, which is not fully reversible.  Manifestations of COPD 
include chronic bronchitis, obstructive bronchiolitis, and emphysema.  Emphysema pathology is 
characterized by permanent airspace enlargement and alveolar wall destruction (Snider, 1985).  
Hallmarks of emphysema pathophysiology include parenchymal destruction resulting in loss of 
alveolar-capillary units and lung elasticity, as well as largely-irreversible airflow obstruction 
(Hogg, 2004).  The most common risk factor for COPD development is cigarette-smoking, 
although only 15-20 percent of smokers develop the disease.  Other factors likely contributing to 
disease progression include genetic and environmental factors, as well as infectious agents, 
which may amplify local inflammation (Hogg, 2001; Morris et al., 2004c). 
1.6.1 COPD Association with HIV 
HIV-infected patients, especially smokers, are at increased risk for developing emphysema (Diaz 
et al., 1992; Diaz et al., 2000a).  One study that examined HIV-infected smokers reported that 37 
percent had emphysema, as determined by pulmonary function testing and chest computed 
tomography (CT) scan (Diaz et al., 2000a).  For comparison, this study examined smoking-
history-matched, HIV-negative patients and found that none of these patients exhibited 
emphysema.  Another study presented evidence that even HIV-infected patients who do not 
smoke are at increased risk for airflow obstruction and respiratory symptoms (Diaz et al., 2003).  
Importantly, prolonged life expectancy of the HIV+ population because of ART, as well as a 
high smoking rate in this population, may be associated with increased frequency of chronic 
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health issues, including HIV-associated COPD (Collins et al., 2001; Gritz et al., 2004).  Finally, 
it has been reported that HIV-infected patients develop permanent COPD-like changes after 
having PcP (Morris et al., 2000).   
1.6.2 Pneumocystis Colonization and COPD  
Evidence has accumulated suggesting a role for infectious agents as co-factors in the 
pathogenesis and exacerbation of COPD (Sethi and Murphy, 2008), in which pulmonary 
inflammation due to cigarette smoke may be amplified by the presence of persistent infectious 
agents. This chronic inflammation is thought to contribute to the development of COPD in HIV+ 
patients (Morris et al., 2008b; Sethi and Murphy, 2008). 
There is increasing evidence to suggest an association between persistent Pc colonization 
and the development of chronic obstructive pulmonary disease (COPD).  Inflammatory changes 
associated with Pc colonization and PcP, such as lung infiltration of CD8+ T cells and 
neutrophils, and increased levels of IL-8, are similar to those in COPD (Keatings et al., 1996; Di 
Stefano et al., 1998; Saetta et al., 1998).  Additionally, studies have reported increased 
prevalence of Pc colonization among patients with COPD (10-63%) (Calderon et al., 1996; 
Probst et al., 2000; Helweg-Larsen et al., 2002), and recently, it was reported that Pc 
colonization is associated with increased airway obstruction in HIV+ subjects (Morris et al., 
2009).  One study found that Pc colonization was most common in those with severe airway 
obstruction, and this association was independent of clinical factors such as smoking history or 
steroid use.  Colonization rates were compared in patients with various end-stage lung diseases, 
and, of subjects colonized with Pc, 73 percent carried a diagnosis of COPD, compared with only 
32 percent of non-colonized subjects that had a diagnosis of COPD (Morris et al., 2004a).   
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Furthermore, animal models also support the role of Pc colonization in the pathogenesis 
of COPD.  In a model of immunocompetent mice, cigarette exposure and Pc colonization 
resulted in greater pulmonary function deficits compared to cigarette exposure alone 
(Christensen et al., 2008).  Our laboratory has reported that experimental immunosuppression of 
non-human primates resulting in Pc colonization, without the development of overt clinical PcP, 
was associated with pulmonary inflammation, airway obstruction and anatomic emphysema, 
further supporting the association of Pc colonization and development of COPD (Norris et al., 
2006; Shipley et al., in press).  Recent findings also suggest that antibodies to the recombinant Pc 
antigen kexin are associated with protection from increased severity of obstruction in HIV-
negative COPD patients (Morris et al., 2008a).  These reports lend further support to a growing 
body of evidence that suggests an association between Pc-colonization and the development of 
COPD.   
1.7 HIV-ASSOCIATED EFFECTS ON B CELLS  
In primary HIV infection B cell abnormalities represent an important feature of HIV 
pathogenesis (De Milito, 2004), and may contribute to the increased risk and incidence of 
opportunistic infections in HIV-infected patients.  Such abnormalities include reduced total and 
memory B cells (De Milito et al., 2001; Nagase et al., 2001), increased B cell activation (Lane, 
1983; Mizuma et al., 1988; Shirai et al., 1992; DeMilito, 2001; Titanji et al., 2005; Moir et al., 
2008), resulting in hypergammaglobulinemia and spontaneous Ig secretion in vitro (Nagase et 
al., 2001; De Milito et al., 2004; Titanji et al., 2005), higher percentages of apoptotic naïve and 
memory B cells, decreased circulating antigen-specific Ig, impaired responsiveness to 
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stimulation (Jiang et al., 2008), germinal center abnormalities (Guarda et al., 1983; Chalifoux et 
al., 1984; Chalifoux et al., 1987; Margolin et al., 2002; Margolin et al., 2006), and decreased 
subsets of memory B cells, including IgM+ memory B cells (Titanji et al., 2005; Hart et al., 
2007).   
In early studies of HIV-associated dysfunctions, researchers reported on abnormal levels 
of B-cell activation (Lane, 1983) and resulting spontaneous secretion of immunoglobulins 
(Mizuma et al., 1987; Mizuma et al., 1988), which provide evidence of in vivo polyclonal 
activation.  Serum IgD was identified early as a marker of B cell activation during HIV-
infection, and appeared to correlate with level of immunosuppression as measured by percentage 
of peripheral blood CD4+ T cells (Mizuma et al., 1987).  Additionally, levels of spontaneous 
cellular secretion of IgD, IgM and IgG, measured in PBMC culture supernatants, correlate with 
serum levels of these isotypes, all of which are reported to be elevated in HIV-infected patients 
(Mizuma et al., 1988).  Circulating levels of IgG have been reported as a prognostic marker of 
infection, because patients with symptomatic infection exhibit higher levels of plasma IgG than 
asymptomatic patients, which is likely a consequence of chronic immune activation.  The 
observed hypergammaglobulinemia may be related to increased expression of activation 
markers, which result in elevated rates of differentiation of memory cells to Ig-secreting plasma 
cell and increased activation of naïve B cells (Nagase et al., 2001; De Milito et al., 2004; Cagigi 
et al., 2008; Moir and Fauci, 2009).  In HIV-infection, this hypergammaglobulinemia has been 
reported to be both virus-specific and polyclonal; however, it seems that as disease progresses, 
the HIV-specific response declines, while the polyclonal response is increased (De Milito 2004).  
Additionally, specific antibody responses to opportunistic pathogens and immunizing antigens, 
such as Streptococcus pneumoniae, Cryptococcus neoformans, measles, and influenza, also 
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appear decreased in HIV+ patients, compared with HIV-negative controls (Titanji et al., 2006, 
Cagigi et al., 2007).  This chronic immune activation is accompanied by decreased proliferative 
responses to T-cell independent B cell mitogens ex vivo (Lane et al., 1983; Jiang et al., 2008), in 
both the naïve and memory B cell populations (Jiang et al 2008).  Thus, B cell function, 
measured by the B cell response to specific stimuli or by the capacity to provide co-stimulatory 
signals to CD4+ T cells, appears impaired during HIV-infection (Malaspina et al., 2003; Moir et 
al., 2003).  A mechanism hypothesized to account for poor proliferative responses of B cells 
from HIV-infected patients is the elevated level of CD21-low/negative B cells in these subjects 
(Moir et al., 2001; Jiang et al., 2008; Moir and Fauci, 2009).  These cells are thought to be 
terminally differentiated and thus, proliferate poorly in response to mitogenic stimulation.  
Evidence from the literature suggests that the frequency of CD21+ memory B cells is directly 
related to the capacity of these cells to proliferate in response to stimulation (Jiang et al., 2008).  
Of note, these abnormalities of B cell hyperactivation and hypersecretion of Ig have been 
demonstrated to be reversible by effective anti-retroviral therapy (ART).  These types of B cell 
abnormalities appear to be closely related to subject viremia; thus, with effective reduction in 
viral load following ART, many such abnormalities are reversed (Moir et al., 2001; Fournier et 
al., 2002; De Milito, 2004; Moir and Fauci, 2009). 
In addition to hyperactivation, HIV-infection is also associated with a loss of memory B 
cells and decreased memory B cell function, which, in contrast to what has been reported for 
activation abnormalities, do not seem to be restored by ART (Hart et al., 2007).  Studies have 
demonstrated: a loss of total memory B cells, impairment of long-term serological memory to 
immunizing antigens (Titanji et al., 2006), decreased proliferative capacity of memory B cells 
(Jiang et al., 2008), and a selective loss of particular subsets of memory B cells, such as IgM 
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memory B cells (Hart et al., 2007) and marginal-zone like populations (Morrow et al., 2008).  
Because IgM+ memory B cells are believed to function in protection against encapsulated 
bacterial and other T-independent-type antigens, selective depletion of these types of subsets 
may aid in explaining the increased susceptibility of HIV-infected individuals to infections like 
pneumococcal disease.  Impaired B cell memory may contribute to the observed reduced 
capacity of HIV-infected individuals to respond effectively to pathogens, diminished responses 
to vaccination (Malaspina et al., 2005), and may also contribute to the increased susceptibility of 
HIV-infected individuals to opportunistic pathogens.   
 
1.8 SUMMARY 
Despite increased availability of anti-retroviral therapies and of Pneumocystis prophylaxis, this 
opportunistic pathogen continues to be a major source of morbidity and mortality in 
immunocompromised populations in both industrialized and developing countries. Additionally, 
a general lack of understanding regarding Pc transmission, life cycle and prevalence in the 
general population still exits despite abundant research.  Although it is know that Pc colonization 
in HIV-infected patients is quite common, the clinical consequences of colonization with this 
pathogen are undefined.  Mounting evidence suggests that even in subjects who do not present 
with clinical signs or symptoms of Pneumocystis pneumonia, persistent Pc colonization, even at 
low levels, may elicit a potentially damaging inflammatory response.  In this respect, it is 
plausible that colonization of host lungs with Pc organisms may contribute to or exacerbate the 
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development of chronic obstructive pulmonary disease (COPD).  This hypothesis is supported by 
reports of high rates of Pc colonization in COPD patients. 
The concern for development of Pc resistance to current medications used for PcP 
treatment and prophylaxis underscores the importance of exploring other avenues of prevention 
and treatment.  Although CD4+ T cells are critical in controlling Pc infection, B cells play a vital 
role in protection of the host from development of Pneumocystis pneumonia, and many 
experiments in the mouse model demonstrate the importance of B cells and Pc-specific 
antibodies in host protection from this pathogen.  Although the vast majority of information 
known about host immune responses to Pc infection has been generated through use of the 
mouse model, this system has some inadequacies, which can be addressed through the use of a 
non-human primate model of Pc infection.  The macaque model uses SIV or SHIV, which bear 
many similarities to HIV-infection in humans, to induce immunosuppression, which permits 
natural persistent Pc colonization, or with experimental Pc inoculation, development of PcP.  
This is a highly relevant system for examining host immune responses to Pc infection, which, in 
this model, can be examined in the context of AIDS immunosuppression.  HIV-infection is 
associated with various B cell abnormalities, dysregulations and dysfunctions, which may 
diminish the capacity of the host immune system to respond to a secondary infection.  
Additionally, further understanding and characterization of SHIV-associated B cell deficits or 
abnormalities in the macaque model are needed.  Finally, the central role of the B cell response 
during Pc infection coupled with the known HIV-associated abnormalities underscore the 
importance of investigating B cell responses during a SHIV/Pc co-infection. 
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1.9 SPECIFIC AIMS 
1.9.1 Specific Aim 1.  To establish a model of natural Pneumocystis (Pc) colonization, and 
to develop this model in SIV/SHIV-infected macaques.   
We hypothesize that SIV- or Simian- HIV (SHIV)-infected macaques immunosuppressed by 
depressed CD4+ T cell numbers will naturally acquire Pc as a result of co-housing, and are able 
to generate an immune response to Pc colonization in advance of the development of PCP.  The 
humoral immune response of these animals can be used to track Pc colonization.  Using the 
recombinant Pc antigen Kexin (KEX1), ELISA will be used to evaluate systemic (plasma) and 
local (bronchoalveolar lavage fluid supernatant) production of Pc-specific immunoglobulins in 
SIV/SHIV-infected macaques.  The model will allow for the characterization of antibody 
dynamics associated with and following Pc colonization in a model of SIV/SHIV 
immunosuppression. 
 
1.9.2 Specific Aim 2.  To evaluate the capacity of antibodies to the recombinant Pc 
antigen kexin (KEX1) to protect SHIV-immunosuppressed macaques from naturally 
acquired Pc infection and subsequent lung injury.   
We will characterize the humoral response to Pc in healthy macaques, and examine whether 
differential Pc-antibody titer levels prior to immunosuppression contributes to the delay or 
prevention of Pc colonization.  We hypothesize that macaques with high plasma anti-KEX1 
antibody titers prior to SHIV-induced immunosuppression will be less likely to become naturally 
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Pc-colonized following SHIV-infection than macaques with low/negative KEX1 titers.  High 
KEX1 titers will correlate with the delay or prevention of Pc colonization and prevention of 
subsequent pulmonary disease in SHIV-immunosuppressed macaques.   
 
1.9.3 Specific Aim 3.  To evaluate the effect of SHIV-infection on peripheral blood B cell 
populations in cynomolgus macaques, and to determine whether SHIV-
immunosuppression results in an impaired memory response to a secondary, opportunistic 
infection, Pc.   
We will investigate whether SHIV-infection results in declines or deficits in B cell populations in 
macaques similar to what has been reported in HIV+ patients, to determine whether the SHIV-
macaque model is appropriate for studying AIDS-associated B cell dysfunctions.  We will 
investigate whether B cell defects due to SHIV-infection result in an impaired humoral response 
to Pc colonization.  We hypothesize that we will observe similar phenotypic changes in B cell 
populations as have been reported for HIV-infected subjects, such as declines in total and 
memory populations and increased activation of B cells. However, we anticipate that these 
changes or defects will not contribute to Pc colonization status because we hypothesize that a 
strong antibody response to Pc at baseline will be protective following SHIV-infection despite B 
cell deficits induced by SHIV-infection.   
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2.1 ABSTRACT 
Pneumocystis (Pc) colonization is common among HIV-infected subjects, though the clinical 
consequences of Pc carriage are not fully understood.  We examined the frequency of 
asymptomatic carriage in normal and SIV-infected cynomolgus macaques using polymerase 
chain reaction and changes in the serologic response to a recombinant fragment of the Pc protein, 
kexin (KEX1).  Anti-KEX1 antibodies were detected in 95% of healthy monkeys.  To model 
natural transmission of Pc, SIV-infected monkeys were co-housed with SIV-Pc co-infected 
macaques.  Pc colonization occurred when CD4+ T cells declined below 500 cells/µl, despite 
anti-Pc prophylaxis with trimethoprim-sulfamethoxazole.  
 
Increased anti-KEX1 titers preceded 
polymerase chain reaction detection of Pc DNA in BAL samples. These results demonstrate the 
utility of recombinant KEX1 in serologic studies of Pc colonization and will improve the 
understanding of Pc transmission and the clinical consequences of Pc colonization in HIV-
infected patients. 
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2.2 INTRODUCTION 
Pneumocystis pneumonia (PCP) remains a common serious infection in immunocompromised 
individuals, particularly those with AIDS (Kaplan et al., 2000; Morris et al., 2004b).   Although 
anti-Pneumocystis (Pc) prophylaxis and highly active anti-retroviral therapy (HAART) have 
resulted in a significant decline in PCP frequency, it remains the most common AIDS-defining 
opportunistic infection in the United States (Kaplan et al., 2000; Morris et al., 2002; Morris et al., 
2004b).  
   A clear understanding of the Pc route of transmission is lacking due to inability to 
culture the organisms in vitro. Several hypotheses exist regarding transmission of PCP in 
immunocompromised persons, including reactivation of latent infection acquired during 
childhood, active acquisition of infection from environmental exposure, and person-to-person 
transmission (Morris et al., 2002).  Airborne transmission has been demonstrated in animal 
models and has been used experimentally to initiate infection in normal rodents and in 
immunocompromised rodent models of PCP (Powles et al., 1992; Wolff et al., 1993).  PCP has 
been documented in experimental macaque models of AIDS (Baskin et al., 1988; Vogel et al., 
1993), but a naturally occurring model of transmission and colonization in primates has not been 
described.  
Evidence from experimental systems and serologic studies in humans suggests exposure 
to Pc stimulates a humoral response and antibodies play a significant role in host defense against 
PCP (Gigliotti and Hughes, 1988; Harmsen et al., 1995; Garvy et al., 1997; Bartlett et al., 1998; 
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Gigliotti et al., 1998a; Pascale et al., 1999; Gigliotti et al., 2002).  Clinical application of Pc 
serology has been of limited use in understanding transmission and progression of Pc infection 
due to the frequency of antibodies in both healthy and immunocompromised hosts (Walzer, 
1999; Walzer, 2005).  Recent studies using the major surface glycoprotein (MSG) of Pc have 
shown a high frequency of serum antibodies among normal and immunosuppressed subjects 
(Peglow et al., 1990; Wakefield et al., 1990a; Smulian et al., 1993; Lundgren et al., 1997), and 
changes in MSG-specific antibody levels were detected in sequential serum samples in response 
to Pc infection and treatment (Daly et al., 2006). These studies suggest recombinant Pc antigens 
may be useful in distinguishing past and current Pc exposure. 
Highly sensitive techniques such as polymerase chain reaction have been used to detect 
very low levels of Pc DNA in asymptomatic persons (Nevez et al., 1997; Morris et al., 2004a; 
Medrano et al., 2005).   Detection of Pc DNA by PCR in asymptomatic individuals has been 
defined as colonization or subclinical carriage (Morris et al., 2004b), although clinical 
consequences of Pc colonization are unknown.  Pc colonization may be important for several 
reasons: it may increase risk for progression to PCP in susceptible individuals, carriers may 
transmit infection, and organism persistence may induce chronic inflammation resulting in lung 
damage. Pc colonization is not common in immunocompetent adults, but can be detected in 
individuals with mild to severe immunosuppression (Rabodonirina et al., 1997; Morris et al., 
2004a). In HIV-infected subjects, frequency of Pc colonization has been reported to be between 
5 and 69% (Huang et al., 2003).   We have previously reported that experimental, intrabronchial 
inoculation of Pc in simian immunodeficiency virus (SIV)-infected rhesus macaques could lead 
to persistent, sub-clinical Pc colonization and PCP.  Pc colonization in this model resulted in a 
chronic inflammatory response in the lungs prior to PCP development with prominent CD8+ T 
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cell infiltration and cytokine production (Board et al., 2003).  A shortcoming of this model is 
lack of purity of the inoculum due to inability to culture Pc in vitro, which may induce a 
transient, non-specific inflammatory response.   
In the present study, we aimed to determine the antibody response and frequency of Pc 
colonization in a cohort of normal monkeys, to establish a model of airborne transmission of Pc 
colonization in SIV-infected macaques, and to evaluate the dynamics of anti-Pc antibody 
response in peripheral blood and bronchoalveolar lavage (BAL) fluid during colonization in SIV-
infected macaques.    
2.3 MATERIALS AND METHODS 
2.3.1 Animals. 
Cynomolgus macaques (Macaca fasicularis, ages 3.5 to 4.5 years old) used in this study were 
housed in an American Association for Accreditation of Laboratory Animal Care-accredited 
biosafety level 2+ primate facility at the University of Pittsburgh.  Prior to initiation of the study, 
all animal experiments were approved by the Institutional Animal Care and Use Committee of 
the University of Pittsburgh.  
2.3.2 Study Design. 
Seventy-four healthy, non-SIV-infected monkeys were tested to determine frequency and 
magnitude of anti-Pc antibody titers using recombinant Pc KEX1 ELISA, described below.  Five 
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monkeys were subsequently SIV-infected and used to examine natural transmission of Pc 
colonization and the development of a humoral response to Pc.  Prior to SIV infection, monkeys 
underwent BAL, and samples were evaluated for presence of Pc by microscopic examination of 
Giemsa-stained BAL fluid and by Pc-specific, nested PCR (Board et al., 2003).  In addition, 
baseline serologic analysis was performed for detection of anti-KEX1 antibodies (described 
below).  Monkeys were then infected with a pathogenic strain of SIV (SIV/Delta B670) (Amedee 
et al., 1995), and clinical evaluation and plasma viral levels were performed as described (Board 
et al., 2003).  
At the time of SIV infection, monkeys were treated daily with trimethoprim (20 mg/kg)-
sulfamethoxazole (100 mg/kg) (TMP-SMX) in two divided doses to clear any pre-existing Pc 
colonization and co-housed with SIV macaques that had not received anti-Pc treatment.  When 
plasma antibody titers declined to background levels (4 months post-SIV infection), TMP-SMX 
was reduced to 10 mg/kg TMP and 50 mg/kg SMX, 3 times weekly, on alternate days to 
approximate a prophylactic regimen (2003).  Treatment and prophylactic doses were based on 
the American Academy of Pediatrics Red Book recommendations for Pneumocystis (2003).  
Based on previous studies of experimental Pc infection in SIV-immunosuppressed macaques, we 
predicted monkeys would be susceptible to natural Pc colonization when peripheral blood CD4+ 
T cell levels fell below 30% of the total T cells (Board et al., 2003; Norris et al., 2006).  Thus, 
TMP-SMX prophylaxis was discontinued when CD4+ T cell counts declined below this level 
(approximately 500 CD4+ T cells/µl), to allow natural Pc colonization to occur.  Discontinuation 
of TMP-SMX occurred at 9 months post-SIV infection for monkeys 133, 157, 158 and at 15 
months for monkeys 143 and 156. 
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2.3.3 BAL and blood collection.  
Serial plasma, PBMC and BAL samples from normal and SIV-infected monkeys were collected 
monthly for longitudinal analyses as described (Board et al., 2003).  Aliquots were removed for 
flow cytometric analysis, microscopic and microbiologic analyses and Pc-specific PCR.  Plasma 
and BAL fluid were heat inactivated (56°C, 30 min) and used in ELISA for detection of Pc-
specific antibodies.  BAL fluid samples were normalized based on plasma urea concentration 
(Rennard et al., 1986). Percentages and absolute numbers of CD4+ and CD8+ T cells were 
calculated based on flow cytometry of PBMC (Croix et al., 2002).  Pc colonization was defined 
as a three-fold increase in anti-KEX1 reciprocal endpoint titer over baseline titer and confirmed 
by detection of Pc DNA by nested PCR in BAL fluid, as described below.  
 
2.3.4 Western blot analysis. 
A partial fragment of the macaque-derived, Pc kexin gene in the pBAD expression vector (gift 
from C.G. Haidaris, University of Rochester, GenBank accession number EU918304) was used 
to produce recombinant kexin protein (KEX1).  Briefly, KEX1 expression was induced in E. coli 
Top10 (Invitrogen Corp., Carlsbad, CA) containing the pBAD-KEX1 plasmid; cells were lysed, 
centrifuged and supernatant was purified by affinity chromatography.  Purified protein was 
subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), 
transferred to nitrocellulose, blocked, and incubated with plasma from a macaque with PCP, and 
with plasma from SIV-infected macaques from this study.  Filters were washed, incubated with 
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horseradish peroxidase-conjugated IgG secondary antibody, and developed according to standard 
protocols (more details included in Supplementary Methods, Appendix B).   
2.3.5 Endpoint antibody titer determination. 
Microtiter plates (Immunolon 4HBX, Thermo Fisher Scientific, Inc., Waltham, MA) were coated 
with purified KEX1 at 5 µg/ml in Na2CO3, (pH 9.5).  Heat-inactivated plasma samples were 
diluted 1:100 in blocking buffer (PBS, 5% non-fat milk).  Fifty µL of plasma were plated into 
KEX1-coated wells and serial dilutions were made to determine endpoint titers.  Goat anti-
monkey immunoglobulin-conjugated horseradish peroxidase (1:10,000 for IgG, 1:2000 for IgM) 
(Nordic Immunology, Tilburg, Netherlands) was used for detection and plates were developed by 
standard methods. Normal (uninfected, Pc-negative) macaque plasma was used as negative 
control and plasma from a monkey with PCP was used for positive control (more details 
included in Supplementary Methods).  The reciprocal endpoint titer was calculated as the highest 
dilution at which the optical density (O.D.) values for the test sample were the same or less than 
the normal sample O.D.   
2.3.6 Nested PCR of BAL fluid. 
BAL fluid cell lysate samples were analyzed for presence of Pc DNA by nested PCR of the 
mitochondrial large subunit ribosomal RNA gene (mtLSU), as described (Board et al., 2003; 
Patil et al., 2003).  Nested PCR was performed on 5 µL of the first round product using primers 
P1 and P2 (Savoia et al., 1997).  PCR for β-globin was also performed on BAL samples to 
control for DNA quality (Croix et al., 2002). 
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2.3.7 Flow Cytometry. 
Mouse anti-monkey CD3-fluorescein isothiocyanate (clone SP34), mouse anti-human CD8-Cy-
Chrome (clone SK1) and mouse anti-monkey CD4- allophycocyanin (clone L200) were 
purchased from BD Pharmingen (San Diego, CA).  Cells were isolated from whole blood and 
stained as previously described (Croix et al., 2002).  
2.4 RESULTS 
2.4.1 Western blot analysis of KEX1. 
After confirming reactivity of purified recombinant KEX1 to plasma from a macaque with 
microscopically-confirmed PCP (data not shown), plasma samples from the SIV-infected 
monkeys were examined by western blot; a sample from one animal is shown in Figure 2.  SDS-
PAGE analysis of purified KEX1 demonstrates purity achieved from a typical protein 
preparation in Figure 2A.  Western blot analysis showed that plasma reacted with KEX1 at the 
expected molecular mass of 30 kDA, but not with proteins encoded by the vector only, 
demonstrating the specificity of the antigen, (Fig. 2B).   
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Figure 2. SDS-PAGE and Western blot analysis of recombinant Pc KEX1.  A.  Coomassie 
blue-stained SDS- polyacrylamide gel of purified KEX1 protein (lane 2) and preparation of 
protein purified from the pBAD expression vector not containing the KEX1 insert (lane 1).  
Equal amounts of protein were applied to both lanes (2.5µg). The migration of molecular mass 
markers (kilodalton) is indicated at left, and applies to the Western blot (in part B) as well.  B. 
Western blot of recombinant KEX1 (lane 2) or proteins from E. coli expression vector (lane 1) 
using plasma from a Pc-colonized macaque.  Equal amounts of protein were applied to both 
lanes (2.5µg).  
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2.4.2 Anti-KEX1 serology and Pc colonization in normal cynomolgus macaques. 
The majority of healthy cynomolgus macaques (95%, n=74) had detectable reciprocal endpoint 
titers (RET) (>100).   Of those, 59% had RET between 100 and 4800 and the remaining 41% had 
RET greater than 6400. 
We observed transient Pc colonization in 2 healthy monkeys as indicated by an increase 
in antibody titer and detection of Pc DNA in BAL fluid.   At study entry, one monkey had no 
detectable Pc DNA in BAL, and a plasma anti-KEX1 IgG reciprocal titer of 100.  Six weeks 
later, this animal had detectable Pc DNA (by nested PCR) in the BAL sample and had a 32-fold 
increase in anti-KEX1 endpoint titer.  At subsequent monthly time points, the plasma Pc-specific 
reciprocal IgG titer declined to 400 and Pc DNA could no longer be detected in BAL samples.  
Transient colonization was also detected in another monkey by nested PCR of Pc DNA in the 
BAL fluid at entry into the study, but was not positive by nested PCR 4 weeks later. 
2.4.3 Natural Pc colonization of SIV-infected macaques. 
To evaluate baseline Pc colonization status prior to SIV infection, nested PCR was performed on 
BAL samples, and plasma and BAL supernatant samples were analyzed for anti-KEX1 
antibodies.  Pc DNA was not detected in experimental monkeys prior to SIV infection, though 4 
of 5 monkeys (133, 156, 157 and 158) had detectable anti-KEX1 IgG reciprocal titers, ranging 
from 600 to 1,600 (Fig. 3 and 4).  Monkeys were treated with TMP-SMX, and antibody titers 
declined to background levels. Monthly BAL samples were negative by nested PCR except for a 
single time point (3 months) in monkeys 156 and 157 (Fig. 3).  Treatment doses were then 
decreased to prophylactic doses and within three months of co-housing with Pc-infected 
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monkeys, all monkeys experienced a serial rise in anti-KEX1 antibody titers, and Pc DNA was 
detected in BAL samples from 3 of 5 monkeys, suggesting re-emergence or secondary 
colonization by Pc despite use of anti-Pc prophylaxis (Fig. 3).  
When CD4+ T cells fell below 500 cells/µL, all monkeys eventually experienced an 
increase in anti-KEX1 plasma antibody titers (Fig 3).  Anti-KEX1 IgG did not increase above 
background in monkey 133; however, by 9 months post-SIV infection serial increases in anti-
KEX1 IgM titers were detected, suggesting a primary exposure to Pc (Fig. 3 and 4). After 
monkeys had seroconverted, Pc DNA was detected by nested PCR in multiple monthly BAL 
samples confirming Pc colonization.  During the course of the study, the SIV-immunosuppressed 
monkeys were unable to clear Pc colonization.   
2.4.4 Anti-KEX1 antibody response in BAL fluid. 
Serial BAL samples were analyzed for the presence of anti-KEX1 IgG, IgA and IgM.  Increases 
in anti-KEX1 titers in the BAL fluid occurred at approximately the same time points as in plasma 
samples (Fig. 4 and 5), and followed a similar dynamic with respect to class switching, despite 
low peripheral blood CD4+ T cell levels.  
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Figure 3. Natural Pc colonization of SIV-infected macaques.  Following SIV infection, blood 
and bronchoalveolar lavage (BAL) fluid were collected at monthly intervals.  Anti-KEX1 IgG 
(for monkeys 143, 156, 157 and 158) or IgM (for monkey 133) (solid black bar) reciprocal 
endpoint titers (RET) of individual monkeys are shown on the left y-axis and peripheral blood 
CD4+ T cell numbers (solid black line) are shown on the right y-axis.  Detection of Pc DNA by 
nested PCR of BAL samples is indicated by +.  The duration of trimethoprim-sulfamethoxazole 
(TMP-SMX) treatment (solid black bracket) or prophylaxis (segmented bracket) are shown.   
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Figure 4. Comparison of anti-KEX1 antibody response in the bronchoalveolar lavage 
(BAL) fluid supernatant with anti-KEX1 antibody response in the plasma for two 
representative animals.  Blood and BAL fluid supernatant were collected for each animal at 
monthly time-points following SIV-infection.   Anti-KEX1 IgM (-*-), IgG (-○-) and IgA (-■-) 
reciprocal endpoint titers (RET) were determined.  
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Figure 5. Comparison of anti-KEX1 antibody response in the bronchoalveolar lavage 
(BAL) fluid supernatant with anti-KEX1 antibody response in the plasma for three SIV-
infected macaques.  Blood and BAL fluid supernatant were collected for each animal at 
monthly time-points following SIV-infection.  Anti-KEX1 IgM (-*-), IgG (-○-) and IgA (-■-) 
reciprocal endpoint titers (RET) were determined. 
 
2.5 DISCUSSION 
We have developed an anti-Pc antibody ELISA to evaluate Pc colonization and established a co-
housing model of Pc colonization in SIV-infected macaques.  Using these tools, we found: the 
majority of immunocompetent adult cynomolgus macaques have detectable anti-Pc antibody 
titers; transient Pc colonization occurs in healthy macaques and can be monitored by anti-KEX1 
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serology and nested PCR of BAL samples; co-housing of SIV-infected macaques with SIV/Pc 
co-infected animals results in Pc colonization which is not prevented by anti-Pc prophylaxis; and 
anti-KEX1 seroconversion precedes detection of Pc by nested PCR of BAL samples.  
 In the present study, we used a serologic assay based on a recombinant fragment of Pc 
kexin.  Pc kexin shares sequence homology with a family of fungal serine endoproteases, and in 
P. jirovecii (human-derived Pc), kexin is encoded by a single copy gene (Lugli et al., 1997; Lee 
et al., 2000; Kutty and Kovacs, 2003).  Thus, as a serologic target KEX1 does not present the 
complexity of multiple gene copies and antigenic variation associated with MSG (Kovacs et al., 
1993; Smulian et al., 1997).  Immune responses to Pc kexin have been associated with control of 
Pc infection in experimental models (Zheng et al., 2005; Wells et al., 2006a), thus changes in 
anti-KEX1 titers and antibody isotypes during and after infection may serve as a useful correlate 
of protection.Human prevalence studies are limited in ability to correlate antibody levels with Pc 
colonization and exposure due to difficulty of obtaining serial samples of blood and BAL in 
subjects.  The non-human primate model enables evaluation of anti-Pc antibody responses in 
serial samples and correlation of results with detection of Pc DNA in BAL samples in both 
immunocompetent and immunosuppressed animals. We found that approximately 95% of 
healthy macaques had detectable plasma anti-KEX1 reciprocal endpoint titers, ranging from 100 
to >12,800, suggesting the majority of healthy macaques were exposed to Pc.  Similar 
frequencies of anti-Pc antibodies other than kexin have been documented in human 
epidemiologic studies, with up to 84% of adults having antibodies to Pc (Peglow et al., 1990; 
Wakefield et al., 1990a; Smulian et al., 1993; Lundgren et al., 1997; Walzer, 1999; Daly et al., 
2002; Walzer, 2005).  We also found that normal monkeys developed transient colonization as 
defined by an increase in anti-KEX1 titers followed by detection of Pc DNA by nested PCR of 
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BAL fluid.  Antibody titers subsequently decreased and Pc DNA was no longer detectable, 
indicating normal monkeys become transiently colonized and are able to clear the organism.  
Similar results have been reported in immunocompetent rodents when exposed to 
immunosuppressed rodents with PCP (An et al., 2003; Gigliotti et al., 2003).  
Previously, we showed that SIV-infected macaques are susceptible to Pc infection when 
intrabronchially inoculated with macaque-derived Pc (Board et al., 2003).  Because Pc cannot be 
cultured in vitro, one drawback of earlier studies was the use of Pc derived from BAL fluid 
obtained from SIV-infected monkeys with fulminant PCP for infection initiation.  Although 
inocula were enriched for Pc, introduction of alloantigen and SIV as a component of the Pc 
inocula could not be excluded and increased the likelihood of transient, non-specific 
inflammatory responses.  Additionally, the inoculum used in previous studies was a high dose of 
Pc, which facilitated progression to PCP in these monkeys.  
For these reasons and to investigate the earliest points following Pc colonization, we 
examined natural acquisition of Pc during SIV infection. Pc colonization status was evaluated 
prior to SIV infection, and although nested PCR of BAL was negative for all monkeys, 4 of 5 
monkeys had detectable anti-KEX1 IgG titers ranging from 600 to 1600 (Fig. 2 and 3). Detection 
of anti-KEX1 antibodies in monkeys without detectable PCR products in BAL may reflect prior 
Pc exposure or current colonization below the detectable limit of nested PCR.   To clear potential 
Pc colonization at the start of SIV infection, all monkeys received treatment doses of TMP-SMX 
for 4 months, which resulted in undetectable antibody titers and negative nested PCR of BAL for 
Pc DNA.  Monkeys then continued on a prophylactic dose of TMP-SMX to prevent Pc 
colonization until peripheral blood CD4+ T cells declined to a level predicted to allow 
colonization.   A rise in anti-KEX1 titers subsequently occurred in all SIV-infected monkeys 
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followed by detection of Pc DNA in BAL samples, indicative of newly acquired Pc colonization.  
Interestingly, we observed a serial rise in anti-Pc antibody titers and positive PCR results in some 
animals during the period of TMP-SMX prophylaxis, indicating this regimen did not adequately 
prevent Pc colonization.  These results support human epidemiologic studies that showed the risk 
of Pc colonization was not related to prophylaxis (Huang et al., 2003; Morris et al., 2004a).  
While Pc prophylaxis may reduce organism burden sufficiently to prevent active PCP, the results 
suggest Pc colonization may persist or recur during prophylaxis.  In addition, the serial rise in 
anti-KEX1 titers occurred prior to detection of Pc DNA in BAL, suggesting the serial KEX1 
ELISA is a more sensitive indicator of early Pc colonization in this model.   
These results indicate co-housing of SIV-infected primates is an efficient method to 
establish colonization and will allow us to examine long-term consequences of Pc colonization in 
a model of AIDS.  Development of this model is important because a large number of HIV-
infected persons appear to be colonized with Pc and effects of such colonization are unknown 
(Huang et al., 2003; Morris et al., 2004a).    Given the high rate of seropositivity of normal 
monkeys in this study, it is likely Pc colonization of SIV-infected macaques represents secondary 
exposure and the antibody response is a secondary response rather than a primary response.  This 
is likely the case in HIV-infected subjects, thus this model may be used to address questions 
regarding the effect of HIV on the development and strength of memory responses to 
opportunistic pathogens.  Although antibody responses were predominantly IgG, one monkey 
had an IgM response (Fig. 3-5).  Since this monkey had detectable anti-KEX1 IgG titers at 
baseline, the IgM production may reflect exposure and response to a new Pc strain. 
While all SIV-infected monkeys became colonized with Pc and colonization appeared to 
persist, none developed PCP during the course of this study (>15 months) despite the fact that 
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none of the monkeys received treatment or prophylaxis for Pc after becoming colonized.  These 
results contrast to our previous studies using intrabronchial inoculation of Pc in SIV-infected 
macaques, where most monkeys developed PCP (Board et al., 2003).  This discrepancy may be 
due to the larger inoculum used in previous studies compared to the low level of Pc exposure that 
likely occurs during co-housing.  In addition, it may be that the duration of the study was 
insufficient to allow for development of PCP from low-level colonization.  Others have shown 
development of PCP in SIV-infected, co-housed macaques was associated with duration of SIV 
infection (Vogel et al., 1993).  While Pc colonization was detected at necropsy in monkeys SIV-
infected for less than 2 years, development of PCP was significantly higher in monkeys infected 
between 2 and 4 years (Vogel et al., 1993).  Likewise, our laboratory and others have reported 
development of active PCP in an SIV model (Baskin et al., 1988; Baskerville et al., 1991; Furuta 
et al., 1993; Yanai et al., 1999; Croix et al., 2002; Board et al., 2003), though development of Pc 
colonization in SIV-infected macaques has not been addressed.   
Apparent control of Pc infection in these monkeys might also be due to development of a 
strong IgG response in the majority of monkeys, despite progressive immunosuppression due to 
SIV.  We have previously reported development of an anti-Pc humoral response in SIV-infected 
macaques and ability to undergo immunoglobulin class switching may contribute to control of Pc 
and conversely, a diminished secondary humoral response may be associated with progression to 
PCP (Board et al., 2003).    Although the precise role of antibodies in Pc infection is not well-
defined, experimental immunization studies in rodent models of Pc infection indicate the 
humoral response plays an important role in prevention of PCP (Harmsen et al., 1995; Garvy et 
al., 1997; Gigliotti et al., 1998a; Gigliotti et al., 1998b; Gigliotti et al., 2002; Empey et al., 2004; 
Wells et al., 2006a).  Control of experimental Pc infection can be enhanced by either 
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establishment of a Pc-specific antibody response prior to CD4+ T cell depletion sufficient to 
resolve infection (Harmsen et al., 1995; Garvy et al., 1997; Theus et al., 1998; Pascale et al., 
1999; Zheng et al., 2005; Wells et al., 2006a) or by passive transfer of polyclonal immune sera or 
monoclonal Pc-specific antibodies (Gigliotti et al., 2002; Empey et al., 2004). The immune 
responsiveness of SIV-infected monkeys to Pc colonization is an important finding since it 
suggests that although monkeys are susceptible to Pc colonization during SIV infection, they are 
capable of mounting a strong humoral response even with diminished CD4+ T cell help.  The 
KEX1 ELISA is also useful in distinguishing primary and secondary humoral responses and 
evaluating the role of a secondary response in preventing PCP in SIV-immunosuppressed 
monkeys.   
In summary, we have developed an antibody test for Pc colonization that appears to be 
more sensitive than PCR.  Using this test, we found the majority of immunocompetent monkeys 
have detectable anti-Pc antibody titers and transient Pc colonization occurs in these animals.  
Further, we have established a reliable, efficient model of Pc colonization induced by co-housing 
of monkeys in the setting of AIDS-like immunodeficiency.  Although PCP treatment was able to 
clear colonization, colonization still developed in these animals despite administration of PCP 
prophylaxis.  These studies have direct clinical relevance to HIV-infected patients as Pc-
colonization may occur despite use of Pc prophylaxis and HAART (Morris et al., 2004a).       
 While active PCP has been described in SIV-immunosuppressed monkeys by our 
laboratory (Croix et al., 2002; Board et al., 2003) and others (Baskerville et al., 1991; Furuta et 
al., 1993; Vogel et al., 1993; Yanai et al., 1999), the present model of Pc colonization will be 
useful in studies examining the role of the immune response in development and progression of 
colonization and in examining long-term effects of colonization on the lung.  By defining 
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circumstances associated with early Pc colonization we will be able to address specific questions 
regarding transmission, clearance, susceptibility and clinical consequences of persistence of the 
organisms in an AIDS model.  
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3.1 ABSTRACT 
Pulmonary colonization by the opportunistic pathogen Pneumocystis (Pc) is common in HIV+ 
subjects and has been associated with the development of chronic obstructive pulmonary disease 
(COPD).   Host and environmental factors associated with susceptibility to colonization are 
undefined. Using a simian-human immunodeficiency virus (SHIV) model of HIV infection, 
immunologic parameters associated with natural transmission of Pc colonization were evaluated. 
Two independent experiments were conducted in which SHIV infected macaques were exposed 
to Pc transmission by co-housing with immunosuppressed, Pc colonized macaques.  Serial 
plasma and bronchoalveolar lavage (BAL) fluid samples were examined for changes in anti-Pc 
antibodies titers to recombinant Pc kexin protein (KEX1) and evidence of Pc colonization by 
nested PCR of BAL fluid samples.  In Experiment 1, ten of fourteen monkeys became colonized 
with Pc (Pc+) by 8 weeks post-SHIV infection, while four animals remained Pc-negative (Pc-) 
throughout the duration of the study.  In Experiment 2, eleven of seventeen animals became 
colonized with Pc by 16 weeks post-SHIV infection, while six monkeys remained Pc-.  Baseline 
plasma anti-KEX1 IgG titers were significantly higher in monkeys that did not become Pc-
colonized, compared with Pc-colonized monkeys, in Experiment 1 (p=0.013) and in Experiment 
2 (p=0.022).  Pc-negative monkeys had greater percentages of Pc-specific memory B cells 
following SHIV-infection, compared with Pc-colonized monkeys (p=0.037). SHIV-infected, Pc-
colonized monkeys developed progressive obstructive pulmonary disease, while monkeys 
infected with SHIV alone maintained normal lung function throughout the study.  These results 
support the concept of a protective role for anti-KEX1 humoral response in preventing Pc 
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colonization and the development of obstructive lung disease in the SHIV model.  In addition, 
these results indicate that an effective Pc-specific memory B cell response is maintained despite 
progressive loss of CD4+ T cells during SHIV infection. 
3.2 INTRODUCTION 
Despite the introduction of anti-retroviral therapy (ART) and advances in treatment strategies, 
pulmonary diseases remain a leading cause of morbidity and mortality in HIV infected patients 
(Louie et al., 2002).  Both emphysema and chronic obstructive pulmonary disease (COPD) have 
been reported at an increased frequency in HIV-infected patients (Diaz et al., 2000b; Crothers et 
al., 2006), and unlike many AIDS-associated opportunistic infections, HIV-associated COPD 
may be increasing due to prolonged life expectancy of the HIV+ population with ART, and the 
high smoking rate in this population (Collins et al., 2001; Gritz et al., 2004).  While cigarette 
smoking is a primary risk factor for the development of COPD, it is interesting to note that HIV+ 
non-smokers may also be at increased risk of disease (Diaz et al., 1992).  In addition, the 
observation that most smokers do not develop the COPD (Lokke et al., 2006), indicates that 
other factors may play a role in disease development. 
Evidence has accumulated suggesting a role for infectious agents as co-factors in the 
pathogenesis and exacerbation of COPD (Sethi and Murphy, 2008), where pulmonary 
inflammation due to cigarette smoke may be amplified by the presence of persistent infectious 
agents.  The chronic inflammation associated with infectious agents is also thought to contribute 
to the development of COPD in HIV+ patients (Morris et al., 2008b; Sethi and Murphy, 2008).  
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This possibility is highlighted by the observation that HIV infected patients may be more prone 
to develop subclinical lung infections even if successfully treated with ART (Diaz et al., 2003). 
Our laboratory and others have accumulated evidence in humans and in animal models 
that the fungal opportunistic pathogen, Pneumocystis jirovecii (formerly Pneumocystis carinii f. 
sp. hominis) is an important pathogen in COPD in both HIV+ and HIV- populations.  COPD-like 
changes have been reported in HIV+ patients with Pneumocystis pneumonia (PcP) (Morris et al., 
2000), and recent studies suggest that low level asymptomatic carriage of Pc may be associated 
with lung damage.  An increased frequency of Pc colonization has been reported in HIV+ 
patients, including those on ART (Morris et al., 2004a), and we have recently shown that HIV+ 
subjects that were Pc colonized have worse airway obstruction compared to HIV+ subjects who 
were Pc-negative (Morris et al., 2009).   An association between Pc colonization and COPD has 
also been shown in HIV- subjects (Calderon et al., 1996; Probst et al., 2000; Morris et al., 
2004c).  
Animal models also support the role of Pc colonization in the pathogenesis of COPD.  In 
a model of immunocompetent mice, cigarette exposure and Pc colonization resulted in greater 
pulmonary function deficits compared to cigarette exposure alone (Christensen et al., 2008).  Our 
laboratory has reported that in a simian immunodeficiency virus (SIV)- primate model of HIV 
infection, Pc colonization results in pulmonary inflammation, pulmonary function deficits, and 
anatomic emphysema (Croix et al., 2002; Board et al., 2003; Norris et al., 2006; Shipley, et al., in 
press).  Despite the clear evidence that Pc colonization is associated with development of 
obstructive lung disease, particularly among HIV+ patients, factors the influence susceptibility to 
Pc colonization are not clearly understood. 
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Immunologic control of Pc infection is strongly correlated with CD4+ T cell responses, 
although B cells and antibodies also play a role in prevention of PcP (Harmsen et al., 1995; 
Marcotte et al., 1996; Garvy et al., 1997; Gigliotti et al., 1998a; Gigliotti et al., 1998b; Gigliotti 
et al., 2002; Empey et al., 2004; Wells et al., 2006a).  There is a high frequency of Pc-specific 
seroprevalence in immunocompetent adults (Daly et al., 2002; Bishop and Kovacs, 2003), as 
well as in non-human primates (Demanche et al., 2005; Kling et al., 2009), suggesting the 
persistence of serological memory or Pc-specific, long-lived plasma cells in response to natural 
Pc exposure. Antibodies to the Pc endoprotease kexin (KEX1) may be particularly important, 
because immune responses to Pc KEX1 have been associated with control of Pc
In the current study, we investigated the capacity of simian/human immunodeficiency 
virus (SHIV)-infected macaques to generate a humoral immune response to KEX1 in response to 
natural Pc exposure and examined the relationship between anti-Pc humoral immunity, the 
development of Pc-colonization, and the development of COPD.  
 infection in 
immunosuppressed murine models (Zheng et al., 2005; Wells et al., 2006a). 
3.3 MATERIALS AND METHODS 
3.3.1 Animals.  
Adult, Chinese origin cynomolgus macaques (Macacca fasicularis), weighing between 5-8 kg, 
were used in this study.  All animals were purchased from National Primate Centers or vendors 
approved by the University of Pittsburgh, Department of Laboratory Animal Research.  Prior to 
admission to the study, all animals underwent complete physical examination (pulmonary and 
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cardiac auscultation, thoracic radiographs, computer tomography scanning, tuberculin skin 
testing, complete blood count, chemistry panel, urinalysis, and flow cytometric analysis of 
peripheral blood mononuclear and BAL cells) and were screened for simian retroviruses (SIV, 
SRV, and STLV) to verify that they were free of any pre-existing disease. The animals were 
housed in an American Association for Accreditation of Laboratory Animal Care-accredited, 
biosafety level 2+ primate facility at the University of Pittsburgh.  Animal husbandry and 
experimental procedures were conducted in accordance with standards set forth by the Guide for 
the Care and Use of Laboratory Animals (ref. National Research Council, 1996) 
3.3.2 Study Design.  
and the 
Provisions of the Animal Welfare Act.  Prior to the initiation of this study, all animal 
experiments were approved by the Institutional Animal Care and Use Committee of the 
University of Pittsburgh.   
Two independent experiments were performed using 14 monkeys (Experiment #1) and 17 
monkeys (Experiment #2).  Monkeys were intravenously inoculated with 1x104.9 TCID50 (50% 
tissue culture infectious doses) of SHIV89.6P (gift of Dr. Opendra Narayan, University of 
Kansas), which induces CD4+ T cell lymphopenia and AIDS-like disease with wasting and 
opportunistic infections (Reimann et al., 1996; Pawar et al., 2008).  To facilitate natural 
transmission of Pc, SHIV-infected macaques were continuously exposed by co-housing in the 
same room with 10-20 SIV- or SHIV-immunosuppressed macaques which served as a Pc source 
(Kling et al., 2009).  None of the macaques (source or recipients) contracted acute Pneumocystis 
pneumonia (PcP) during the study. Determination of Pc colonization status was performed by 
detection of Pc DNA in the BAL fluid samples by nested PCR and by anti-Pc KEX1 serology 
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(Board et al., 2003; Kling et al., 2009).  Pc colonization was defined as a positive nested PCR of 
BAL fluid and at least a 3-fold change in plasma anti-Pc KEX1 titers (Board et al., 2003; Kling 
et al., 2009).  Additionally, BAL samples were stained for organisms by modified Geimsa and 
silver staining (Board et al., 2003).  
3.3.3 BAL and blood collection.   
Peripheral blood and BAL samples were collected at baseline on all animals.  Serial 
plasma and PBMC samples from SHIV-infected monkeys were collected weekly for the 
first 8 weeks following SHIV-infection and monthly thereafter.  BAL fluid samples were 
collected monthly.  Samples were collected and processed as described previously (Board 
et al., 2003; Kling et al., 2009).  Briefly, plasma was isolated from 10mL of EDTA 
(ethylenediaminetetraacetic acid)-treated whole blood by centrifugation; PBMC were 
purified over a Percoll gradient (Amersham Bioscience, Piscataway, NJ) and washed 
with sterile phosphate buffered saline (PBS) (Shipley et al., in press).   Plasma aliquots 
were stored at -80°C prior to assay.  PBMC were counted, stained and fixed for analysis 
by flow cytometry.    BAL fluid was processed for cell isolation as previously described 
(Croix et al., 2002; Kling et al., 2009).  Unfractionated BALF aliquots were used for 
bacterial, fungal and viral culture (Antech Diagnostics, Pittsburgh, PA) and PCR 
detection of Pc DNA.  Remaining fluid was filtered through a 40-micron cell strainer and 
manual cell counts were performed using a hemocytometer.  1 x 105 cells were removed 
and stained with modified Giemsa stain (Dade Behring, Newark, DE) and differential 
counts performed manually (Croix et al., 2002).  Remaining cells were pelleted and 
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supernatant fluid was collected and stored at -80°C.  Recovered cells were prepared for 
flow cytometry as described (Croix et al., 2002; Board et al., 2003). 
3.3.4 Endpoint antibody titer determination.   
A partial fragment of the macaque-derived, Pc kexin gene in the pBAD expression vector (gift 
from C.G. Haidaris, University of Rochester) (Kling et al., 2009) was used to produce 
recombinant kexin for ELISA.  ELISA was performed as previously described (Kling et al., 
2009).  Plasma and BAL fluid supernatant were heat inactivated (56°C, 30 min) prior to use in 
ELISA for detection of Pc-specific antibodies.  BAL fluid samples were normalized based on 
plasma urea concentration (Rennard et al., 1986). Microtiter plates (Immunolon 4HBX, Thermo 
Fisher Scientific, Inc., Waltham, MA) were coated with purified KEX1 at 5 µg/ml in Na2CO3, 
(pH 9.5).  Heat-inactivated plasma samples were diluted 1:100 in blocking buffer (PBS with 5% 
non-fat milk).  BAL fluid supernatant samples were diluted according to normalized 
concentrations in PBS.  Fifty µL of diluted plasma or BAL fluid supernatant were plated into 
KEX1-coated wells and serial dilutions were made to determine endpoint titers.  Goat anti-
monkey immunoglobulin-conjugated horseradish peroxidase (1:10,000 for IgG, 1:2000 for IgM) 
(Nordic Immunology, Tilburg, the Netherlands) was used for detection and plates were 
developed by standard methods. Normal (uninfected, Pc-negative by antibody titer) macaque 
plasma or BAL fluid supernatant was used as negative control and sample from a monkey with 
PCP was used for positive control.  The reciprocal endpoint titer was calculated as the highest 
dilution at which the optical density (O.D.) values for the test sample were the same or less than 
the normal sample O.D.   
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3.3.5 Nested PCR of BAL fluid.   
BAL fluid cell lysate samples were analyzed for the presence of Pc DNA by nested PCR of the 
mitochondrial large subunit ribosomal RNA gene (mtLSU), as described (Board et al., 2003; 
Patil et al., 2003).  Nested PCR was performed on 5 μl of the first round product using primers 
P1 and P2 (Savoia et al., 1997).   PCR fo r β-globin was also performed on BAL samples to 
control for DNA quality (Croix et al., 2002). 
3.3.6 Flow Cytometry.   
Stained, fixed cells from whole blood and BAL fluid were analyzed by flow cytometry (Croix et 
al., 2002).  The following antibodies were used: mouse anti-monkey CD3-fluorescein 
isothiocyanate (clone SP34), mouse anti-human CD8-Pacific Blue (clone RPA-T8) and mouse 
anti-monkey CD4-allophycocyanin (clone L200), all purchased from BD Pharmingen (San 
Diego, CA).  Acquisition was performed on BD LSRII flow cytometer using BD FacsDiva 
software.  Forward/side scatter dot plot was used to gate the live lymphocyte population.  All 
analyses were performed using FlowJo flow cytometry analysis software (Tree Star Inc., 
Ashland, OR).   
3.3.7 Plasma SHIV viral load determination.  
Virus loads in plasma and BAL fluid supernatant were determined as described elsewhere 
(Pawar et al., 2008).  Briefly, RNA was extracted from plasma and BAL fluid supernatant and 
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was quantified as RNA copies per ml using an adapted protocol for quantitative real-time reverse 
transcriptase PCR detecting the SIV gag sequence. 
3.3.8 Determination of SHIV-antibody titers.   
Anti-Gag antibody titers were measured by ELISA in serial plasma samples.  Samples were 
assayed as described elsewhere (Pawar et al., 2008) for antibody response to SIV core Gag 
protein.  Briefly, ELISA plates were coated with detergent-disrupted SIV-B7, washed and 
blocked.  Serial dilutions of monkey plasma were made to determine endpoint titers.  Anti-Gag 
IgG atibodies were detected using anti-monkey IgG-HRP and TM blue substrate.  Reactions 
were stopped with 1N sulfuric acid. 
3.3.9 Enzyme-linked Immunospot (ELISPOT) assay for quantification of IgG- and 
KEX1-specific antibody secreting cells (ASC).   
For detection of plasma cells, freshly-isolated PBMC were assayed directly ex vivo.  ASC 
ELISPOT assays were adapted from a protocol published elsewhere (Crotty et al., 2004).  
Briefly, ELISPOT plates (non-sterile MultiScreen IP HTS plates, Milllipore Billerica, MA) were 
coated with either purified recombinant kexin protein (KEX1) (5μg/mL), Keyhole limpet 
hemocyanin (Pierce Imject mcKLH, Thermo-Scientifc, Rockford, IL) (2.5μg/mL), or affinity 
purified anti-monkey IgG (5μg/mL, Rockland, Inc., Gilbertsville, PA) at 4°C overnight.  Plates 
were washed with PBS + 0.05% Tween-20 (PBS-T) (1x) and PBS (3x) then blocked in complete 
R-10 for at least 2 hours at 37°C, 5% CO2.  Blocking media was removed and 1x106 PBMC 
were added in duplicate wells of the coated plates, and serial 3-fold dilutions were made in the 
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plate.  PBMC were incubated at 37°C, 5% CO2 overnight, and then cells were washed away with 
PBS and PBS-T (4x each).  For detection, biotin-conjugated secondary antibody (50μL per well, 
Rockland Inc.) was then added, diluted at 1:1000 in PBS-T + 10% FBS, and plates were 
incubated overnight at 4°C.  Plates were removed, washed with PBS-T (5x), and 50μL of 
streptavidin-horseradish peroxidase (BD Biosciences, San Diego, CA) diluted 1:1000 in PBS-T 
+ 10% FBS was added to each well, followed by incubation for 60 minutes at room temperature.  
Plates were washed and then developed with AEC substrate (BD Biosciences, San Diego, CA) 
(50μL per well) in the dark for 8-15 min at room temperature.  Plates were washed with water 
and then air-dried overnight while protected from light exposure.   Plate images were acquired 
using Immunospot CTL plate reader (CTL Technologies Limited, Shaker Heights, OH) and 
Image Acquisition 4.5 software (CTL Technologies Ltd.).  Spots were enumerated using 
Immunospot 5.0 Professional software (CTL Technologies Ltd.).  KEX1-specific plasma cells 
are reported as ASC (number of spots) per 1x106
3.3.10 Memory B cell ELISPOT.   
 PBMC.   
PBMC from animals in Experiment #2 were assayed following 6-7 day stimulation, as reported 
elsewhere (Crotty et al., 2004).  Briefly, cells were freshly isolated from whole blood and 
washed with PBS.  Cells were cultured in complete GIBCO RPMI-1640 (Invitrogen, Carlsbad, 
CA) supplemented with 10% FBS and Pen/Strep (R-10) in 24-well plates at a concentration of 
0.5 x 106 cells per well with the following: 1:10,000 Staphylococcus aureus protein A Cowan 
strain (SAC, Sigma-Aldrich, St. Louis, MO), Phytolacca americana pokeweed mitogen (PWM 
Emory Stock, gift from S. Crotty), and 2μg/mL CpG ODN 2006 (5’-
TCGTCGTTTTGTCGTTTTGTCGTT-3’; Oligos, Etc., Wilsonville, OR).  Cells were expanded 
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in culture for 6-7 days (37°C, 5% CO2
 
) to induce differentiation into plasma cells, washed with 
R-10, then assayed by ELISPOT for IgG- and KEX1-specific secreting cells, as described above.   
KEX1-specific memory B cells are expressed as a percentage of total IgG-secreting cells.  
PBMC were evaluated for KEX1-specific memory cells at approximately 9-12 months post-
SHIV infection.   
3.3.11 Pulmonary Function Testing.   
To assess airflow obstruction, pulmonary function tests (PFT) were performed at baseline and 
every other month after SHIV infection using whole body plethysmography (Proskocil et al., 
2005) and forced deflation technique (Shipley et al., in press).  Intravenous propofol (7.5-12.5 
mg/kg body weight) was used to anesthetize monkeys, and 2% lidocaine was given prior to 
intubation (3.5 mm endotracheal tube) to desensitize the oropharynx.  Chest radiograph was 
performed to verify endotracheal tube placement, which was monitored using a disposable CO2
For bronchodilator challenge, standard PFTs were performed, followed by 
administration of one pediatric dosette of nebulized albuterol (3 ml of 0.083% albuterol 
for a total dosage of 2.5 mg) (Nephron Pharmaceuticals Corp., Orlando, FL).  Fifteen 
minutes after administration, PFTs were repeated and compared to baseline values. 
 
detector (Nellcor Pedi-cap, Boulder, CO).  Pulmonary function testing was performed using a 
Buxco whole body plethysmograph (Buxco Electronics, Inc., Sharon, CT), and data on flow rates 
and volumes were collected using the BioSystems for Maneuvers Software (Buxco Electronics, 
Inc.). Tests were considered valid when three measurements for forced vital capacity (FVC) 
were within 10% of each other. 
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3.3.12 Statistical Analyses.   
Statistical analyses for both Experiments #1 and #2 were performed using Prism software or 
InStat software, both by GraphPad (La Jolla, CA).  Unpaired two-tailed Student’s t-test was used 
to compare Pc+ and Pc- monkeys, unless otherwise noted.  Paired two-tailed student’s t-test was 
used to compare different time-points with baseline values.  When comparing Pc+ and Pc- 
monkeys over multiple time-points, two-way repeated measures ANOVA was used for 
comparison.  A p value of less than 0.05 was considered significant. 
3.4 RESULTS 
3.4.1 Natural Pc Colonization of SHIV-infected macaques.   
Prior to SHIV-infection, macaques were determined to be negative for Pc colonization by nested 
PCR of BAL fluid. Baseline anti-Pc KEX1 plasma IgG reciprocal endpoint titers ranged from 
undetectable (<1:100) to 1:12,800 in macaques in Experiment 1 and undetectable to 1:22,400 in 
macaques in Experiment 2.  In Experiment #1, 10 of 14 monkeys became naturally colonized 
with Pc (Pc+) by 8 weeks post-SHIV infection, while 4 monkeys remained Pc-negative (Pc-) 
throughout the study (53 weeks).  In Experiment #2, 11 of 17 SHIV-infected monkeys became 
naturally colonized with Pc by 16 weeks post-SHIV infection, while six monkeys remained Pc- 
for the duration of the experiment (58 weeks). 
In both Experiments 1 and 2, rapid declines in peripheral blood CD4+ T cells were 
observed within 2 to 4 weeks following SHIV-infection (Fig 6A, D). There was no difference 
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between Pc+ and Pc- monkeys in mean CD4+ T cell numbers during SHIV infection in 
Experiment 1 (p=0.488, 2-way repeated measures ANOVA) or in Experiment 2 (p=0.326, 2-way 
repeated measures ANOVA).  Additionally, peak plasma viral titers were similar between Pc+ 
and Pc- monkeys in both Experiment 1 (p = 0.749, Fig 6B) and Experiment 2 (p=0.595, Fig 6E).    
No significant differences in anti-Gag antibody responses were observed in Pc+ and Pc- animals 
(p=0.419, Fig 6C), indicating that susceptibility to Pc colonization was not a result of a 
generalized humoral defect in the monkeys that became Pc-colonized or more severe 
immunosuppression. 
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Figure 6.  CD4+ T cell counts, peak plasma viral loads, and gag antibody responses were 
not significantly different between Pc-colonized and Pc-negative monkeys.  No significant 
difference in mean CD4+ T cell counts in peripheral blood of Pc+ and Pc- monkeys in either 
Experiment 1 (p=0.488, 2-way ANOVA) (A) or Experiment 2 (p=0.326, D) were observed.   
Peak plasma viral titers were also similar between Pc+ and Pc- monkeys in both Experiment 1 (p 
= 0.749, B) and 2 (p=0.595, E).  Pc+ and Pc- monkeys produced similar antibody responses to 
SHIV gag protein (p=0.419, 2-way ANOVA) (C).   
3.4.2 Anti-KEX1 antibodies and KEX1-specific antibody secreting cells at baseline 
correlate with protection from Pneumocystis colonization.   
Baseline anti-KEX1 endpoint titers were compared between macaques that became naturally Pc-
colonized and those that remained Pc-negative post-SHIV infection.  Baseline plasma KEX1 IgG 
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antibody titers were significantly higher in monkeys that did not become Pc-colonized, compared 
with Pc-colonized monkeys in both Experiments 1 (p=0.013, Fig 7A) and 2 (p=0.022, Fig 7B).  
These data suggest that a low KEX1-antibody titer prior to immunosuppression predicts 
susceptibility to Pc colonization, and that conversely, a high KEX1 titer at baseline correlates 
with protection.  Baseline KEX1-IgG reciprocal endpoint titer (RET) of less than 10,000 was 
associated with Pc-colonization following immunosuppression (p=0.011, Fisher’s exact test, Fig 
7C).  PBMC were examined for KEX1-specific antibody secreting cells by plasma cell 
ELISPOT, and a similar trend was observed. Pc- animals had significantly greater numbers of 
KEX1-specific antibody secreting cells at baseline than did animals that became Pc-colonized 
following SHIV infection (p=0.018, Fig 7D). 
Representative longitudinal profiles of Pc anti-KEX1 antibody production, peripheral 
blood CD4+ T cells numbers, and nested PCR results are shown in Figure 8.  Macaques with a 
low baseline anti-KEX1 titer (<1:4000) exhibited evidence of Pc colonization generally by 8-12 
weeks post-SHIV inoculation (Fig 8A).  These animals had increases in anti-KEX1 titers of at 
least three-fold over baseline, generally by 3-4 weeks post-SHIV infection.  The rise in anti-
KEX1 titers was followed by nested-PCR detection of Pc DNA in the BAL fluid, approximately 
5-12 weeks later (Fig 8A, and data not shown).  Macaques with high baseline anti-KEX1 titers 
(≥1:10,691), however, maintained a high titer throughout infection, but did not exhibit either a 3-
fold increase over baseline titer or a positive nested PCR for Pc, which would indicate active 
colonization (Fig 8B).     
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Figure 7.  Baseline plasma anti-KEX1 IgG reciprocal endpoint titer and numbers of KEX-
specific antibody secreting cells (ASC) predict Pneumocystis colonization following SHIV-
immunosuppression.  Comparative analysis of baseline anti-KEX1 IgG titers between monkeys 
that became colonized following SHIV-infection and monkeys that remained Pc-negative.  
Monkeys that remained Pc-negative had significantly higher baseline KEX-titers than monkeys 
that remained Pc-colonized in Experiment 1 (A), with similar results in Experiment 2 (B).  Panel 
C indicates the numbers of macaques in the combined set of both experimental groups with 
baseline KEX1-IgG titers of less than and greater than 10,000 that became Pc-colonized 
following SHIV-infection.  These data demonstrate that monkeys with a baseline KEX1-IgG 
reciprocal endpoint titer of less than 10,000 are significantly more likely to become Pc-colonized 
following immunosuppression than those with a titer of greater than 10,000 (C, p=0.011, Fisher’s 
Exact Test).  A subset of baseline samples from Experiment 1 was examined for KEX1-specific 
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ASC (D).  Monkeys that that remained Pc-negative also had higher numbers of KEX1-specific 
ASC at baseline than monkeys that became Pc-colonized (p=0.018). 
 
 
 
Figure 8.  Representative KEX1-antibody production and CD4+ T cell profiles of a 
macaque with low baseline KEX1 titer (A) and a macaque with a comparably higher 
baseline KEX1-titer (B).  Macaques with a low baseline anti-KEX1 titer exhibited evidence of 
Pc colonization quickly after SHIV-infection (A).  These animals demonstrated increases of at 
least 3-fold over baseline anti-KEX1 titer, by 3-4 weeks post-SHIV infection, which was 
followed by nested PCR detection of Pc DNA in the BAL fluid, approximately 5-12 weeks later 
(A, and data not shown).Macaques with high baseline anti-KEX1 titers, however, maintained a 
high titer throughout infection, suggesting exposure to Pc, but did not exhibit either a 3-fold 
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increase over baseline titer or a positive nested PCR for Pc (B), and were therefore considered 
Pc-negative 
 
3.4.3 Earlier detection of anti-KEX1 antibodies in the BAL fluid supernatant correlates 
with protection from Pc colonization.   
To determine whether KEX1-specific antibodies could be detected in the BAL fluid supernatant 
and to evaluate the possible role of KEX1-specific antibodies in promoting protection from Pc 
colonization, BAL fluid supernatant anti-KEX1 titers were determined. (Fig 9). There was a 
significant positive correlation between baseline plasma anti-KEX1 IgG and peak BAL fluid IgA 
titer following SHIV-infection (Fig 9A, p=0.043, R2=0.279).   In addition, the kinetics of a class-
switched anti-KEX1 response was examined.  Earlier production of KEX1-specific IgA was 
observed in monkeys that resisted Pc-colonization (Fig. 9B, p=0.041, Fisher’s exact test).  
Monkeys in which Pc KEX1-specific IgA antibodies were detectable in the BAL fluid by 4 
weeks post-SHIV infection were less likely to become Pc colonized than monkeys that were not 
making Pc-specific IgA by this time-point (Fig 9B).  The timing (detection post-SHIV infection) 
and levels of KEX1-specific IgG or IgM production in BAL was not significantly different 
between Pc+ and Pc- monkeys (data not shown).   
 72 
 
 
Figure 9. KEX1-IgA production in the BAL fluid.  Baseline plasma KEX1-IgG titers 
positively correlate with peak KEX1-IgA titers in the BAL fluid (A, p=0.043).  Seventy-five 
percent of Pc- macaques were producing KEX1-IgA in the BAL fluid by week 4 post-SHIV 
infection, compared with only 10 percent of Pc-colonized macaques that were production KEX1-
IgA by this time-point (B, p=0.041, Fisher’s Exact Test). 
 
3.4.4 KEX1-specific memory response correlates with protection from Pc-colonization.   
In Experiment 2, PBMC were evaluated to assess the Pc-specific memory response in SHIV-
infected monkeys.  PBMC were evaluated at approximately 9-12 months post-SHIV infection; 
Pc- monkeys had significantly higher percentages of KEX1-specific memory B cells than Pc+ 
monkeys (Fig 10).  These results suggest that a stronger Pc-specific memory response persists 
during SHIV infection and correlates with protection from natural Pc-colonization in 
immunosuppressed macaques.   
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Figure 10. Percentages of peripheral blood KEX1-specific memory B cells were 
significantly higher in Pc- monkeys than in Pc+ monkeys (p=0.037).  PBMC from macaques 
in Experimental group #2 were isolated at 9-12 months post-SHIV infection and stimulated in 
culture for 6-7 days and assayed by B cell ELISpots for total IgG and KEX1-specific IgG-
secreting cells.  KEX1-specific cells are expressed as a percentage of total IgG-secreting cells. 
Mean percentages of KEX1-specific memory cells for Pc- monkeys were significantly higher 
than for Pc+ monkeys (p=0.037, Student’s t-test).   
3.4.5 Pc-colonized monkeys exhibit evidence of pulmonary obstruction.   
Previous studies have shown an association between persistent Pc colonization and 
COPD in HIV and non-HIV infected human subjects and in animal models (Morris et al., 
2004c; Morris et al., 2008a; Morris et al., 2009); Shipley et al, in press).  We therefore 
investigated whether Pc colonization correlated with preserved lung function in long-term 
SHIV-infected macaques.   Pulmonary function tests were performed at baseline and at 1-
2 month intervals, up to 50 weeks post-SHIV infection.  Declines in peak expiratory flow 
 74 
(PEF) and forced expiratory volume in 0.4 seconds (FEV0.4) were evaluated to assess 
progression of airway obstruction.  Declines in these parameters are indicative of 
obstructive disease. 
In Experiment 1, 6 of 8 Pc+ monkeys demonstrated significant decreases in PEF 
and FEV0.4 from baseline, whereas no significant declines from baseline were observed in 
Pc- monkeys (Fig. 11A, B).  PEF in Pc+ monkeys declined from 526.8 ml/s at baseline to 
452.9ml/s at study endpoint (p=0.020), compared with Pc- monkeys who did not exhibit 
a significant change from baseline (p=0.854).  Pc+ monkeys declined significantly in 
FEV0.4
In Experiment 2, Pc+ monkeys also showed significant declines in pulmonary 
function parameters from baseline levels.  From baseline to 10 months post-SHIV 
infection, Pc+ monkeys declined from a mean PEF of 555.3mL/s to 484.4mL/s 
(p=0.002), while Pc- monkeys did not decline significantly from baseline (p=0.320, Fig 
11C).  FEV0.4 values exhibited a similar trend, with a mean of 198.1mL at baseline to 
173.0mL at 10 months post-SHIV infection for the Pc+ monkeys (p=0.002, Fig 11D).  
Again, no significant changes were observed for the Pc- group of animals (p=0.122, Fig 
11D). 
, from a mean of 188.6mL at baseline to 165.8mL at 10 months post-SHIV 
infection (p=0.023), whereas Pc- monkeys did not exhibit significant declines in FEV0.4  
(Fig 11B).   
We also examined whether administration of the bronchodilator, albuterol, 
affected pulmonary function because airflow limitation associated with COPD is poorly 
reversible in response to bronchodilator treatment.  No significant differences were 
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observed for either group in any pulmonary function measurement post-treatment (data 
not shown).   
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Figure 11. Pc-colonization of immunosuppressed monkeys results in pulmonary 
obstruction, as measured by pulmonary function testing.  Pulmonary function 
parameters were measured using whole body plethysmography (Proskocil et al., 2005) at 
baseline and serially every one (Experiment 2) or two (Experiment 1) months following 
SHIV-infection, and changes were analyzed according to Pc colonization status.  PEF 
(peak expiratory flow) and FEV0.4 
 
(forced expiratory volume in 0.4 seconds) are 
measures used to evaluate airway obstruction.  Pulmonary function test values for Pc+ 
and Pc- animals in both Experiment 1 (A, B) and Experiment 2 (D, E) were compared by 
paired Student’s T-test from baseline to 10 months post-SHIV infection.  Significant 
declines from baseline occurred in the Pc+ group, but not in the Pc- group of animals.  
Corresponding p-values for each comparison are given in each panel. 
3.4.6 KEX1-specific antibody production is associated with protection from pulmonary 
function decline.   
To investigate whether there was an association between KEX1 titers at baseline and protection 
from pulmonary function decline, we examined baseline KEX1-IgG RET in the combined data 
set from animals in Experiments 1 and 2.  We found animals that exhibited at least a 12 percent 
decline in PEF had a significantly lower baseline KEX1-IgG titer than animals that did not 
exhibit this decline (p=0.021).  The timing of the KEX1-IgA response in the BAL fluid was also 
examined for correlation with protection from pulmonary function decline.  Monkeys that 
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produced KEX1-IgA later than 4 weeks post-SHIV infection exhibited a greater decline in PEF 
(average decline of 12 +/- 4.3 percent), compared with monkeys that were producing KEX1-IgA 
by week 4 (on average, no significant decline, Fig 12B).  Although this association did not reach 
statistical significance (p=0.062), the trend suggests that earlier production of KEX1-IgA in the 
BAL fluid may be associated with protection from pulmonary damage. 
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Figure 12. KEX1-specific antibody production is associated with protection from 
pulmonary function decline.  In the combined data set from animals in Experiments 1 and 2,  
animals that exhibited at least a 12% decline (clinically significant decline in pulmonary function 
(ref) in peak expiratory flow (PEF), following immunosuppression and subsequent Pc-exposure, 
had a mean baseline KEX1-IgG titer of 4,405, while animals that did not exhibit this decline 
exhibited a mean baseline KEX1-IgG RET of 9,650 (A, p=0.021).  In Experiment 1, timing of 
the KEX1-IgA response in the BAL fluid was examined for correlation with pulmonary function 
decline.  Monkeys that produced KEX1-IgA later than 4 weeks post-SHIV infection exhibited a 
greater decline in PEF (mean change in PEF = 12% decrease from baseline), compared with 
monkeys that were producing KEX1-IgA by week 4 (mean change in PEF = 1% increase, B).  
This association did not reach statistical significance (p=0.062); however, the trend suggests that 
earlier production of KEX1-IgA in the BAL fluid may be associated with protection from 
pulmonary damage. 
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3.5 DISCUSSION 
SIV and SHIV infection of macaques are valuable models of HIV infection (Li et al., 1992; 
Dunn et al., 1996; Reimann et al., 1996; Joag, 2000) and of HIV-associated opportunistic 
infection (Croix et al., 2002; Board et al., 2003; Pawar et al., 2008; Kling et al., 2009).  We have 
previously used SIV and SHIV models to characterize natural transmission and persistence of Pc 
colonization (Kling et al., 2009; Shipley et al., in press).  In previous studies, persistent Pc 
colonization of SHIV-infected macaques was associated with inflammatory responses in the 
lungs and the development of COPD-like changes in lung function (Norris et al., 2006; Shipley 
et al., in press).  In the present study, we used a SHIV model to 1) determine the relationship 
between baseline anti-KEX1 antibody titers, susceptibility to Pc colonization and the 
development of COPD and, 2) to test the hypothesis that an effective, Pc-KEX1-specific, B cell 
response is maintained despite persistent SHIV-induced immunosuppression. 
 In this study, we showed that higher baseline anti-KEX1 titers and higher numbers of 
KEX1-specific ASC prior to immunosuppression correlated with prevention or delay of Pc 
colonization following SHIV-immunosuppression.  Furthermore, high plasma anti-KEX1 titers 
at the time of SHIV infection correlated with improved kinetics and increased magnitude of a 
KEX1-specific IgA levels in the lung, upon Pc exposure. Macaques with a high baseline anti-
KEX1 IgG response maintained this response throughout SHIV infection and remained free from 
detectable Pc colonization.  Differences in susceptibility to Pc colonization were not due to lack 
of environmental exposure to Pc, as all monkeys were housed together for the duration of the 
experiments, but only monkeys with lower baseline anti-KEX1 titers became Pc colonized.  The 
failure of monkeys with low anti-KEX1 baseline titers to prevent Pc colonization was not due to 
a more severe SHIV infection or greater loss of CD4+ T cells as indicated by the finding that 
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both groups (Pc+ and Pc-) had similar viral loads, CD4+ T cell counts and antibody titers to the 
SHIV protein, Gag throughout the study. 
These results support the findings of previous studies that have shown the importance of 
Pc-specific humoral responses in murine models of PcP (Harmsen et al., 1995; Garvy et al., 
1997; Gigliotti et al., 1998a; Gigliotti et al., 2002; Empey et al., 2004; Wells et al., 2006a).  In 
the experimental mouse model of infection, passive transfer of immune sera or monoclonal Pc-
specific antibodies affords protection (Gigliotti et al., 2002; Empey et al., 2004).  Additionally, 
experimental immunization with Pc organisms/antigens of mice prior to T-cell depletion results 
in high levels of specific antibody production and clearance of Pc organisms following challenge 
(Garvy et al., 1997; Theus et al., 1998; Pascale et al., 1999).  Murine studies have also provided 
evidence of the protective capacity of Pc-kexin (Gigliotti et al., 1998a; Zheng et al., 2005; Wells 
et al., 2006a).   
The current study extends this knowledge by demonstrating that Pc-KEX1 antibody 
responses were important in preventing or resolving Pc colonization in a highly-relevant non-
human primate model of Pc transmission and HIV infection (Li et al., 1992; Dunn et al., 1996; 
Reimann et al., 1996; Pawar et al., 2008).   These results are consistent with previous findings 
that SIV-infected macaques with high Pc-specific antibody titers prior to intrabronchial 
inoculation with Pc organisms were less likely to develop PcP compared to animals with lower 
antibody responses prior to Pc inoculation (Board et al., 2003).   
In addition to predicting resistance to Pc colonization, high baseline anti-KEX1 plasma 
IgG titers were associated with higher levels and earlier detection of specific IgA in the lungs of 
Pc- monkeys..  These results support the concept of a role for IgA-mediated protection from Pc 
colonization, and are consistent with clinical studies that showed mucosal antibodies to Pc are 
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decreased in patients with PCP, compared with HIV+ patients without PCP or with HIV-
negative controls (Laursen et al., 1994; Jalil et al., 2000).  
 In addition to the association of baseline KEX1 antibodies and ASC with protection from 
Pc colonization, we also determined that Pc- animals maintained a significantly higher KEX1-
specific B cell memory response compared with animals that became Pc colonized. Murine 
models of Pc infection have demonstrated the importance of B cells in controlling Pc infection, 
as it has been shown that B cell-deficient mice are highly susceptible to PcP (Marcotte et al., 
1996), and other studies have demonstrated that antibody-independent B cell effector functions 
may be important in control of Pc infection (Lund et al., 2003; Lund et al., 2006).  Our results 
correlating baseline KEX1-specific antibody titers, ASC and persistence of antigen-specific 
memory cells to prevention of Pc colonization highlight the importance of a robust memory 
response to KEX1 during SHIV infection and identify low baseline KEX1 B cell response as a 
predictor of susceptibility to Pc infection during SHIV infection.   
Several studies of HIV+ patients report B cell functional deficits and abnormalities that 
may contribute to poor responses to antigenic stimulation, and result in their diminished vaccine 
responsiveness and increased susceptibility of opportunistic infections (De Milito, 2004; 
Malaspina et al., 2005; Titanji et al., 2006; Jiang et al., 2008; Moir and Fauci, 2009). The 
diminished humoral responses in HIV-infected individuals upon vaccination with carbohydrate 
antigens and T-independent antigens, such as the pneumococcal vaccine, may be due to a deficit 
in a particular subset of memory B cells, such as IgM memory cells (Hart et al., 2007) or splenic 
marginal zone-like peripheral blood populations (Morrow et al., 2008), whereas memory 
responses to other types of antigens have not been thoroughly investigated. Recent studies from 
our laboratory suggest similar phenotypic alterations occur during SHIV-infection as have been 
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reported in HIV+ patients, such as a decrease in total and memory B cells, significantly increased 
percentages of activated B cells, reduced percentages of CD21+ B cells, and a significant 
reduction in the percentages of IgM memory B cells (Kling et al., in preparation; see Chapter 4).  
These results support the use of the SHIV-macaque model to investigate HIV-related B cell 
dysfunctions. 
Several studies of HIV+ patients focus on recall responses to antigens or pathogens 
against which study participants have been vaccinated (Malaspina et al., 2005; Titanji et al., 
2006), or to antigens that they are not likely to be naturally exposed (i.e., tetanus toxoid) (De 
Milito et al., 2004; Hart et al., 2007). The current study explores humoral responses to a 
naturally-acquired, ubiquitous organism to which most humans (Peglow et al., 1990; Daly et al., 
2002; Morris et al., 2008a) and non-human primates (Dei-Cas et al., 1998; Kling et al., 2009) 
have been continuously exposed before and after HIV or SHIV-infection. The maintenance of 
the Pc-KEX1-specific antibody responses and B cell memory during SHIV-induced 
immunosuppression in monkeys that had high Pc humoral immunity pre-infection, suggests that 
responses to this antigen were not significantly affected by SHIV-infection. Thus, Pc-KEX1 is a 
potential model antigen for longitudinal analysis of the preservation of functional humoral 
responses in patients with defects in CD4+ T cell numbers, due to lentivirus infection or other 
immunosuppressive states (Duchini et al., 2003).    
We further investigated the potential clinical consequence of persistent Pc colonization 
and the role of a humoral response to Pc in prevention of pulmonary damage.  It has been 
postulated that persistent microbial colonization may be involved in perpetuating the 
inflammatory response, eventually leading to tissue destruction, airway thickening and clinical 
COPD (Sethi and Murphy, 2008).  HIV+ patients are at increased risk for Pc colonization 
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(Morris et al., 2004a) as well as an accelerated form of emphysema (Diaz et al., 2000b), and 
additional evidence suggests a role for Pc colonization in development of COPD in HIV-
negative patients (Calderon et al., 1996; Probst et al., 2000).  In HIV+ subjects, the prevalence of 
Pc colonization is high and occurs even in patients with high CD4+ T cells counts on ART 
(Morris et al., 2009).  Recently, Morris et al. demonstrated a link between Pc colonization and 
airway obstruction in HIV+ patients, and those who were colonized had a significantly lower 
spirometric values compared to non-colonized subjects (Morris et al., 2009).  These results 
demonstrate a link between Pc colonization and airway obstruction in HIV.  The longitudinal 
study of pulmonary function in SHIV-infected macaques presented here support these findings as 
well as confirm our previous studies proposing a role for Pc colonization and COPD 
development in the SHIV model (Norris et al., 2006; Shipley et al., in press).  The current study 
extends these findings by identifying an association between baseline anti-KEX1 antibody titers 
and susceptibility to Pc colonization and development of COPD.  These results are also 
consistent with our previous findings that showed a correlation between low KEX1 titers and 
COPD in non-HIV infected smokers (Morris et al., 2008a).  In addition, preliminary studies from 
our group also show that low KEX1 antibody levels are associated with subsequent development 
PcP in HIV+ subjects (Gingo, M. et al., submitted). Results from the current study in 
combination with previously published reports suggest that vaccination for the prevention of Pc 
colonization and development of obstructive lung disease may be feasible in humans.  
In summary, these results support the concept that Pc-specific humoral immunity 
established prior to immunosuppression is associated with improved resistance to subsequent Pc 
colonization and pulmonary obstruction, despite declining CD4+ T cell numbers.  These data 
further suggest that the humoral effector mechanisms responsible for this protection include high 
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levels of circulating KEX1-specific IgG, KEX1-specific IgA present in the lung, and the 
maintenance of a KEX1-specific memory B cell pool following immunosuppression,.  These 
results underscore the importance of a Pc-specific humoral response resistance to Pc colonization 
and prevention of pulmonary damage and support the feasibility of a Pc-KEX1 vaccine strategy 
for protection of high risk populations.    
3.6 AUTHOR CONTRIBUTIONS AND ACKNOWLEDGEMENTS 
Heather M. Kling (Molecular Virology and Microbiology Graduate Program, University of 
Pittsburgh School of Medicine) generated the majority of the data and prepared the manuscript.  
Timothy W. Shipley (Immunology Graduate Program, University of Pittsburgh School of 
Medicine) provided assistance with sample processing and analysis, especially with regard to 
pulmonary function testing and data analysis.  Sangita Patil (Department of Immunology, 
University of Pittsburgh School of Medicine) provided assistance with sample processing and 
analysis, and assisted with generation of PCR and flow cytometry data.  Jan Kristoff 
(Department of Immunology, University of Pittsburgh School of Medicine) provided assistance 
with sample processing, collection of flow cytometry data, and generation of PCR data.  
Marianne Bryan (Immunology Graduate Program, University of Pittsburgh School of Medicine) 
and Alison Morris (Division of Pulmonary, Allergy, and Critical Care Medicine, University of 
Pittsburgh) assisted with providing insight and critique of the project and the manuscript.  Karen 
A. Norris (Department of Immunology, University of Pittsburgh School of Medicine), as the 
mentor and principal investigator on the project, provided extensive scientific knowledge, insight 
and critique of the project and the manuscript.  Ronald C. Montelaro (Department of 
 85 
Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine) provided 
the virus used for experimental inoculation of animals.  All authors, especially Karen A. Norris, 
contributed to scientific discussion regarding the project and critical reading and editing of the 
manuscript. 
The authors would like to thank Chris Janssen, D.V.M, Ph.D. and Nicole Banichar, 
C.V.T. for excellent veterinary care.  Funding for these experiments was provided by the 
National Institutes of Health grants HL077095-01A1 and HL077914-01 (KAN), and National 
Institutes of Health training grant T32 AI49820 (HMK). 
 
 86 
4.0  SHIV-INFECTED CYNOMOLGUS MACAQUES EXHIBIT ABNORMALITIES 
IN PERIPHERAL BLOOD B-CELL POPULATIONS 
Portions of this chapter are being prepared for submission to an academic journal.  The authors 
are Heather M. Kling, Timothy W. Shipley, and Karen A. Norris. 
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4.1 ABSTRACT 
In addition to CD4+ T cell depletion, abnormalities in the B cell compartment of HIV-infected 
individuals are also reported, including deficits and diminished responses to ex vivo antigenic 
stimulation and in vivo vaccination.  In the current study we used chimeric Simian-Human 
Immunodeficiency Virus (SHIV)-infection of cynomolgus macaques to investigate phenotypic 
changes in peripheral blood B cell populations.   We observed similar alterations in B cell 
populations of SHIV-infected macaques as have been reported in HIV-infected patients.   
Compared with pre-SHIV infection values, we observed significant declines in total (CD20+), 
memory (CD20+CD27+), CD21+, and naïve (CD20+CD27-) B cells in the peripheral blood of 
cynomolgus macaques following SHIV-infection.  Additionally, we also noted declines in 
subsets of memory B cells, including both IgM+ and class-switched (IgM-IgD-) memory cells, 
with sustained deficits in the IgM+ memory population. Compared with baseline, we also report 
significantly elevated levels of B cell activation, as measured by CD95 (Fas) expression, as well 
as hypergammaglobulinemia. We also investigated whether phenotypic or activation 
abnormalities in B cell populations correlated with natural colonization of SHIV-infected 
macaques by the opportunistic pathogen, Pneumocystis.  We found similar perturbations in B 
cell populations of both Pneumocystis-positive and Pneumocystis-negative animals; therefore, 
although the B cell compartment of macaques appears to be significantly affected by SHIV-
infection, these abnormalities do not contribute to susceptibility to infection by this opportunistic 
pathogen.  The similarity of B cell alterations observed in these studies to those observed in 
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HIV+ subjects support the utility of the SHIV-macaque model for examination of HIV-related B 
cell dysfunction.   
4.2 INTRODUCTION 
In addition to severe depletion of CD4+ T cells, major immune abnormalities occur within the B 
cell compartment during HIV-infection (De Milito, 2004).  HIV infection has been associated 
with reduced total and memory B cells (De Milito et al., 2001; Nagase et al., 2001), increased B 
cell activation (Mizuma et al., 1988; Shirai et al., 1992; Titanji et al., 2005; Moir et al., 2008), 
decreased circulating antigen-specific Ig, impaired responsiveness to stimulation (Jiang et al., 
2008), hypergammaglobulinemia and spontaneous Ig secretion in vitro (Nagase et al., 2001; De 
Milito et al., 2004; Titanji et al., 2005), and germinal center abnormalities (Guarda et al., 1983; 
Chalifoux et al., 1984; Chalifoux et al., 1987; Margolin et al., 2002; Margolin et al., 2006).   
In vivo polyclonal activation of B cells in the peripheral blood of HIV-infected persons is 
evidenced by abnormal levels of B cell activation in HIV-infected individuals (Lane et al., 1983), 
resulting in spontaneous secretion of immunoglobulins (Mizuma et al., 1987; Mizuma et al., 
1988).  Symptomatic HIV-infected patients tend to have higher levels of circulating IgG than 
asymptomatic patients (De Milito, 2004); thus, IgG levels have been reported as a prognostic 
marker of infection.  Decreased proliferative responses to T-cell independent B cell mitogens ex 
vivo (Lane et al., 1983; Jiang et al., 2008), in both the naïve and memory B cell populations 
(Jiang et al., 2008), accompany the chronic immune activation reported in HIV+ patients.  Thus, 
B cell function, measured by the B cell response to specific stimuli or by the capacity to provide 
co-stimulatory signals to CD4+ T cells, appears impaired during HIV-infection (Malaspina et al., 
 89 
2003; Moir et al., 2003).  Elevated levels of CD21-low/negative B cells in HIV-infected subjects 
is hypothesized to account for poor proliferative responses of B cells (Moir et al., 2001; Jiang et 
al., 2008; Moir and Fauci 2009).  CD21+ B cells are thought to be terminally differentiated and 
thus, proliferate poorly in response to mitogenic stimulation.  Reports indicate that the frequency 
of CD21+ memory B cells is directly related to the capacity of these cells to proliferate in 
response to stimulation (Jiang et al., 2008).  However, abnormal levels of B cell hyperactivation 
and hypersecretion of Ig appear to be closely related to viremia levels, thus, appear to be 
reversible by effective anti-retroviral therapy (ART) (Moir et al., 2001; Fournier et al., 2002; De 
Milito, 2004; Moir and Fauci, 2009). 
In contrast to what has been reported for activation level abnormalities, HIV- associated 
loss of memory B cells and decreased memory B cell function (Titanji et al., 2006) does not 
seem to be restored by ART.  Loss of memory B cells may be due to increased expression of 
particular surface makers, as a result of HIV-infection, which contributes to increased apoptosis 
rates of B cells, in particular, memory B cells (De Milito et al., 2001).  Upregulated expression of 
activation markers may be responsible for the elevated rates of differentiation from memory cells 
to immunoglobulin-secreting cells, which, along with increased activation of naïve B cells, 
results in the observed hypergammaglobulinemia associated with HIV-infection (Nagase et al., 
2001; De Milito et al., 2004; Cagigi et al., 2008; Moir and Fauci, 2009).   
Impaired B cell memory may contribute to the observed reduced capacity of HIV-
infected individuals to respond effectively to pathogens, diminished responses to vaccination 
(Malaspina et al., 2005), and may also contribute to the increased susceptibility of HIV-infected 
patients to opportunistic pathogens.  HIV-infected patients have deficits in circulating antibodies 
to immunizing antigens, such as measles and influenza, as well as antibodies to opportunistic 
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pathogens, such as Streptococcus pneumonia and Cryptococcus neoformans, deficits which are 
not restored by ART (Titanji et al., 2006).  Specific subsets of memory B cells have also been 
reported to be diminished, such as IgM memory B cells (Titanji et al., 2005; Hart et al., 2007) 
and peripheral blood marginal zone-like populations (Morrow et al., 2008), both of which are 
hypothesized to contribute to defective immune responses to T-independent pathogens, such as 
Pneumococcus, as a consequence of HIV infection.   
The fungal opportunistic pathogen, Pneumocystis jirovecii (formerly Pneumocystis 
carinii f. sp. hominis) (Pc) is an important pathogen in HIV+ populations.  Despite advances in 
treatment strategies, Pneumocystis pneumonia (PcP) remains one of the most common serious 
infections associated with HIV infection (Kaplan et al., 2000; Morris et al., 2004b).  Several 
studies have shown that subpopulations of HIV-infected individuals remain at risk for 
development of PcP despite anti-retroviral therapy (Connors et al., 1997; Morris et al., 2004b), 
although the basis of susceptibility is poorly understood.   
Pc colonization is defined as the presence of Pc in respiratory samples from subjects 
without overt signs of clinical disease, and is uncommon in immunocompetant subjects 
(Wakefield et al., 1990c; Peters et al., 1992; Leigh et al., 1993; Tamburrini et al., 1997).  An 
increased frequency of Pc colonization has been reported in HIV+ patients, including those on 
anti-retroviral therapy (ART) (Morris et al., 2004a).  Pc colonization is important as it not only 
may increase risk for progression to PcP in susceptible individuals, but even at low levels may 
cause pulmonary damage, and has been shown to be associated with chronic obstructive 
pulmonary disease in both human subjects (Morris, Huang et al. 2000, Calderon 1996, Probst 
2000, Helweg-Larsen 2002, Morris 2009) and in animal models (Shipley et al., in press). 
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Although effective CD4+ T cell responses are important in immunologic control of Pc 
infection, B cells and antibodies also play a role in prevention of PcP (Harmsen et al., 1995; 
Marcotte et al., 1996; Garvy et al., 1997; Gigliotti et al., 1998a; Gigliotti et al., 1998b; Gigliotti 
et al., 2002; Empey et al., 2004; Wells et al., 2006a).  There is a high frequency of Pc-specific 
seropositivity in immunocompetent adults (Daly et al., 2002; Bishop and Kovacs, 2003), as well 
as in non-human primates (Demanche et al., 2005; Kling et al., 2009), suggesting the persistence 
of serological memory in response to natural Pc exposure. The experimental murine model 
demonstrates the importance of B cells in controlling Pc infection; B cell-deficient mice are 
highly susceptible to Pc (Marcotte et al., 1996), and B cells may play other roles aside from 
antibody production in control of Pc infection (Lund et al., 2003; Lund et al., 2006).   
Limited studies using non-human primate (NHP) models of HIV infection have been 
used to investigate virus-induced B cell dysfunction (Margolin et al., 2002; Margolin et al., 
2006).  Infection of macaques with SHIV induces follicular hyperplasia and germinal center 
abnormalities similar to those associated with HIV infection, although a comprehensive study of 
B cell abnormalities in this model has not been reported.  In the current study we investigated 
phenotypic changes to B cell populations commonly reported to be affected by HIV to ascertain 
the strength of the SHIV-NHP model for examining AIDS/HIV-associated B cell dysfunction.  
Because of the importance of B cells in controlling Pc infection, we also used our model of 
natural Pc-colonization (Kling et al, 2009) to investigate whether B cell abnormalities induced by 
SHIV-infection affected the animals’ susceptibility to colonization by this opportunistic 
pathogen. 
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4.3 MATERIALS AND METHODS 
4.3.1 Animals.  
Adult, Chinese origin cynomolgus macaques (Macacca fasicularis), weighing between 5-8 kg, 
were used in this study.  All animals were purchased from National Primate Centers or vendors 
approved by the University of Pittsburgh, Department of Laboratory Animal Research.  Prior to 
admission to the study, all animals underwent complete physical examination (pulmonary and 
cardiac auscultation, thoracic radiographs, computer tomography scanning, tuberculin skin 
testing, complete blood count, chemistry panel, urinalysis, and flow cytometric analysis of 
peripheral blood mononuclear and BAL cells) and were screened for simian retroviruses; SIV, 
SRV, and STLV to verify that they are free of any pre-existing disease that may confound the 
study. The animals were housed in an American Association for Accreditation of Laboratory 
Animal Care-accredited, biosafety level 2+ primate facility at the University of Pittsburgh.  
Animal husbandry and experimental procedures were conducted in accordance with standards set 
forth by the Guide for the Care and Use of Laboratory Animals (ref. National Research Council, 
1996) 
4.3.2 Study Design.  
and the Provisions of the Animal Welfare Act.  Prior to the initiation of this study, all 
animal experiments were approved by the Institutional Animal Care and Use Committee of the 
University of Pittsburgh.   
Twenty-nine macaques were intravenously inoculated with 1x104.9 TCID50 (50% tissue culture 
infectious doses) of SHIV89.6P (gift of Dr. Opendra Narayan, University of Kansas), which 
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induces CD4+ T cell lymphopenia and AIDS-like disease with wasting and opportunistic 
infections (Reimann et al., 1996; Pawar et al., 2008).  To promote natural transmission of Pc, 
SHIV-infected macaques were continuously exposed by co-housing in the same room with 10-20 
SIV- or SHIV-immunosuppressed macaques which served as a Pc source (Kling et al., 2009).  
None of the macaques (source or recipients) contracted fulminate Pneumocystis pneumonia 
(PcP) during the study. Determination of Pc colonization status was performed by detection of 
Pc DNA in the BAL fluid samples by nested PCR and by anti-Pc KEX1 serology (Board et al., 
2003; Kling et al., 2009).  Pc colonization was defined as a positive nested PCR of BAL fluid 
and at least a 3-fold change in plasma anti-Pc KEX1 titers (Board et al., 2003; Kling et al., 
2009).  Additionally, BAL samples were stained for organisms by modified Giemsa and silver 
staining (Board et al., 2003). 
4.3.3 BAL and blood collection.   
Peripheral blood and BAL samples were collected at baseline on all animals.  Serial 
plasma and PBMC samples from SHIV-infected monkeys were collected weekly for the 
first 8 weeks following SHIV-infection and monthly thereafter.  BAL fluid samples were 
collected monthly.  Samples were collected and processed as described previously (Board 
et al., 2003; Kling et al., 2009).  Briefly, plasma was isolated from 10mL of EDTA 
(ethylenediaminetetraacetic acid)-treated whole blood by centrifugation; PBMC were 
purified over a Percoll gradient (Amersham Bioscience, Piscataway, NJ) and washed 
with sterile phosphate buffered saline (PBS) (Shipley et al. in press).   Plasma aliquots 
were stored at -80°C prior to assay.  PBMC were counted, stained and fixed for analysis 
by flow cytometry. BAL fluid was processed for cell isolation as previously described 
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(Croix et al., 2002; Kling et al., 2009).  Unfractionated BALF aliquots were used for 
bacterial, fungal and viral culture (Antech Diagnostics, Pittsburgh, PA) and PCR 
detection of Pc DNA.  Remaining fluid was filtered through a 40-micron cell strainer and 
manual cell counts were performed using a hemocytometer.  1 x 105
4.3.4 Flow cytometry.  
 cells were removed 
and stained with modified Giemsa stain (Dade Behring, Newark, DE) and differential 
counts performed manually (Croix et al., 2002).  Remaining cells were pelleted and 
supernatant fluid was collected and stored at -80°C.  Recovered cells were prepared for 
flow cytometry as described (Croix et al., 2002; Board et al., 2003). 
Stained, fixed cells from whole blood were analyzed by flow cytometry (Croix et al., 2002).  
Antibodies used were: mouse anti-monkey CD3-fluorescein isothiocyanate (clone SP34), mouse 
anti-human CD8-Pacific Blue (clone RPA-T8) and mouse anti-monkey CD4-allophycocyanin 
(clone L200), mouse anti-human CD21 (clone B-ly4)- phycoerythrin, mouse anti-human CD95 
(clone DX2)- fluorescein isothiocyanate, anti-human IgM-fluorescein isothiocyanate, all 
purchased from BD Pharmingen (San Diego, CA); mouse anti-human CD20 (clone 2H7)-Pacific 
Blue, mouse anti-human CD27 (clone O323)-allophycocyanin, purchased from eBioscience (San 
Diego, CA), and anti-human IgD-biotin, purchased from Southern Biotech (Birmingham, AL).  
A streptavidin-Pacific Orange conjugate (Invitrogen, Carlsbad, CA) was used to detect biotin-
conjugated antibodies.  Acquisition was performed on BD LSRII flow cytometer using BD 
FacsDiva software.  Forward/side scatter dot plot was used to gate the live lymphocyte 
population.  All analyses were performed using FlowJo flow cytometry analysis software (Tree 
Star Inc., Ashland, OR).   
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4.3.5 Total immunoglobulin quantification.  
Plasma samples were heat-inactivated at 56°C for 30 minutes, and then diluted in blocking buffer 
(PBS, 5% non-fat milk) prior to assay. Microtiter plates (Immunolon 4HBX, Thermo Fisher 
Scientific, Inc., Waltham, MA) were coated with affinity purified anti-monkey IgG (1μg/mL, 
Rockland, Inc) at 4°C overnight.  One-hundred µL of plasma were plated in triplicate into anti-
monkey IgG-coated wells.  Goat anti-monkey immunoglobulin-conjugated horseradish 
peroxidase (1:10,000 for IgG, 1:2000 for IgM) (Nordic Immunology, Tilburg, Netherlands) was 
used for detection and plates were developed by standard methods. Normal (uninfected) 
macaque plasma was used as a plate control.  Serial dilutions of whole molecule monkey IgG 
(Rockland, Inc) were used to generate a standard curve.   
4.3.6 Statistical Analyses.   
Statistical analyses were performed using Prism software, by Graphpad (La Jolla, CA).  
Comparisons among multiple time-points were made using repeated measures ANOVA, with 
Bonferroni post-tests. Additionally, paired two-tailed student’s t-test was used to compare post-
SHIV-infection time-points with baseline values.  When comparing Pc+ and Pc- monkeys over 
multiple time-points, two-way ANOVA was used for comparison.  A p value of less than 0.05 
was considered significant. 
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4.4 RESULTS 
4.4.1 Natural Pc Colonization of SHIV-infected macaques.   
Prior to SHIV-infection, macaques were determined to be negative for Pc colonization by nested 
PCR of BAL fluid. Plasma antibodies to the recombinant Pc protein, kexin (KEX1), were 
examined by ELISA, as described in Chapter 3.  Baseline anti-Pc KEX1 plasma IgG reciprocal 
endpoint titers ranged from undetectable (<1:100) to 1:22,400.  Following SHIV-inoculation, 
nineteen of the animals became naturally colonized with Pc (Pc+) by 16 weeks post-SHIV 
infection, while ten animals remained Pc-negative (Pc-) throughout the duration of the 
experiment (53 weeks), as determined by nested PCR of BAL fluid and anti-KEX1 antibodies.  
Rapid declines in peripheral blood CD4+ T cells were observed within 2 to 4 weeks following 
SHIV-infection (see Fig 8 in Section 3.4.2), and CD4+ T cell numbers remained depressed 
throughout the experiment (see Fig 6 and 8 in Section 3.4). Additionally, SHIV viral loads and 
antibody responses are given in Section 3.4.2, Figure 7.  There was no difference between Pc+ 
and Pc- monkeys in mean CD4+ T cell numbers or in SHIV viral loads during SHIV infection 
(see Fig 6, Section 3.4.1).  Representative profiles of Pc-antibody production, CD4+ T cell 
decline, and nested PCR results are shown in Figure 8 in Section 3.4.2.   
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4.4.2 Significant declines in total B cell populations and increased percentages of CD95+ 
B cells in peripheral blood following SHIV-infection.    
In order to examine whether similar B cell deficits or dysfunctions occur during SHIV89.6-
infection of cynomolgus macaques as have been reported in HIV-infected patients, and whether 
these dysfunctions may correlate with the animals’ susceptibility to Pc colonization, we 
examined B cell populations and subsets in these animals.  Baseline and serial time-points 
following SHIV-infection were examined by flow cytometry of PBMC for changes in B 
(CD20+) cell populations.  PBMC from all animals (n=29) were assessed at serial time-points for 
approximately one year post-SHIV infection.  Percentages (Fig 13A) and numbers (Fig 13B) of 
CD20+ cells from Pc+ (n=19) and Pc- (n=10) monkeys were then compared (2-way repeated 
measures ANOVA).  Significant changes in proportions (p=0.0004, repeated measures ANOVA, 
Fig 13A) (CD20+) and numbers (p<0.0001, repeated measures ANOVA, Fig 13B) of B 
lymphocytes, compared with baseline values, were observed following SHIV-infection.  When 
comparing individual time-points, significant declines in percentages (week 2, p=0.026, Fig 
13A) and numbers (week 2, p=0.0008, Fig 13B) of CD20+ cells were observed early following 
SHIV-infection.  However, CD20+ cells as a percentage of total lymphocytes had rebounded 
somewhat by approximately 7 months post-SHIV infection (week 28, p=0.17, paired Student’s t-
test) and remained near baseline levels by one-year following SHIV-infection (week 53, p=0.23, 
paired Student’s t-test).  Absolute numbers of CD20+ cells remained depressed throughout the 
experiment (Fig 13B, p<0.0001, repeated measures ANOVA), and by week 53 remained 
significantly declined from baseline (p=0.0019, Fig 13B).  CD20+ B cell percentages and 
numbers of Pc+ and Pc- monkeys were compared (Fig 13A, B), and there was no significant 
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difference between the percentages (p=0.6, 2-way ANOVA) or numbers (p=0.763, 2-way 
repeated measures ANOVA) of CD20+ cells between these two groups of animals (Fig 13A, B). 
Activation of B cells was measured via CD95 (Fas) surface expression.  PBMC in a 
subset of SHIV-infected macaques (n=17) were examined at serial time-points for CD95+ B 
(CD20+CD95+) cells.  Percentages and numbers of CD95+ B cells from Pc+ (n=11) and Pc- 
(n=6) monkeys were then compared (Fig 14).  Percentages of CD95+ B cells were markedly 
increased early following SHIV-infection (Fig 14A, weeks 1-4 post-SHIV infection, p<0.0001, 
paired Student’s t-test), increasing from 12.7±8.1% at baseline to 52.4±12.9% at week 1 post-
infection, and percentages of activated B cells remained significantly increased at 51.1±10.0% of 
total B cells by 58 weeks post-SHIV infection (p<0.0001, Fig 14A).    Absolute numbers of 
CD95+ B cells declined with total B cells following SHIV-infection (Fig 14B); however, by 
approximately 7 months post-SHIV infection, had returned to baseline levels (week 28, p=0.96, 
paired Student’s t-test) and remained near baseline levels at around one-year post-infection 
(week 58, p=0.38, paired Student’s t-test), despite the fact that total B cell numbers remained 
depressed at this point (Fig 13).  Activation levels were similar between Pc+ and Pc- monkeys 
pre- (week 0, p=0.29, Student’s t-test) and post-SHIV infection (p>0.05 at all time-points, 2-way 
repeated measures ANOVA with Bonferroni post-tests, Fig 14A).    Numbers of CD95+ B cells 
were also similar between Pc+ and Pc- monkeys (Fig 14B, p=0.45, 2-way repeated measures 
ANOVA), indicating similar levels of expression of this activation marker regardless of Pc-status 
in immunosuppressed animals. 
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Figure 13. Peripheral blood total B (CD20+) cells declined following SHIV-infection.  B 
cells were assessed by flow cytometry of PBMC, using the surface marker CD20 to distinguish B 
cells from other cells in the lymphocyte gate.  PBMC from all animals (n=29) were assessed at 
serial time-points for approximately one year post-SHIV infection, by repeated  measures 
ANOVA and paired Student’s t-tests.  Shown here, percentages (A) and numbers (B) of CD20+ 
cells from Pc+ (n=19) and Pc- (n=10) monkeys were then compared by 2-way repeated measures 
ANOVA.  Individual time-points in which values were significantly different from baseline 
values are indicated by * (p<0.05, paired Student’s t-test).  There was no significant difference 
between the percentages (p=0.6, 2-way repeated measures ANOVA, A) or numbers (p=0.763, 2-
way repeated measures ANOVA) of CD20+ cells between Pc+ and Pc- monkeys. 
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Figure 14. Significant B cell activation was observed following SHIV-infection.  Activation 
of B cells was determined by flow cytometry for the surface marker CD95 (fas) in a subset of 
SHIV-infected macaques (n=17), and serial time-points were evaluated by repeated  measures 
ANOVA and paired Student’s t-tests.  Shown here, percentages (A) and numbers (B) of CD95+ 
B cells (CD20+CD95+) from Pc+ (n=11) and Pc- (n=6) monkeys were then compared by 2-way 
repeated measures ANOVA.  Individual time-points in which values were significantly different 
from baseline values are indicated by * (p<0.05, paired Student’s t-test). 
4.4.3 Decreased surface expression of CD21 on peripheral blood B cells in SHIV-infected 
macaques.   
The surface marker CD21 is part of the B cell co-receptor (BCR) complex, which serves to 
strengthen the signal resulting from antigen recognition. Signaling pathways activated by CD21 
amplify antibody responses and induce costimulatory molecules on the B cell, thereby increasing 
effectiveness at eliciting T-cell help.  HIV+ patients demonstrate diminished CD21 expression 
on B cells (Moir et al., 2001; Jiang et al., 2008), which may result in reduced B cell 
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responsiveness to antigen and subsequent proliferation.  To examine this phenotype as a correlate 
of antigen responsiveness capacity in SHIV-infected monkeys, we evaluated expression of the 
CD21 surface marker on peripheral blood B cells (CD20+CD21+) of macaques (n=29).  The 
absolute number of CD21+ B cells in the peripheral blood was significantly declined following 
SHIV-infection (p<0.0001, repeated measures ANOVA, Fig 15A, B).  Early significant declines 
in the percentages (week 2, p=0.0012, paired Student’s t-test, Fig 15A) and absolute numbers 
(week 2, p=0.0007, paired Student’s t-test, Fig 15B) of these cells were observed following 
SHIV-infection.  Neither percentages nor numbers of CD21+ B cells returned to baseline levels 
by approximately one year post-SHIV infection (p<0.0001, percentages; p=0.0003, numbers; 
paired Student’s t-test).  However, Pc+ and Pc- animals exhibited similar declines in percentages 
(p=0.73, 2-way repeated measures ANOVA) and numbers (p=0.52, 2-way repeated measures 
ANOVA) of CD21+ B cells, demonstrating that colonized and non-colonized monkeys were 
similarly affected by SHIV-infection with regard to decreased percentages and numbers of 
CD21+ B cells.  
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Figure 15. B cells expressing CD21 were significantly decreased following SHIV-infection.  
Percentages of peripheral blood B cells expressing the surface marker CD21 (CD20+CD21+) 
were determined by flow cytometry of PBMC of macaques (n=29) at serial time-points for 
approximately one year post-SHIV infection.  Changes from baseline in the CD21+ B cell 
population were evaluated by repeated measures ANOVA and paired Student’s t-tests.  Shown 
here, percentages (A) and numbers (B) of CD21+ B cells from Pc+ (n=19) and Pc- (n=10) 
monkeys were then compared by 2-way repeated measures ANOVA.  Individual time-points in 
which values were significantly different from baseline values are indicated by * (p<0.05, paired 
Student’s t-test). 
4.4.4 Peripheral blood memory and naïve B cells are affected in SHIV-infected macaques.   
Memory B cells were assessed by CD27 surface marker expression (Vugmeyster et al., 2004).  
Flow cytometry of PBMC revealed significant changes in numbers (p<0.0001, repeated 
measures ANOVA, Fig 16A) of CD27+ B cells.  CD27+ B cells declined significantly during 
acute SHIV-infection (week 2 post-SHIV infection, p=0.037, Fig 16A), but rebounded thereafter, 
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and by one-year post-SHIV infection remained near baseline levels (p=0.18, week 0 compared 
with week 53, Fig 16A).  Similar to what was observed for other surface markers, there were no 
significant differences in numbers of CD27+ B cells (p=0.75, 2-way repeated measures 
ANOVA) between Pc+ and Pc- monkeys (Fig 16A).  These results indicate that although there is 
an acute deficit in the memory B cell compartment following SHIV-infection, Pc+ and Pc- 
monkeys were equivalently affected.   
It has been hypothesized that subsets of memory B cells may be differentially affected 
during HIV infection, especially with regard to class-switched (CD27+IgM-IgD- B cells) versus 
IgM+ memory (CD27+IgM+) B cells, with IgM+ memory cells reported to be significantly 
reduced in HIV+ patients (Hart et al 2007).  Because we observed an early loss of total memory 
(CD27+) B cells, we further investigated whether SHIV infection induced alteration in subsets of 
memory B cells to examine whether differential effects of SHIV on those populations may exist 
between Pc+ and Pc- monkeys.  Following SHIV-infection, percentages (p=0.0005, repeated 
measures ANOVA, Fig 16B) and numbers (p=0.0003, repeated measures ANOVA, Fig 16C) of 
class-switched (IgM-IgD-) memory (CD27+) B cells were significantly reduced. However, by 45 
weeks post-SHIV infection, percentages (p=0.2) and numbers (p=0.16) of class-switched CD27+ 
B cells returned to baseline levels (Fig 16B, C).    Additionally, percentages (p<0.0001, repeated 
measures ANOVA, Fig 16D) and numbers (p<0.0001, repeated measures ANOVA, Fig 16E) of 
IgM memory B cells (IgM+CD27+) were also significantly reduced following SHIV-infection.  
Percentages and numbers of IgM+ CD27+ B cells significantly declined by 16 weeks post-SHIV 
infection, and, in contrast to the rebound observed for class-switched memory B cells by 45 
weeks post-SHIV infection, remained depressed for the duration of the experimental infection 
(week 0 vs. 58; p=0.014, percentages; p=0.007, numbers; Fig 16D, E).  Pc+ and Pc- monkeys 
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had similar percentages (p=0.33, Fig 16B) and numbers (p=0.55, Fig 16C) of class-switched 
CD27+ B cells, as well as percentages (p=0.47, 2-way repeated measures ANOVA, Fig 16D) 
and numbers (0.89, 2-way repeated measures ANOVA, Fig 16E) of IgM+ memory B cells.   
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Figure 16. CD27+ B cells and subsets in peripheral blood of SHIV-infected macaques.  
Flow cytometry was used to evaluate memory B cells (CD27+CD20+ lymphocytes) of macaques 
(n=29) at serial time-points for approximately one year post-SHIV infection.  Changes from 
baseline in the CD27+ B cell population were evaluated by repeated measures ANOVA and 
paired Student’s t-tests.  Shown here, numbers (A) of CD27+ B cells from Pc+ (n=19) and Pc- 
(n=10) monkeys were then compared by 2-way repeated measures ANOVA.  Percentages (B) 
and numbers (C) of class-switched (IgM-IgD-) and IgM (percentages, D; numbers, E) memory 
(IgM+CD27+) subsets of CD27+ B cell were also investigated by 2-way repeated measures 
ANOVA in a subset of macaques (n=17).  Individual time-points in which values were 
significantly different from baseline values are indicated by * (p<0.05, paired Student’s t-test). 
 
 
We also examined the naïve (CD20+CD27-) B cell population in PBMC of SHIV-
infected macaques (n=29).  During HIV infection, naïve B cells are reported to be increased in 
peripheral blood (Chong et al., 2004); however, in a recent report of SIV-infected rhesus 
macaques, naïve B cells exhibited declines at early time-points following viral infection (Kuhrt 
et al., 2010).   In the current examination of SHIV-infection of cynomolgus macaques, we also 
observed significant changes in percentages (p<0.0001, repeated measures ANOVA, Fig 17A) 
and numbers (p<0.0001, repeated measures ANOVA, Fig 17B) of CD27- B cells.  Percentages of 
CD27- B cells (Fig 17A) declined significantly from baseline by week 12 (p=0.0038).  Numbers 
of CD27- B cells (Fig 17B) declined significantly acutely following SHIV-infection (week 2, 
p=0.0006) and did not return to baseline levels for the duration of the experiment (week 53, 
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p=0.0011).  Percentages (Pc+ vs Pc-, p=0.90 Fig 17A) and numbers (Pc+ vs Pc-, p=0.75, Fig 
17B) of CD27- B cells were similarly affected in Pc+ and Pc- animals. 
 
 
 
Figure 17. Naïve B cells (CD20+CD27- lymphocytes) were significantly declined from 
baseline following SHIV-infection.  Flow cytometry was used to distinguish CD27- from 
CD27+ B cells in PBMC of macaques (n=29) at serial time-points for approximately one year 
post-SHIV infection.  Changes from baseline in the CD27- B cell population were evaluated by 
repeated measures ANOVA and paired Student’s t-tests.  Shown here, percentages (A) and 
numbers (B) of CD27- B cells from Pc+ (n=19) and Pc- (n=10) monkeys were then compared by 
2-way ANOVA.  Individual time-points in which values were significantly different from 
baseline values are indicated by * (p<0.05, paired Student’s t-test). 
4.4.5 Evidence of hypergammaglobulinemia in the plasma of SHIV-infected macaques.   
Chronic immune activation and hypergammaglobulinemia are well-documented in HIV-infection 
(Lane et al., 1983; Nagase et al., 2001), and is comprised of both virus specific and polyclonal 
antibodies.  Several isotypes are increased, but IgG is predominantly affected, and serum IgG 
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levels may represent a prognostic marker of disease progression (De Milito, 2004; De Milito et 
al., 2004).  To assess whether this abnormality occurs in SHIV-infected macaques, total plasma 
IgG levels were measured at baseline and at serial time-points following SHIV-infection (n=12).  
A significant change from baseline was observed over the course of SHIV-infection (Fig 18A, 
p=0.0041, repeated measures ANOVA), particularly at 7 months post-infection (Fig 18A, week 0 
vs. week 29, p=0.0009, paired Student’s t-test).  Plasma IgG levels were not significantly 
different between Pc+ (n=8) and Pc- (n=4) monkeys (Fig 18B, p=0.54, 2-way repeated measures 
ANOVA).  Thus, evidence of hypergammaglobulinemia was similar in both groups of animals 
and did not correlate with Pc colonization. 
 
 
Figure 18.  Evidence of hypergammaglobulinemia in SHIV-infected macaques.  Levels of 
total IgG were measured by ELISA in plasma of a subset of macaques (n=12), at baseline and at 
serial time-points following SHIV-infection.  Individual time-points in which values were 
significantly different from baseline values are indicated by * (p<0.05, paired Student’s t-test). 
 108 
4.5 DISCUSSION 
The current study investigates the impact of SHIV-infection on peripheral blood B cell 
populations and subsets in cynomolgus macaques to examine whether similar abnormalities are 
observed in this model as have been reported in HIV-infected individuals.  Compared with pre-
SHIV infection values, we observed significant declines in total (CD20+), memory 
(CD20+CD27+), CD21+, and naïve (CD20+CD27-) B cells in the peripheral blood of 
cynomolgus macaques following SHIV-infection.  Significant declines compared with pre-SHIV 
infection values were observed in both class-switched (IgD-IgM-) and IgM+ memory B cell 
subsets; however, class-switched memory cells appeared to recover later in infection, while 
IgM+ memory cells remained depressed.  Compared with baseline, we also report significantly 
elevated levels of B cell activation as measured by CD95 (Fas) expression, as well as 
hypergammaglobulinemia.  A subset of SHIV-infected macaques became naturally colonized 
with the opportunistic pathogen, Pneumocystis, upon immunosuppression and airborne exposure 
by co-housing (Kling et al., 2009; Shipley et al., in press).  For each of the B cell populations we 
examined, we compared the Pc-colonized and Pc-negative groups of animals for any differential 
effects of SHIV-infection that may correlate with their colonization status.  No significant 
differences were observed between the Pc-colonized and Pc-negative groups of animals with 
respect to B cell population abnormalities that were observed following SHIV-infection. 
HIV+ patients are at increased risk for opportunistic infections, which may be attributed 
to generalized B cell deficits and dysfunctions, such as decreased numbers of memory B cells 
(De Milito et al., 2001), high levels of activation that result in hypergammaglobulinemia (Nagase 
et al., 2001; De Milito et al., 2004), and possibly the exhaustion of the memory B cell 
compartment (Moir et al., 2008).  Studies that examine B cell subsets in HIV-infected patients 
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report a variety of reductions and dysfunctions in these populations (Moir et al., 2001; De Milito, 
2004), including diminished total and memory (CD27+) B cells (De Milito et al., 2001; Titanji et 
al., 2006), increased activation (Mizuma et al., 1988; Amadori et al., 1989; Shirai et al., 1992; De 
Milito et al., 2004), reductions in subsets of memory B cells, such as IgM memory (Hart et al., 
2007) and marginal-zone like B cells (Morrow et al., 2008), diminished responses to antigenic 
stimulation and immunization (Malaspina et al., 2005; Titanji et al., 2006; Moir et al., 2008), 
decreased expression of important co-stimulatory markers (Malaspina et al., 2003; Jiang et al., 
2008), and hypergammaglobulinemia (Nagase et al., 2001; De Milito et al., 2004).  Phenotypic B 
cell alterations induced by HIV may have functional consequences resulting in diminished host 
capacity to respond to invading pathogens, thereby increasing susceptibility to opportunistic 
infections.  It is for these reasons that we examined B cells and B cell subsets by flow cytometry 
in SHIV-infected macaques.   
Here, several aspects of HIV-induce B cell alterations were observed in the SHIV-
macaque model.  We observed significantly increased percentages of CD95+ B cells following 
SHIV-infection, indicating increased activation.  Similar to what has been reported for activated 
T cells, B cells from HIV-infected subjects show elevated expression of Fas/Fas-ligand (De 
Milito et al., 2001; Titanji et al., 2003).  Upregulation of this surface marker not only indicates 
high levels of activation, but also suggests a dysregulation of the Fas apoptotic pathway, and 
may contribute to increased susceptibility of B cells to CD95-mediated apoptosis (Moir and 
Fauci, 2009). 
Percentages and absolute numbers of CD21+ B cells were significantly reduced in the 
peripheral blood of SHIV-infected macaques.  Reports from studies of HIV-infected persons also 
report abnormalities in this population of B cells (Moir et al., 2001; Jiang et al., 2008; Moir and 
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Fauci, 2009).  Evidence from the literature suggests that the frequency of CD21+ memory B 
cells is directly related to the capacity of these cells to proliferate in response to stimulation 
(Jiang et al., 2008).  Thus, poor proliferative responses of B cells from HIV-infected subjects 
may be accounted for by the increased level of CD21-low/negative B cells in these subjects 
(Moir et al., 2001; Jiang et al., 2008; Moir and Fauci, 2009), as these cells are thought to be 
terminally differentiated and thus, proliferate poorly in response to mitogenic stimulation.   
CD27 is a marker for memory B cells in humans, and CD27 has been shown to be a 
marker of B cell memory in macaques by evaluation of somatic hypermutation in CD27+ vs 
CD27- cells and by the lack of CD27+ cells in macaque cord blood samples (Kuhrt, et al., 
submitted).  Several studies have reported a loss of CD27+ cells in HIV-infected subjects (De 
Milito et al., 2001; Nagase et al., 2001; Titanji et al., 2006) in addition to decreased levels of 
circulating antibodies to immunizing antigens, such as to measles or tetanus (De Milito et al., 
2004).  A suggested mechanism for this loss is the chronic immune activation and upregulation 
of CD70 on T cells, and subsequent increased CD70-CD27 interaction and activation (De Milito 
et al., 2001; Nagase et al., 2001), which results in terminal differentiation of CD27+ memory B 
cells into antibody-secreting plasma cells.  This increased rate of terminal differentiation of 
memory cells into plasma cells may also then account for the hypergammaglobulinemia reported 
in HIV-infected patients. 
 Upon examination of IgM+ and class-switched (IgM-IgD-) memory B cell subsets, we 
found that both types of CD27+ B cells were affected by SHIV-infection.  Although the class-
switched CD27+ B cells experienced early deficits following SHIV-infection, this population 
appeared to recover in the later time-points of infection, and returned to baseline levels.   In 
contrast, the IgM+ CD27+ B cell subset exhibited declines in both percentage and absolute 
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number around 4 months post-SHIV infection and remained depressed for the study duration, 
which was approximately one year.  These results are comparable to what has been reported in 
HIV-infected patients, in which mean percentages of IgM+ memory, but not class-switched 
memory cells, are significantly reduced compared with healthy controls (Hart et al., 2007).  
IgM+ memory B cells are hypothesized to function in protection from T-independent-type 
antigens (Weller et al., 2004), such as encapsulated bacteria, and a reduction in this population in 
HIV-infected patients may account for their increased susceptibility to invasive pneumococcal 
disease (Hart et al., 2007).   
We report significant declines in naïve (CD27-) B cells in SHIV-infected macaques.  
Recently it was reported that SIV-infected Rhesus macaques experience significant deficits in 
naïve B cells early following SIV-infection (Kuhrt et al., 2010).  This study reported, similar to 
what we present here, that, compared with baseline levels, naïve B cell numbers remained 
depressed for longer after SIV-inoculation than did memory B cells (Kuhrt et al., 2010).  Reports 
also indicate that naïve B cells in HIV-infected patients exhibit an activated and more 
differentiated phenotype, as well as increased spontaneous IgG-secretion (De Milito et al., 2004), 
and have been hypothesized to contribute to the hypergammaglobulinemia reported during HIV-
infection.  Further study is needed to determine whether naïve B cells in macaques during SHIV-
infection play a role in the chronic immune activation state. 
We observed statistically similar B cell declines and increased percentages of activated B 
cells in both the Pc-colonized and Pc-negative animals, suggesting that B cell declines in various 
subsets due to SHIV-infection did not correlate with susceptibility to Pc colonization.  
Previously, we reported that Pc-negative monkeys were capable of mounting a significantly 
higher Pc-specific memory response compared with Pc-colonized monkeys (Section 3.4.4, 
 112 
Figure 10).  Thus, it appears that Pc-protected monkeys may retain a Pc-specific memory B cell 
pool, despite an early loss of total CD27+ (memory) B cells.  Data from these experiments 
suggest that exposure to Pc/Pc antigens, prior to immunosuppression, which results in high levels 
of circulating antibodies/plasma cells (Section 3.4.2), sufficient to prevent or delay Pc-
colonization, contributes to the maintenance of a Pc-specific memory B cell pool following 
immunosuppression, higher levels of which also correlate with protection.   
Previous studies of SHIV effects on B cells in macaques have been limited (Margolin et 
al., 2002; Margolin et al., 2006).  Little has been reported, and to our knowledge, this is the first 
report of phenotype alterations of B cell subsets demonstrated in cynomolgus macaques as a 
result of SHIV-infection.  The results presented here suggest similar phenotypic alterations occur 
during SHIV-infection as have been reported in HIV+ patients, such as a decrease in total and 
memory B cells, significantly increased percentages of activated B cells, reduced numbers of 
CD21+ B cells, and a significant reduction in IgM memory B cells.  A significant advantage of 
this model for the study of the mechanisms responsible for altered humoral immune responses 
due to SHIV infection, is the ability to examine serial time points for multiple parameters in the 
same individual animals, which is often difficult to do in clinical studies.  This model may be 
particularly useful for the examination of early disturbances in the B cell compartment early after 
infection, where changes were observed 2-4 weeks post-infection.  Overall, these results provide 
a strong rationale for the use of the SHIV-macaque model to investigate HIV-related B cell 
dysfunctions, which may direct more efficient means of induction of protective, vaccine-induced 
HIV immunity. 
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5.0  SUMMARY AND CONCLUSIONS 
Pneumocystis (Pc) infection remains a significant source of morbidity and mortality in 
immunocompromised populations, despite the increased availability and efficacy of anti-
retroviral therapies as well increased use of Pc prophylaxis.  Furthermore, despite abundant 
research, a general lack of understanding still exists regarding Pc transmission, biology and 
prevalence in both immunocompetent and immunocompromised hosts.  Although Pc 
colonization in HIV patients is quite common, the clinical consequences of colonization with this 
pathogen are undefined.  Pc contact with and/or attachment to host alveolar epithelial cells 
results in elevated levels of pro-inflammatory cytokines (Limper 1998, Pottratz 1998), and thus, 
even low-level persistent Pc colonization may elicit a potentially damaging inflammatory 
response.  For these reasons, it is plausible that colonization of host lungs with Pc organisms may 
contribute to or exacerbate the development of chronic obstructive pulmonary disease (COPD).  
This hypothesis is supported by reports of high rates of Pc colonization in COPD patients 
(Calderon et al., 1996; Probst et al., 2000; Helweg-Larsen et al., 2002), as well as because 
similar inflammatory processes are described in both Pc infection and in COPD (Di Stefano et 
al., 1998; Saetta et al., 1998).   
The central goal of this research was to establish immune correlates of protection from 
natural Pc infection in a macaque model of immunosuppression.  The first aim of this research 
was to develop a model of natural Pc colonization in macaques immunosuppressed by infection 
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with SIV or SHIV.  The macaque model of Pc infection possesses a number of advantages.  
Because this is a model of co-infection, we have the unique opportunity to assess the effects of 
prolonged Pc colonization in the context of AIDS immunosuppression.  Because this is a 
longitudinal model of disease progression, we also have the opportunity to examine serial time-
points and evaluate the host immune response at the earliest possible time-points of Pc 
colonization.  Additionally, because our model uses natural airborne exposure, achieved via co-
housing, as the route of infection, it emulates natural conditions of host exposure and Pc 
infection.  This model of Pc colonization is useful for studies examining the role of the immune 
response in development and progression of colonization and in examining long-term effects of 
colonization on the lung.  Development of this model is important because a large number of 
HIV-infected persons are colonized with Pc and effects of such colonization are unknown 
(Huang et al., 2003; Morris et al., 2004a).     
Because Pc cannot be cultured in vitro, organisms used for inoculation must be derived 
from lung tissue or BAL fluid of another experimental animal.  This is a major drawback of 
intratracheal inoculation with Pc because, although inocula have been enriched for Pc in previous 
experiments (Board et al., 2003), introduction of alloantigen and SIV as a component of the Pc 
inocula could not be avoided and increased the likelihood of transient, non-specific inflammatory 
responses.  For these reasons, and because this model allowed us to investigate the earliest points 
following Pc colonization, the natural Pc colonization model was preferred over intratracheal Pc 
inoculation of macaques.  
During this experiment monkeys received treatment doses of the anti-Pc medication, 
trimethoprim-sulfamethoxazole (TMP-SMX), in order to clear potential Pc colonization at the 
start of SIV infection.  In order to prevent Pc colonization until peripheral blood CD4+ T cells 
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declined to a sufficient level to permit natural Pc colonization, monkeys then continued on a 
prophylactic dose of TMP-SMX.   However, we observed a serial rise in anti-Pc antibody titers 
and positive PCR results in some animals during the period of TMP-SMX prophylaxis, 
indicating this regimen did not adequately prevent Pc colonization.  While Pc prophylaxis may 
reduce organism burden sufficiently to prevent active PcP, the results suggest Pc colonization 
may persist or recur during prophylaxis.  These studies have direct clinical relevance to HIV-
infected patients as Pc-colonization may occur despite use of Pc prophylaxis and ART (Morris et 
al., 2004a).       
For these studies, we developed an anti-Pc antibody ELISA to evaluate Pc colonization of 
SIV-infected macaques.  Using this method, we were able to detect anti-Pc antibodies the plasma 
of both healthy and immunosuppressed macaques. Because we were also able to monitor Pc 
colonization by nested PCR of Pc DNA in the bronchoalveolar lavage (BAL) fluid, in this way 
we were able to validate changes in antibody responses detected by the ELISA, which indicated 
Pc colonization.  The monkey model was useful to validate the reliability of the assay because, 
due to difficulties in obtaining serial samples of blood and BAL fluid from human subjects, 
studies of Pc prevalence in humans are limited in ability to correlate antibody levels with Pc 
colonization and exposure.  In addition, the serial rise in anti-Pc antibody titers occurred prior to 
detection of Pc DNA in BAL, suggesting the serial ELISA is a more sensitive indicator of early 
Pc colonization in this model.   
The target antigen for detection of anti-Pc antibodies is a recombinant fragment of Pc 
kexin (KEX1).  Pc kexin shares sequence homology with a family of fungal serine 
endoproteases, and in P. jirovecii (human-derived Pc), kexin is encoded by a single copy gene 
(Lugli et al., 1997; Lee et al., 2000; Kutty and Kovacs, 2003).  This makes KEX1 advantageous 
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over the use of the multicopy Pc MSG genes for detection of Pc-specific antibody responses 
(Kovacs et al., 1993; Smulian et al., 1997).  Experimental mouse models of Pc infection have 
demonstrated that immune responses to Pc kexin are associated with control of infection and 
prevention of PcP (Zheng et al., 2005; Wells et al., 2006a), thus changes in anti-KEX1 titers and 
antibody isotypes during and after infection may serve as a useful correlate of protection.  
The next aim of this research was then to evaluate the capacity of Pc KEX1 antibodies to 
protect immunosuppressed macaques from naturally acquired Pc infection and subsequent lung 
injury.  Macaques were infected with chimeric SHIV89.6P
However, when we evaluated baseline (pre-SHIV infection) KEX1 antibody titers and 
KEX1-specific antibody secreting cells (ASC), we found that higher baseline anti-KEX1 titers 
and higher numbers of KEX1-specific ASC prior to immunosuppression correlated with 
prevention or delay of Pc colonization following SHIV-immunosuppression.  These data support 
what has been reported in mouse models of PcP, which demonstrate the protective capacity of 
Pc-specific antibody responses through both passive and active immunization (Harmsen et al., 
1995; Garvy et al., 1997; Gigliotti et al., 1998a; Gigliotti et al., 2002; Empey et al., 2004; Wells 
et al., 2006a), especially with respect to Pc-kexin (Gigliotti et al., 1998a; Zheng et al., 2005; 
 to achieve immunosuppression (Li et 
al., 1992; Dunn et al., 1996; Reimann et al., 1996; Pawar et al., 2008), and allowed to become 
naturally Pc colonized using the cohousing model. However, not all animals became Pc 
colonized.  A subset of animals remained Pc-protected (Pc-) for the duration of the experiment 
(approximately one year).  SHIV viral loads and CD4+ T cell counts, standard measures of 
immunosuppression in lentiviral infections, were comparable in protected versus Pc-colonized 
animals, indicating that the observed differences in outcome were not due to variable 
immunosuppression levels.    
 118 
Wells et al., 2006a).  Here, we extend this knowledge by demonstrating that Pc-specific antibody 
responses were important in preventing or resolving Pc colonization in a highly-relevant non-
human primate model of HIV infection.   
Data from these experiments also suggest importance for IgA production in the lungs.  
Earlier production of KEX1-IgA in the lungs correlated with protection from Pc colonization in 
these animals.  A plausible mechanism for this protection could be that IgA may block 
attachment of Pc organisms to alveolar epithelial cells. Human studies, which show that mucosal 
antibodies to Pc are decreased in patients with PcP, compared with HIV+ patients without PcP or 
with HIV-negative controls (Laursen et al., 1994; Jalil et al., 2000) support the concept of a 
protective role for mucosal IgA.   
In these studies, we also showed that Pc-protected monkeys demonstrated a stronger 
KEX1-specific memory B cell response than Pc-colonized monkeys following SHIV-
immunosuppression. B cells are known to be important in controlling infection in murine models 
of PcP as it is reported that B cell-deficient mice are highly susceptible to Pc (Marcotte et al., 
1996), and others have suggested the importance of antibody-independent B cell functions in 
control of infection (Lund et al., 2003; Lund et al., 2006).  Our results suggest the importance of 
a robust memory response in control of Pc infection and that susceptibility to Pc can be predicted 
by a low baseline KEX1-antibody/B cell response.   
The implication of the importance of a strong B cell response needed for a secondary 
infection acquired during SHIV-immunosuppression is significant in light of reports of HIV-
associated B cell deficits and abnormalities that may contribute to poor responses to antigenic 
stimulation, diminished vaccine responsiveness and increased susceptibility of opportunistic 
infections (De Milito, 2004; Malaspina et al., 2005; Titanji et al., 2006; Jiang et al., 2008; Moir 
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and Fauci, 2009).  Our results suggest similar declines in B cell populations occur in SHIV-
infected macaques as have been reported in HIV-infected individuals.  Following SHIV-
infection, we observed significant declines in numbers of total (CD20+), memory 
(CD20+CD27+), and naïve (CD20+CD27-) B cells in the peripheral blood of cynomolgus 
macaques following SHIV-infection.  Numbers of CD21+ B cells were also significantly 
diminished, similar to what has been reported in HIV+ patients, which may contribute to reduced 
antigen responsiveness and proliferation (Jiang et al., 2008).  Additionally, there was evidence of 
chronic immune activation, exhibited by sustained increased levels of CD95 (fas) expression on 
B cells following SHIV-infection and hypergammaglobulinemia.   
HIV-infection is also associated with deficits in specific subsets, like IgM memory cells 
(Hart et al., 2007) or splenic marginal zone-like peripheral blood populations (Morrow et al., 
2008), which may contribute to diminished responses of HIV-infected patients to vaccination 
with carbohydrate antigens and T-independent antigens, such as the pneumococcal vaccine.  We 
also observed significant declines compared with baseline in numbers of both class-switched 
(IgD-IgM-) and IgM+ memory B cell subsets; however, IgM+ memory cells remained depressed 
for the duration of the experiment, whereas class-switched memory cells appeared to recover 
later in infection.   
Previous studies of SHIV effects on B cells in macaques have been limited (Margolin et 
al., 2002; Margolin et al., 2006), and to our knowledge, this is the first report of phenotype 
alterations of B cell subsets demonstrated in cynomolgus macaques as a result of SHIV-
infection.  This model is advantageous for the study of the mechanisms responsible for altered 
humoral immune responses due to SHIV infection because it allows investigators to examine 
serial time points for multiple parameters in the same individual animals, as well as to investigate 
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perturbations in the B cell compartment that occur early after infection, which would be difficult, 
if not impossible, in clinical studies.  Overall, the similarities in B cell phenotypic alterations and 
activation levels in SHIV-infected macaques to B cell abnormalities reported in HIV+ patients 
(De Milito et al., 2001; De Milito, 2004; Hart et al., 2007; Cagigi et al., 2008; Jiang et al., 2008; 
Moir and Fauci, 2009), as well as to those recently reported in SIV-infection of Rhesus monkeys 
(Kuhrt et al., 2010), coupled with the advantages of using a macaque model for examining serial 
time-points of longitudinal disease progression, provide strong rationale for the use of the SHIV-
macaque model to investigate HIV-related B cell dysfunctions.   
Although studies of HIV-infected subjects have reported diminished responses to 
vaccination with carbohydrate antigens and T-independent antigens, memory responses to other 
types of antigens, such as Pc-KEX1, require further investigation.  In our experiments, similar 
effects of SHIV on B cell populations were seen in both the Pc-colonized and Pc-negative groups 
of animals, indicating overall B cell abnormalities did not contribute to Pc-colonization status.  
Instead,  Pc-negative monkeys appear to possess a Pc-specific memory B cell pool, despite an 
early loss of total CD27+ (memory) B cells.  These results suggest that exposure to Pc/Pc 
antigens, prior to immunosuppression, which results in high levels of circulating 
antibodies/plasma cells sufficient to prevent or delay Pc-colonization, contributes to the 
maintenance of a Pc-specific memory B cell pool following immunosuppression.   
Exposure to Pc is likely frequent in humans (Peglow et al., 1990; Daly et al., 2002; 
Morris et al., 2008a) and non-human primates (Kling et al., 2009); thus, a study evaluating the 
humoral response to this pathogen is also qualitatively different than many studies of impaired 
humoral responses of HIV+ patients, which focus on recall responses to antigens or pathogens 
against which study participants have been vaccinated (Malaspina et al., 2005; Titanji et al., 
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2006), or to antigens to which they are not likely to be naturally exposed (e.g., tetanus toxoid) 
(De Milito et al., 2004; Hart et al., 2007).  Maintenance of the Pc-KEX1-specific antibody 
responses and B cell memory during SHIV-induced immunosuppression in monkeys that had 
high baseline Pc humoral immunity, suggests that responses to this antigen were not significantly 
affected by SHIV-infection. Thus, Pc-KEX1 is a potential model antigen for longitudinal 
analysis of the preservation of functional humoral responses in patients with defects in CD4+ T 
cell numbers, due to lentivirus infection or other immunosuppressive states (Duchini et al., 
2003).    
In the described experiments, we also investigated the potential clinical consequence of 
persistent Pc colonization and the role of a humoral response to Pc in prevention of pulmonary 
damage.  The evidence we present here of an association of Pc-colonization with pulmonary 
obstruction supports the concept presented by others that persistent microbial colonization may 
be involved in perpetuating the inflammatory response, eventually leading to tissue destruction 
and clinical COPD (Sethi and Murphy, 2008).  HIV+ patients, including those with high CD4+ T 
cells counts on ART (Morris et al., 2009), are at increased risk for Pc colonization (Morris et al., 
2004a), as well as an accelerated form of emphysema (Diaz et al., 2000b), and additional 
evidence suggests a role for Pc colonization in development of COPD in HIV-negative patients 
(Calderon et al., 1996; Probst et al., 2000)  The longitudinal study of pulmonary function in 
SHIV-infected macaques presented here supports these findings as well as confirm our previous 
studies proposing a role for Pc colonization and COPD development in the SHIV model (Norris 
et al., 2006; Shipley et al., in press).   
Identifying a relationship between baseline anti-KEX1 antibody titers and susceptibility 
to Pc colonization and development of COPD extends these findings and supports recently 
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reported evidence of an association for Pc-kexin antibodies in protection from increased severity 
of obstruction in COPD patients (Morris et al., 2008a).  The publication resulting from this study 
is presented in Appendix C of this document.  This was a cross-sectional pilot study to determine 
the relationship of Pc KEX1 antibodies to severity of airway obstruction in a cohort of former 
and current smokers.  Subjects included in the study were randomly selected from individuals 
enrolled in the Emphysema/COPD Research Center (ECRC) at the University of Pittsburgh. Of 
the 153 subjects included in the study, approximately 63 percent had detectable KEX1 antibody 
titers.  This report that a majority of subjects had detectable KEX1 titers is also consistent with 
our findings from investigating KEX1 titers in immunocompetent macaques (Kling et al., 2009; 
reported in Chapter 2 of this dissertation).  In this study of COPD patients, a low or undetectable 
anti‐KEX1 antibody titer was an independent predictor of more‐severe airway obstruction. A 
similar relationship was not observed with anti‐influenza antibody titers, suggesting that the Pc 
KEX1 antibody association was not merely an indicator of a poor humoral immune response in 
these patients.  Findings from this study further support the hypothesis that Pc is involved in the 
pathogenesis or progression of COPD and suggest that the KEX1 antibody assay may be useful 
in humans (Morris et al., 2008a).  
Together with other preliminary work from our group demonstrating an association of 
low KEX1 antibody levels with subsequent PcP development in HIV+ subjects (Gingo et al., 
submitted), these findings support the implications of work presented in this dissertation, 
suggesting that Pc KEX1-antibodies are not only correlative with protection from Pc 
colonization in a macaque model of immunosuppression, but also relevant in human studies and 
may be a useful predictor of disease, in both the context of HIV and in COPD patients. 
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In summary, using a unique model of natural Pc colonization in SIV- or SHIV-
immunosuppressed macaques, we have investigated the use of serology in both monitoring Pc 
colonization and in evaluating the correlation of antibodies to a particular Pc-antigen, kexin, with 
protection.  We have demonstrated that, when examined serially, antibodies to Pc-kexin are more 
sensitive than nested PCR for detecting early Pc colonization.  Additionally, we found that Pc-
specific humoral immunity established prior to immunosuppression protects against subsequent 
Pc colonization and pulmonary obstruction, despite declining CD4+ T cell numbers and 
abnormalities in B cells populations.  Although clinical use of Pc-kexin antibodies as a serum 
marker of active Pc colonization or PcP would be limited, as serial data are needed for 
appropriate interpretation, our data and supporting studies in human subjects indicate that 
instead, early evaluation of KEX1 antibodies may be a useful predictor of clinical outcome or 
severity of disease.  Maintenance of a Pc-kexin-specific memory B cell pool following 
immunosuppression suggests that despite declines in total and subsets of memory B cells 
following SHIV-infection, memory B cell responses to this commonly-encountered antigen 
remain sufficiently intact.  Furthermore, these experiments imply that Pc-kexin-specific 
antibodies may be capable of providing protection of immunocompromised individuals from 
developing pulmonary obstruction, supporting the hypothesis that Pc-colonization is associated 
with COPD development.  These results demonstrate the importance of a Pc-specific humoral 
response in protection from Pc colonization and pulmonary damage and thereby provide a 
rationale for Pc-KEX1 vaccine development to protect at risk populations against this 
opportunistic pathogen.   
Results from these studies suggest the existence of an adequate B cell memory response 
despite substantial loss of CD4+ T cells, suggesting that B cell help may be derived from 
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alternative sources under these conditions.  These studies form a foundation for future 
experiments examining whether the B cell response to Pc-kexin can be augmented after SHIV-
infection.  This could be investigated by immunizing immunosuppressed monkeys with Pc-kexin 
protein, and examining whether there may be alternative sources of B cell help provided, such as 
via innate immune mechanisms.  Generation of help from innate immunity sources could be 
explored through the use of adjuvants directed toward the innate arm of the immune response, 
such as alpha-galactosyl-ceramide (aGC) which has been shown to induce invariant NKT cell 
help for specific antibody responses to protein antigens (Galli et al., 2007). Another mechanism 
that might be explored is through CpG-TLR signaling.  CpG DNA has been well studied with 
respect to stimulating innate immunity (Klinman, 2004; Klinman et al., 2004). However, whether 
these mechanisms of B cell help can function in the context of HIV immunosuppression has not 
been thoroughly examined, but could be uniquely explored using the SHIV-macaque model of 
immunosuppression.   
To examine alternative mechanisms of B cell help and determine the efficacy of Pc-kexin 
immunization, macaques could be immunized with KEX1 in combination with different 
adjuvants (aGC, CpG, etc) to examine whether they can be vaccinated effectively with a T-
dependent antigen while immunosuppressed. Studies using this model would examine the ability 
to induce a memory response to Pc-kexin in SHIV-infected macaques, and determine whether 
vaccination-induced enhancement of the Pc kexin-antibody response after SHIV-infection would 
have the capacity to prevent Pc colonization.  We would use KEX1-specific ELISA and ELISpot 
to determine boosting of responses.  Pc colonization would be determined as before, using nested 
PCR for detection of Pc DNA in the BAL fluid and ELISA for detection of anti-KEX1 
antibodies.  We would also monitor pulmonary function in these animals to investigate 
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development of obstructive lung disease as a correlate of Pc colonization.  The longitudinal 
nature of the model gives us the capacity to examine baseline KEX1 antibody titers and follow 
the progression of individual animals following immunization.  This model also allows us to 
potentially answer other questions regarding the nature of the immune response to Pc, such as 
examining whether long-lived plasma cells are generated in response to Pc exposure or 
vaccination.  When circulating antibody levels are maintained by long-lived plasma cells, then 
the specific antibody levels do not generally correlate with the levels of specific memory B cells 
(Radbruch et al., 2006).  Additionally, other correlates of protection from Pc colonization, such 
as cytokine production, could also be evaluated in these studies.  
The data presented in this dissertation suggest that antibody responses to KEX1 can be 
augmented (via Pc exposure) in immunosuppressed monkeys. Thus, we expect that we will 
detect augmented antibody responses in macaque plasma following vaccination with Pc-kexin.  
Because we have observed that robust antibody responses to KEX1 correlate with protection 
from Pc colonization and subsequent airway obstruction, we hypothesize that augmented KEX1 
responses will be protective in these animals.  These studies would provide rationale for further 
investigation into strategies for Pc immunization of at-risk HIV-infected individuals.  
Additionally, results generated from these experiments may provide insight into potential 
mechanisms of alternative B cell help in the context of HIV-infection. 
 
 
 
 
 126 
APPENDIX A 
PUBLICATIONS 
Kling, H.M., Shipley T.W., and K.A. Norris.  SHIV-infected cynomolgus macaques exhibit 
abnormalities in peripheral blood B cell populations.
 
 In preparation. 
Kling, H.M., Shipley T.W., Patil S., Kristoff J., Montelaro, R., Morris A., and K.A. Norris.  
Relationship of Pneumocystis Humoral Immunity to Prevention of Colonization and COPD in a 
Primate Model of HIV Infection.  
 
In preparation. 
Shipley T.W., Kling H.M., Morris A., Kristoff J., Shao X., and K.A. Norris. Comparison of lung 
tissue gene expression profiles from SHIV-infected cynomolgus macaques with and without 
Pneumocystis colonization-induced COPD.  In preparation. 
 
George, M.P., Brower, A., Kling, H.M., Shipley, T.W., Kristoff, J., Reinhart, T.A., Murphey-
Corb, M., Gladwin, M.T., Champion, H.C., Morris, A., and Karen, A. Norris. Pulmonary 
Vascular Lesions are Common in SIV- and SHIV-Env-infected Macaques.  AIDS and Human 
Retroviruses.  In review. 
 
Shipley T.W., Kling, H.M., Morris A., Patil. S, Kristoff J., Guyach. S.E., Murphy J.M., Shao, 
X., Sciurba F.C., Rogers R.M., Richards T., Thomson P., Montelaro R.C., Coxson H.O., Hogg 
J.C., and K.A. Norris. Persistent Pneumocystis colonization leads to the development of chronic 
obstructive pulmonary disease (COPD) in a non-human primate model of AIDS.
 
 Journal of 
Infectious Diseases. In press. 
Kling H.M., Shipley T.W., Patil S., Morris A., and K.A. Norris. Pneumocystis Colonization in 
Immunocompetent and Simian Immunodeficiency Virus-Infected Cynomolgus Macaques. 
Journal of Infectious Diseases 2009
 
:199(1): 89–96. 
Morris A., Netravali M., Kling H.M., Shipley T., Ross T., Sciurba F.C., K.A. 
Norris.“Relationship of Pneumocystis Antibody Response and Severity of Chronic Obstructive 
Pulmonary Disease.” Clinical Infectious Disease. 2008: 47(S2):e64–e68.   
 
 127 
APPENDIX B 
This section appeared as an online supplement for the publication of “Pneumocystis Colonization 
in Immunocompetent and Simian Immunodeficiency Virus-Infected Cynomolgus Macaques” in 
the Journal of Infectious Diseases 2009: 199(1). 
 
B.1 SUPPLEMENTARY METHODS FROM CHAPTER 2 
B.1.1 Western blot analysis. 
A partial fragment of the macaque-derived, Pc kexin gene in the pBAD expression vector (gift 
from C.G. Haidaris, University of Rochester) was used to produce recombinant kexin protein 
(KEX1).  Western blot E. coli Top10 (Invitrogen Corp., Carlsbad, CA) containing the pBAD-
KEX1 plasmid was grown overnight at 37°C in Luria-Bertani (LB) broth, supplemented with 
carbenicillin (100 µg/mL), then diluted 1:20 in fresh LB broth with 100 µg/ml carbenicillin and 
grown at 37ºC to log phase (OD600 0.7-0.8). KEX1 expression was induced by the addition of L-
arabinose (0.01% final concentration) and continued culture for 4.5 h. at 37ºC.  Cells were 
centrifuged for 10 minutes at 4,000 x g and cell pellets were frozen at -80ºC until use.  Cells 
were lysed by thawing in extraction buffer (6 M guanidine-HCl, 50 mM Na2HPO4, 300 mM 
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NaCl pH 7.0) at room temperature for 20 min.  After centrifugation (20 min at 7,240 x g), the 
supernatant fluid was applied to Talon metal affinity resin (Clontech Laboratories, Inc, Mountain 
View, CA) and KEX1 was eluted with 150 mM imidazole.  Purified protein was subjected to 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to nitrocellulose, blocked 
in 5% nonfat milk with 1% bovine serum albumin and 0.05% Tween 20 in phosphate-buffered 
saline (PBS), and incubated with plasma from a macaque with PCP, as well as with plasma from 
SIV-infected macaques from this study.  Filters were washed (0.05% Tween, PBS), incubated 
with horseradish peroxidase-conjugated IgG secondary antibody, and developed according to 
standard protocols.  Protein from the empty pBAD expression vector was prepared and purified 
in the same manner as KEX1 and used as a negative control in Western blots and ELISA. 
B.1.2 ELISA controls. 
Background was defined by wells coated with antigen, and to which the secondary antibody was 
added, but primary antibody was omitted.  Previously we have tested plasma and BAL samples 
by ELISA for reactivity to protein prepared from the expression vector alone and observed 
negligible reactivity above background. All samples were tested at least twice on separate ELISA 
plates; reciprocal endpoint titers within one dilution (two-fold) were considered equivalent.  
ELISA reactivity was confirmed by Western blot in a small subset of samples (only one is shown 
in Fig 1). 
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C.1 ABSTRACT 
Pneumocystis colonization has been associated with severity of chronic obstructive pulmonary 
disease (COPD). The relationship of Pneumocystis antibody status to COPD severity has not 
been investigated, but antibody levels might relate to both colonization susceptibility and COPD 
progression. We investigated anti‐Pneumocystis antibody titers and airway obstruction in a 
cohort of patients with COPD. Undetectable anti‐Pneumocystis antibody titer was an 
independent predictor of more‐severe airway obstruction, although use of inhaled corticosteroids 
is a possible confounder of this effect. 
C.2 INTRODUCTION 
Smoking is the primary risk factor for chronic obstructive pulmonary disease (COPD), but 
factors that determine which smokers will develop significant disease are largely unknown. 
Infectious agents might play a role in accelerating progression of airway obstruction or in 
perpetuating its progression after discontinuation of tobacco exposure. Pneumocystis jirovecii is 
a fungal pathogen that causes pneumonia in immunocompromised individuals. The presence of 
Pneumocystis in the lungs, even at low levels, produces inflammatory changes similar to those 
seen in COPD (Di Stefano et al., 1998; Saetta et al., 1998).  Colonization is highly prevalent in 
patients with COPD and correlates with disease severity (Calderon et al., 1996; Probst et al., 
2000; Morris et al., 2004c). 
Host defense against Pneumocystis is complex and involves both the humoral and cellular 
immune responses (Steele et al., 2005).  CD4+ T cells have historically been implicated in 
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susceptibility to colonization with Pneumocystis, but an antibody‐mediated response is also 
likely to be important. Antibodies to the Pneumocystis endoprotease kexin (KEX1) may be 
particularly important, because immune responses to Pneumocystis kexin have been associated 
with control of Pneumocystis infection in animal models (Zheng et al., 2005; Wells et al., 
2006a). 
The serum KEX1 antibody response in patients with COPD has not been investigated and 
might be important for further clarifying the role of Pneumocystis in COPD by indicating a 
mechanism by which patients with COPD become colonized and by serving as a noninvasive 
marker of susceptibility to Pneumocystis colonization. We performed a cross‐sectional pilot 
study to determine the relationship of Pneumocystis KEX1 antibodies to severity of airway 
obstruction in a cohort of former and current smokers. 
C.3 PATIENTS, MATERIALS AND METHODS 
Persons who were former or current smokers with a history of smoking at least 10 packs per year 
were randomly selected from individuals enrolled in the Emphysema/COPD Research Center at 
the University of Pittsburgh (Pittsburgh, PA). Participants were recruited for this registry from 
various areas of Pittsburgh and its suburbs. Exclusion criteria included current exacerbation, 
completely reversible airflow obstruction, a significant allergy history, or a history of clinical 
asthma. The University of Pittsburgh Institutional Review Board approved the study, and all 
participants provided informed consent. 
Spirometry and measurement of single breath carbon monoxide diffusing capacity 
(DLCO) were performed at entry into the Emphysema/COPD Research Center, according to 
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American Thoracic Society criteria (Miller et al., 2005). The percentage of forced predicted 
expiratory volume in 1 s (FEV1
A partial fragment of the macaque‐derived Pneumocystis kexin gene in the pBAD 
expression vector (gift from C. G. Haidaris, University of Rochester) was used to produce 
recombinant KEX1. Escherichia coli Top10 (Invitrogen), containing the pBAD‐KEX1 plasmid, 
was grown overnight at 37°C in Luria‐Bertani broth, supplemented with 100 μg/mL of 
carbenicillin, diluted 1:20 in fresh Luria‐Bertani broth with 100 μg/mL of carbenicillin, and 
grown at 37°C to log phase (optical density of liquid medium at 600 nm, 0.7–0.8). KEX1 
expression was induced by the addition of L‐arabinose (0.01% final concentration) and 
continued culture for 4.5 h at 37°C. Cells were centrifuged for 10 min at 4000 g, and cell pellets 
were frozen at −80°C until use. Cells were lysed by thawing in extraction buffer (6 mol/L 
guanidine‐hydrogen chloride, 50 mmol/L disodium hydrogen orthophosphate, and 300 mmol/L 
sodium chloride; pH, 7.0) at room temperature for 20 min. After centrifugation (20 min at 7240 
g), the supernatant fluid was applied to Talon metal affinity resin (Clontech Laboratories), and 
KEX1 was eluted with 150 mmol/L imidazole. Purified protein was subjected to sodium dodecyl 
sulfate–polyacrylamide gel electrophoresis, transferred to nitrocellulose, blocked in 5% nonfat 
milk with 1% bovine serum albumin and 0.05% Tween 20 in PBS, and incubated with a plasma 
sample obtained from a macaque with Pneumocystis pneumonia. Microtiter plates (Immunolon 
4HBX; Thermo Fisher Scientific) were coated with 5 μg/mL of purified KEX1 in sodium 
bicarbonate (pH, 9.5). Heat‐inactivated plasma was diluted 1:100 in blocking buffer (PBS with 
), forced vital capacity (FVC), and DLCO were calculated with 
use of standard reference equations (Crapo and Morris, 1981; Crapo et al., 1981). Plasma 
samples were obtained from patients at enrollment in the Emphysema/COPD Research Center 
registry and were stored at −80°C. 
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5% nonfat milk). Fifty microliters of plasma were plated into KEX1‐coated wells, and serial 
dilutions up to 1:12,800 were made to determine end point titers. Goat antihuman 
immunoglobulin‐conjugated horseradish peroxidase (1:10,000 for IgG; Sigma‐Aldrich) was used 
for detection, and plates were developed by standard methods. Normal human plasma samples 
(Pneumocystis negative by antibody titer assay) were used as negative controls. The reciprocal 
end point titer was calculated as the highest dilution at which the optical density was the same or 
less than that of the control. 
To determine whether patients with low KEX1 levels had a generalized defect in humoral 
immunity, plasma samples were also tested for antibodies to influenza with use of the 
hemagglutinin inhibition assay, adapted from the Centers for Disease Control and Prevention 
laboratory‐based influenza surveillance manual (Bright et al., 2008). Antibody titers against 
A/Fujian/411/2002 (H3N2) and A/Wisconsin/65/2005 (H3N2) were determined. 
Stata, version 8 (Stata), was used for analysis, and statistical significance was determined 
at p < 0.05. Variables were analyzed with use of either Student's t test and the Wilcoxon 
rank‐sum test or the χ2 test and Fisher’s exact test. Demographic variables and antibody levels 
were determined for the entire cohort. Because we hypothesized that COPD severity would be 
associated with decreased antibody titers, we then examined the relationship of antibody levels 
as a continuous variable to pulmonary function parameters. Univariate analyses were also 
performed to determine clinical variables related to an undetectable KEX1 antibody titer (defined 
as a KEX1 titer <1:100). Multivariate linear regression was performed to determine independent 
predictors of FEV1%, FEV1‐to‐FVC ratio, and DLCO by including variables hypothesized to be 
causally related to the outcomes or that were statistically significant at p = 0.1 in univariate 
analyses. Models were run with log‐transformed absolute anti‐Pneumocystis reciprocal end point 
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titers and with antibody status as a dichotomous variable (detectable vs. undetectable antibody 
titer). We explored interactions between model variables, and normality of model residuals was 
assessed. Similar models were performed for influenza antibody titers. 
 
C.4 RESULTS  
One hundred fifty‐three patients were included in the analysis (Table 1). The median anti‐KEX1 
antibody titer was 375 (range, 1–12,800), and 96 patients (62.7%) had detectable titers. Patients 
with undetectable antibody titers were similar to those with detectable titers with regard to age, 
sex, and number of patients who were currently smoking (Table 1). Patients with undetectable 
titers tended to have a lower pack‐year smoking history (defined as the average number of packs 
smoked per day multiplied by the number of years that the person smoked), compared with 
patients with detectable titers (50.2 pack‐years vs. 58.6 pack‐years; p=0.06). Despite a somewhat 
lower pack‐year smoking history, the patients with undetectable titers had a significantly lower 
FEV1‐to‐FVC ratio (0.46 vs. 0.51; p=0.04) and tended to have a lower FEV1% predicted, 
compared with patients with detectable titers (49.9% vs. 57.8%; p=0.08). The DLCO% predicted 
did not differ between groups. Compared with patients with detectable antibody titers, patients 
with undetectable titers were more symptomatic, according to the modified Medical Research 
Council dyspnea index scale (2.0 vs. 1.5; p=0.04), and were more likely to be using inhaled 
corticosteroids (52.6% vs. 32.3%; p=0.04). Patients with undetectable titers also had a lower 
mean (±SD) body mass index (defined as weight in kilograms divided by the square of the height 
in meters) than did patients who had a detectable antibody response (25.9 ± 4.2 vs. 28.4 ± 5.8); 
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however, most patients had a normal body mass index. Only 5 patients had an abnormally low 
body mass index (<19), and there was no relationship between a low body mass index and 
Pneumocystis antibody status. Data on injection or inhaled illicit drug use was not available; 
however, the population consisted of older, HIV‐uninfected patients, and thus, the prevalence of 
drug use was likely to have been low. There were no differences in the percentages of patients 
who had been hospitalized or had experienced exacerbation in the previous year according to 
antibody status. 
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Table C1 Characteristics of patients with chronic obstructive pulmonary disease (COPD), 
by anti‐Pneumocystis antibody status.  
Characteristic 
Patients 
OR (95% 
CI) P 
All 
(n = 
153) 
With undetectable 
antibody 
(n = 57) 
With detectable 
antibody 
(n = 96) 
Age, mean years ± SD 63.3 ± 
8.0 
63.6 ± 8.4 63.1 ± 7.8 …   
Sex           
Male 86 
(56.2) 
30 (52.3) 56 (58.3) …   
Female 67 
(43.8) 
27 (47.7) 30 (41.7) …   
Current smoker 42 
(27.5) 
16 (28.1) 26 (27.1) …   
Smoking history, median 
pack‐years (range)a 55.4 (26.8) 50.2 (18.3) 58.6 (30.5) 1.01 (1.00–1.03) .06 
Mean FEV1% predicted ± SD 54.9 ± 
26.4 
49.9 ± 25.6 57.8 ± 26.6 3.20 (0.88–
11.5) 
.08 
Mean FEV1 0.49 ± 
0.17 
:FVC ± SD 0.46 ± 0.17 0.51 ± 0.17 8.23 (1.07–
63.2) 
.04 
Mean DLCO% predicted ± SD 45.8 ± 
19.0 
45.2 ± 17.4 44.6 ± 20.2 …   
Median MMRC (range) 2 (0–4) 2 (0–4) 1.5 (0–4) 0.72 (0.53–
0.97) 
.04 
Used inhaled corticosteroids 61 
(39.9) 
30 (52.6) 31 (32.3) 0.43 (0.22–
0.84) 
.01 
Used oral corticosteroids 9 (5.9) 4 (7.0) 5 (5.2) …   
Mean BMI ± SD 27.5 ± 
5.4 
25.9 ± 4.2 28.4 ± 5.8 … .009 
Exacerbation within the 
previous year 
37 
(24.2) 
13 (22.8) 24 (25.) …   
Hospitalization within the 
previous year 
29 
(19.0) 
14 (24.6) 15 (15.7) …   
NOTE. Data are no. (%) of patients, unless otherwise indicated. BMI, body mass index (calculated as 
weight in kilograms divided by the square of the height in meters); DLCO, diffusing capacity for carbon 
monoxide; FEV1
 
, forced expiratory volume in 1 s; FVC, forced vital capacity; GOLD, Global Initiative on 
Obstructive Lung Diseases; MMRC, modified Medical Research Council dyspnea index. 
aPack‐years is defined as the average number of packs smoked per day multiplied by the number of years 
that the person smoked. 
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Figure C1. A, Adjusted mean spirometry values and 95% CIs for patients, by Pneumocystis (Pc) 
antibody status. B, Adjusted mean spirometry values and 95% CIs for patients, by anti‐influenza 
antibody status. Data were adjusted for age, pack‐year smoking history (defined as the average 
number of packs smoked per day multiplied by the number of years that the person smoked), 
current smoking status (forced expiratory volume in 1 s [FEV1] and FEV1‐to–forced vital 
capacity [FVC] ratio), and sex (FEV1
 
‐to‐FVC ratio only). 
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C.5 DISCUSSION 
To our knowledge, this study is the first to report the relationship between anti‐Pneumocystis 
antibodies and the degree of COPD in smokers. We found that a low or undetectable anti‐KEX1 
antibody titer was an independent predictor of more‐severe airway obstruction. We did not find a 
similar relationship with anti‐influenza antibody titers, which suggests that the Pneumocystis 
antibody association is not merely a marker of a poor humoral immune response. This finding 
lends additional support to the hypothesis that Pneumocystis is involved in the pathogenesis or 
progression of COPD and suggests that the KEX1 antibody assay is a useful test in humans. 
Previous studies demonstrated that an intact antibody response is important for protection 
from infection due to Pneumocystis. Studies have reported that HIV‐infected patients have lower 
anti‐Pneumocystis antibody levels than do HIV‐uninfected blood donors (Daly et al., 2002; 
Bishop and Kovacs, 2003). Patients who have repeated episodes of P. jirovecii pneumonia fail to 
mount an antibody response to the Pneumocystis major surface glycoprotein (Daly et al., 2006). 
Although data regarding the anti‐KEX1 antibody response in humans are limited, studies of 
rodent vaccine have indicated that immunization with KEX1 can result in a protective antibody 
response (Zheng et al., 2005; Wells et al., 2006a). The current study is, to our knowledge, the 
first to report that the majority of adults have a detectable anti‐KEX1 titer and that this titer 
relates to COPD. Future studies will be necessary to determine whether a particular breakpoint 
can be used to distinguish patients colonized with Pneumocystis from those who are not 
colonized. 
The association of low anti‐Pneumocystis antibody titer with severity of airway 
obstruction is intriguing with regard to susceptibility to Pneumocystis colonization and 
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progression of COPD. Data from nonhuman primates infected with chimeric simian 
immunodeficiency virus/HIV indicate that low or undetectable baseline anti‐KEX1 titers predict 
subsequent susceptibility to colonization with Pneumocystis (H. M. Kling, T. W. Shipley, S. 
Patil, A. Morris, K. A. Norris, unpublished observation). We previously demonstrated that the 
prevalence of colonization with Pneumocystis is increased in patients with COPD, compared 
with the rate among those with other types of end‐stage lung diseases, and that colonization with 
Pneumocystis is associated with COPD severity, independent of smoking history (Morris et al., 
2004c). Although we did not have direct data on colonization with Pneumocystis in these 
patients, the current findings suggest that low or undetectable anti‐Pneumocystis antibody titers 
might increase susceptibility to colonization with Pneumocystis, which in turn might stimulate 
pulmonary inflammation and worsen obstruction. 
This study had several limitations. First, antibody levels were measured at a single time, 
and we did not have corresponding data on colonization with Pneumocystis. We also were 
unable to determine the cause and effect of Pneumocystis infection in patients with COPD in our 
study. The organism might worsen disease or might be an indicator of disease severity. Also, 
Pneumocystis is likely to be one of several pathogens involved in the pathogenesis and 
progression of COPD, and other organisms, such as Haemophilus influenzae and adenovirus, 
may be important (Sethi, 2000; Retamales et al., 2001). Despite these limitations, our study 
involved necessary preliminary work to demonstrate that KEX1 antibodies are detectable in 
humans and are related to COPD. Future studies examining the time course of antibody response 
in patients with COPD, linking antibody levels to detection of Pneumocystis colonization in 
respiratory specimens, and determining the role of Pneumocystis in disease progression will be 
informative. 
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The use of inhaled corticosteroids was a confounding factor in the analysis and 
interpretation of the Pneumocystis antibody response. Patients with a low antibody response 
were more likely than others to be using inhaled corticosteroids, although use of oral 
corticosteroids had no relationship to antibody levels. Because patients with more‐severe COPD 
are more likely to receive prescriptions for inhaled corticosteroids, it is impossible to completely 
separate this effect. We do not think that inhaled corticosteroid use affected the ability to mount 
a systemic humoral immune response, because use of inhaled corticosteroids was not associated 
with influenza antibody response; however, we cannot rule out the possibility that these 
medications altered the immune environment of the lung, thereby decreasing the Pneumocystis 
antibody response. Nonetheless, a decrease in the ability to generate an antibody response that is 
the result of inhaled corticosteroid use might still increase the risk of colonization with 
Pneumocystis and potentially result in worsening of COPD. 
In summary, we found that adult smokers have a detectable anti‐KEX1 Pneumocystis 
titer and that lower antibody levels are independently associated with more‐severe airway 
obstruction. These findings lend additional support to a potential role of Pneumocystis in the 
progression of COPD and suggest that decreased antibody response might be an important 
mechanism by which smokers become colonized. If future studies correlate antibody response 
with susceptibility to colonization with Pneumocystis, serum antibody titer could be used as a 
noninvasive marker of risk of Pneumocystis colonization to identify patients susceptible to such 
colonization. 
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